{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 134, "items": [{"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T08:43:19Z", "timestamp": 1576831399616}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1999, 4, 1]], "date-time": "1999-04-01T00:00:00Z", "timestamp": 922924800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cell Death Differ"], "published-print": {"date-parts": [[1999, 4]]}, "DOI": "10.1038/sj.cdd.4400505", "type": "journal-article", "created": {"date-parts": [[2002, 9, 4]], "date-time": "2002-09-04T16:05:23Z", "timestamp": 1031155523000}, "page": "303-313", "source": "Crossref", "is-referenced-by-count": 224, "title": ["The role of the ubiquitin-proteasome pathway in apoptosis"], "prefix": "10.1038", "volume": "6", "author": [{"given": "Robert Z", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[1999, 4, 9]]}, "container-title": ["Cell Death & Differentiation"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/4400505.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4400505", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/4400505.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 17]], "date-time": "2019-03-17T05:15:33Z", "timestamp": 1552799733000}, "score": 50.553425, "issued": {"date-parts": [[1999, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1999, 4]]}, "issue": "4"}, "alternative-id": ["BF4400505"], "URL": "http://dx.doi.org/10.1038/sj.cdd.4400505", "ISSN": ["1350-9047", "1476-5403"], "issn-type": [{"value": "1350-9047", "type": "print"}, {"value": "1476-5403", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T22:04:12Z", "timestamp": 1575151452113}, "publisher-location": "New Jersey", "reference-count": 0, "publisher": "Humana Press", "isbn-type": [{"value": "1592598951", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1385/1-59259-895-1:339", "type": "book-chapter", "created": {"date-parts": [[2005, 5, 25]], "date-time": "2005-05-25T21:01:54Z", "timestamp": 1117054914000}, "page": "339-350", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Proteasome Inhibitors in Cancer Therapy"], "prefix": "10.1007", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "297", "container-title": ["Ubiquitin-Proteasome Protocols"], "deposited": {"date-parts": [[2013, 1, 3]], "date-time": "2013-01-03T14:05:50Z", "timestamp": 1357221950000}, "score": 38.540348, "issued": {"date-parts": [[null]]}, "ISBN": ["1592598951"], "references-count": 0, "URL": "http://dx.doi.org/10.1385/1-59259-895-1:339"}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T08:28:29Z", "timestamp": 1575188909673}, "reference-count": 42, "publisher": "American Society of Hematology", "issue": "1", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2005, 1, 1]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:p>The validation of the ubiquitin-proteasome pathway as a target for therapy of hematological malignancies stands out as one salient example of the ability to translate laboratory-based findings from the bench to the bedside. Preclinical studies showed that proteasome inhibitors had significant activity against models of non-Hodgkin lymphoma and multiple myeloma, and identified some of the relevant mechanisms of action. These led to phase I through III trials of the first clinically available proteasome inhibitor, bortezomib, which confirmed its activity as a single agent in these diseases. Modulation of proteasome function was then found to be a rational approach to achieve both chemosensitization in vitro and in vivo, as well as to overcome chemotherapy resistance. Based on these findings, first-generation bortezomib-based regimens incorporating traditional chemotherapeutics such as alkylating agents, anthracyclines, immunomodulatory agents, or steroids have been evaluated, and many show promise of enhanced clinical anti-tumor efficacy. Further studies of the pro-and anti-apoptotic actions of proteasome inhibitors, and of their effects on gene and protein expression profiles, suggest that novel agents, such as those targeting the heat shock protein pathways, are exciting candidates for incorporation into these combinations. Phase I trials to test these concepts are just beginning, but have already shown some encouraging results. Finally, novel proteasome inhibitors are being developed with unique properties that may also have therapeutic applications. Taken together, these studies demonstrate the power of rational drug design and development to provide novel, effective therapies for patients with hematological malignancies.</jats:p>", "DOI": "10.1182/asheducation-2005.1.220", "type": "journal-article", "created": {"date-parts": [[2005, 11, 23]], "date-time": "2005-11-23T01:29:34Z", "timestamp": 1132709374000}, "page": "220-225", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 18, "title": ["The Ubiquitin Proteasome Pathway from Bench to Bedside"], "prefix": "10.1182", "volume": "2005", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "234", "reference": [{"key": "2019111711084190200_R1", "unstructured": "Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays. 2000;22:442\u2013451.", "DOI": "10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R2", "unstructured": "Orlowski M, Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys. 2000;383:1\u201316.", "DOI": "10.1006/abbi.2000.2036", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R3", "unstructured": "Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry. 1992;31:9421\u20139428.", "DOI": "10.1021/bi00154a014", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R4", "unstructured": "Imajoh-Ohmi KT, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995;217:1070\u20131077.", "DOI": "10.1006/bbrc.1995.2878", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R5", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res. 1998;58:4342\u20134348."}, {"key": "2019111711084190200_R6", "unstructured": "Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res. 1999;59:2615\u20132622."}, {"key": "2019111711084190200_R7", "unstructured": "Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20133076."}, {"key": "2019111711084190200_R8", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20:4420\u20134427.", "DOI": "10.1200/JCO.2002.01.133", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R9", "unstructured": "Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609\u20132617.", "DOI": "10.1056/NEJMoa030288", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R10", "unstructured": "Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487\u20132498.", "DOI": "10.1056/NEJMoa043445", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R11", "unstructured": "O\u2019Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676\u2013684.", "DOI": "10.1200/JCO.2005.02.050", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R12", "unstructured": "Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:667\u2013675", "DOI": "10.1200/JCO.2005.03.108", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R13", "unstructured": "Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science. 1996;274:784\u2013787.", "DOI": "10.1126/science.274.5288.784", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R14", "unstructured": "Cusack JC, Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535\u20133540."}, {"key": "2019111711084190200_R15", "unstructured": "Ma MH, Yang HH, Parker KM, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136\u20131144."}, {"key": "2019111711084190200_R16", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377\u20132380.", "DOI": "10.1182/blood-2002-06-1768", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R17", "unstructured": "Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002;1:841\u2013849."}, {"key": "2019111711084190200_R18", "unstructured": "Loo TW, Clarke DM. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J. 1999;13:1724\u20131732.", "DOI": "10.1096/fasebj.13.13.1724", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R19", "unstructured": "Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530\u20131534.", "DOI": "10.1182/blood-2002-08-2543", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R20", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525\u20134530.", "DOI": "10.1182/blood.V99.12.4525", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R21", "unstructured": "Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ. Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an anti-apoptotic role. Mol Pharmacol. 2004;66:1478\u20131490.", "DOI": "10.1124/mol.104.003400", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R22", "unstructured": "Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004;127:165\u2013172.", "DOI": "10.1111/j.1365-2141.2004.05188.x", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R23", "unstructured": "Jagannath S, Durie B, Wolf JL, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129:776\u2013783.", "DOI": "10.1111/j.1365-2141.2005.05540.x", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R24", "unstructured": "Harousseau J-L, Attal M, Leleu X, et al. Bortezomib (VELCADE\u00ae) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]. Blood. 2004;104:416a, Abstract 1490."}, {"key": "2019111711084190200_R25", "unstructured": "Berenson J, Yang H, Swift R, et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study [abstract]. Blood. 2004;104:64a, Abstract 209."}, {"key": "2019111711084190200_R26", "unstructured": "Zangari M, Barlogie B, Hollmig K, et al. Marked activity of VELCADE\u00ae plus thalidomide (V+T) in advanced and refractory multiple myeloma [abstract]. Blood. 2004;104:413a, Abstract 1480."}, {"key": "2019111711084190200_R27", "unstructured": "Alexanian R, Wang LM, Weber DM, Delasalle KB. VTD (VELCADE\u00ae, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood. 2004;104:64a, Abstract 210."}, {"key": "2019111711084190200_R28", "unstructured": "Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005;105:3058\u20133065.", "DOI": "10.1182/blood-2004-07-2911", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R29", "unstructured": "Orlowski RZ, Peterson BL, Caligiuri MA, Kelly M, Larson RA. Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301 [abstract]. Haematologica. 2005;90 (s1):151, Abstract 730."}, {"key": "2019111711084190200_R30", "unstructured": "Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755\u2013762.", "DOI": "10.1111/j.1365-2141.2005.05519.x", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R31", "unstructured": "Kawazoe Y, Nakai A, Tanabe M, Nagata K. Proteasome inhibition leads to the activation of all members of the heat-shock-factor family. Eur J Biochem. 1998;255:356\u2013362.", "DOI": "10.1046/j.1432-1327.1998.2550356.x", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R32", "unstructured": "Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem Biophys Res Commun. 2003;304:505\u2013512.", "DOI": "10.1016/S0006-291X(03)00623-5", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R33", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374\u201314379.", "DOI": "10.1073/pnas.202445099", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R34", "unstructured": "Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004;23:8766\u20138776.", "DOI": "10.1038/sj.onc.1208118", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R35", "unstructured": "Chauhan D, Li G, Shringarpure R, et al. Blockade of HSP-27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003;63:6174\u20136177."}, {"key": "2019111711084190200_R36", "unstructured": "Robertson JD, Datta K, Biswal SS, Kehrer JP. Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J. 1999;344 Pt 2:477\u2013485.", "DOI": "10.1042/bj3440477", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R37", "unstructured": "Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003;100:9946\u20139951.", "DOI": "10.1073/pnas.1334037100", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R38", "unstructured": "Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567\u20138572.", "DOI": "10.1073/pnas.0503221102", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R39", "unstructured": "Chanan-Khan A, Alsina M, Carroll M, et al. Dose escalating trial of 17-AAG with bortezomib in patients with relapsed refractory multiple myeloma [abstract]. Proc Amer Soc Clin Oncol. 2005;24:605s, Abstract 6682."}, {"key": "2019111711084190200_R40", "unstructured": "Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 1995;268:726\u2013731.", "DOI": "10.1126/science.7732382", "doi-asserted-by": "crossref"}, {"key": "2019111711084190200_R41", "unstructured": "Chauhan D, Li G, Podar K, et al. A novel orally available proteasome inhibitor NPI-0052 induces killing in multiple myeloma cells resistant to conventional and bortezomib therapies [abstract]. Blood. 2004;104:661a, Abstract 2405."}, {"key": "2019111711084190200_R42", "unstructured": "Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol. 2004;16:76\u201381.", "DOI": "10.1016/j.coi.2003.11.004", "doi-asserted-by": "crossref"}], "container-title": ["Hematology"], "language": "en", "link": [{"URL": "http://ashpublications.org/hematology/article-pdf/2005/1/220/644965/220.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "http://ashpublications.org/hematology/article-pdf/2005/1/220/644965/220.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 17]], "date-time": "2019-11-17T16:08:58Z", "timestamp": 1574006938000}, "score": 38.47315, "issued": {"date-parts": [[2005, 1, 1]]}, "references-count": 42, "journal-issue": {"published-print": {"date-parts": [[2005, 1, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1182/asheducation-2005.1.220", "relation": {"cites": []}, "ISSN": ["1520-4391", "1520-4383"], "issn-type": [{"value": "1520-4391", "type": "print"}, {"value": "1520-4383", "type": "electronic"}], "subject": ["Hematology"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T05:03:24Z", "timestamp": 1574139804111}, "reference-count": 45, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2002, 2, 1]], "date-time": "2002-02-01T00:00:00Z", "timestamp": 1012521600000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Breast Cancer Res"], "published-print": {"date-parts": [[2002, 2]]}, "DOI": "10.1186/bcr460", "type": "journal-article", "created": {"date-parts": [[2002, 11, 1]], "date-time": "2002-11-01T12:09:19Z", "timestamp": 1036152559000}, "source": "Crossref", "is-referenced-by-count": 73, "title": ["The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer"], "prefix": "10.1186", "volume": "5", "author": [{"given": "Robert Z", "family": "Orlowski", "sequence": "first", "affiliation": []}, {"given": "E Claire", "family": "Dees", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2002, 12, 4]]}, "reference": [{"key": "551_CR1", "first-page": "4342", "volume": "58", "author": "RZ Orlowski", "year": "1998", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. 1998, 58: 4342-4348.", "journal-title": "Cancer Res"}, {"key": "551_CR2", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-2622.", "journal-title": "Cancer Res"}, {"key": "551_CR3", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002.", "volume-title": "J Clin Oncol"}, {"key": "551_CR4", "first-page": "2467", "volume": "61", "author": "K Kiyomiya", "year": "2001", "unstructured": "Kiyomiya K, Matsuo S, Kurebe M: Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res. 2001, 61: 2467-2471.", "journal-title": "Cancer Res"}, {"key": "551_CR5", "first-page": "2945", "volume": "56", "author": "H Yoshida", "year": "1996", "unstructured": "Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-retinoic acid receptor \u03b1 (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 1996, 56: 2945-2948.", "journal-title": "Cancer Res"}, {"key": "551_CR6", "first-page": "635", "volume": "4", "author": "GT Budd", "year": "1998", "unstructured": "Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R: Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res. 1998, 4: 635-642.", "journal-title": "Clin Cancer Res"}, {"key": "551_CR7", "doi-asserted-by": "publisher", "first-page": "24159", "DOI": "10.1074/jbc.272.39.24159", "volume": "272", "author": "SD Desai", "year": "1997", "unstructured": "Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the anti-tumor drug camptothecin. J Biol Chem. 1997, 272: 24159-24164. 10.1074/jbc.272.39.24159.", "journal-title": "J Biol Chem"}, {"key": "551_CR8", "first-page": "52a", "volume": "21", "author": "EA Perez", "year": "2002", "unstructured": "Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR: Randomized phase II study of 2 schedules of irinotecan for patients with refractory metastatic breast cancer: an NCCTG Cooperative Group study [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 52a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR9", "doi-asserted-by": "publisher", "first-page": "22796", "DOI": "10.1074/jbc.271.9.4974", "volume": "271", "author": "EG Mimnaugh", "year": "1996", "unstructured": "Mimnaugh EG, Chavany C, Neckers L: Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem. 1996, 271: 22796-22801. 10.1074/jbc.271.9.4974.", "journal-title": "J Biol Chem"}, {"issue": "Suppl 2", "key": "551_CR10", "first-page": "11", "volume": "85", "author": "JF Robertson", "year": "2001", "unstructured": "Robertson JF: ICI 182,780 (Fulvestrant) \u2013 the first oestrogen receptor down-regulator \u2013 current clinical data. Br J Cancer. 2001, 85 (Suppl 2): 11-14.", "journal-title": "Br J Cancer"}, {"key": "551_CR11", "doi-asserted-by": "publisher", "first-page": "E891", "DOI": "10.1152/ajpendo.00353.2001", "volume": "282", "author": "MT Preisler-Mashek", "year": "2002", "unstructured": "Preisler-Mashek MT, Solodin N, Stark BL, Tyriver MK, Alarid ET: Ligand-specific regulation of proteasome-mediated proteolysis of estrogen receptor-\u03b1. Am J Physiol Endocrinol Metab. 2002, 282: E891-E898.", "journal-title": "Am J Physiol Endocrinol Metab"}, {"key": "551_CR12", "doi-asserted-by": "publisher", "first-page": "36062", "DOI": "10.1074/jbc.M007204200", "volume": "275", "author": "P Kapahi", "year": "2000", "unstructured": "Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M: Inhibition of NF-\u03baB activation by arsenite through reaction with a critical cysteine in the activation loop of I\u03baB kinase. J Biol Chem. 2000, 275: 36062-36066. 10.1074/jbc.M007204200.", "journal-title": "J Biol Chem"}, {"key": "551_CR13", "first-page": "633", "volume": "22", "author": "GC Chen", "year": "2002", "unstructured": "Chen GC, Guan LS, Hu WL, Wang ZY: Functional repression of estrogen receptor \u03b1 by arsenic trioxide in human breast cancer cells. Anticancer Res. 2002, 22: 633-638.", "journal-title": "Anticancer Res"}, {"key": "551_CR14", "first-page": "1083", "volume": "10", "author": "S Nam", "year": "2001", "unstructured": "Nam S, Smith DM, Dou QP: Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis. Cancer Epidemiol Biomarkers Prev. 2001, 10: 1083-1088.", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"key": "551_CR15", "doi-asserted-by": "publisher", "first-page": "1327", "DOI": "10.1038/nm1201-1327", "volume": "7", "author": "JS Liang", "year": "2001", "unstructured": "Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Gins-berg HN, Sturley SL: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med. 2001, 7: 1327-1331. 10.1038/nm1201-1327.", "journal-title": "Nat Med"}, {"key": "551_CR16", "doi-asserted-by": "publisher", "first-page": "693", "DOI": "10.1097/00002030-200203290-00004", "volume": "16", "author": "M Piccinini", "year": "2002", "unstructured": "Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, Mostert M, Tovo PA: The human 26S proteasome is a target of antiretroviral agents. AIDS. 2002, 16: 693-700. 10.1097/00002030-200203290-00004.", "journal-title": "AIDS"}, {"key": "551_CR17", "doi-asserted-by": "publisher", "first-page": "7797", "DOI": "10.1073/pnas.96.14.7797", "volume": "96", "author": "S Rao", "year": "1999", "unstructured": "Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA. 1999, 96: 7797-7802. 10.1073/pnas.96.14.7797.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "551_CR18", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1016/S0014-5793(97)00930-7", "volume": "413", "author": "S Meyer", "year": "1997", "unstructured": "Meyer S, Kohler NG, Joly A: Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-\u03baB activation. FEBS Lett. 1997, 413: 354-358. 10.1016/S0014-5793(97)00930-7.", "journal-title": "FEBS Lett"}, {"key": "551_CR19", "doi-asserted-by": "publisher", "first-page": "2781", "DOI": "10.1002/eji.1830271106", "volume": "27", "author": "X Wang", "year": "1997", "unstructured": "Wang X, Omura S, Szweda LI, Yang Y, Berard J, Seminaro J, Wu J: Rapamycin inhibits proteasome activator expression and proteasome activity. Eur J Immunol. 1997, 27: 2781-2786.", "journal-title": "Eur J Immunol"}, {"key": "551_CR20", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1023/A:1012570204923", "volume": "70", "author": "H Pang", "year": "2001", "unstructured": "Pang H, Faber LE: Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells. Breast Cancer Res Treat. 2001, 70: 21-26. 10.1023/A:1012570204923.", "journal-title": "Breast Cancer Res Treat"}, {"key": "551_CR21", "doi-asserted-by": "publisher", "first-page": "16455", "DOI": "10.1074/jbc.271.28.16455", "volume": "271", "author": "ME Figueiredo-Pereira", "year": "1996", "unstructured": "Figueiredo-Pereira ME, Chen WE, Li J, Johdo O: The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J Biol Chem. 1996, 271: 16455-16459. 10.1074/jbc.271.28.16455.", "journal-title": "J Biol Chem"}, {"key": "551_CR22", "doi-asserted-by": "publisher", "first-page": "835", "DOI": "10.1042/bj3560835", "volume": "356", "author": "M Piccinini", "year": "2001", "unstructured": "Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F, Dianzani U, Tovo PA, Mostert M, Musso A, Rinaudo MT: Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J. 2001, 356: 835-841. 10.1042/0264-6021:3560835.", "journal-title": "Biochem J"}, {"key": "551_CR23", "doi-asserted-by": "crossref", "first-page": "336", "DOI": "10.1200/JCO.1994.12.2.336", "volume": "12", "author": "A Romero", "year": "1994", "unstructured": "Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Romero-Acuna L: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994, 12: 336-341.", "journal-title": "J Clin Oncol"}, {"key": "551_CR24", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1006/abbi.2000.2036", "volume": "383", "author": "M Orlowski", "year": "2000", "unstructured": "Orlowski M, Wilk S: Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys. 2000, 383: 1-16. 10.1006/abbi.2000.2036.", "journal-title": "Arch Biochem Biophys"}, {"key": "551_CR25", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1038/sj.cdd.4400505", "volume": "6", "author": "RZ Orlowski", "year": "1999", "unstructured": "Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 1999, 6: 303-313. 10.1038/sj.cdd.4400505.", "journal-title": "Cell Death Differ"}, {"key": "551_CR26", "doi-asserted-by": "publisher", "first-page": "385", "DOI": "10.1016/S1471-4914(02)02375-4", "volume": "8", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Baldwin AS: NF-\u03baB as a therapeutic target in cancer. Trends Mol Med. 2002, 8: 385-389. 10.1016/S1471-4914(02)02375-4.", "journal-title": "Trends Mol Med"}, {"key": "551_CR27", "doi-asserted-by": "publisher", "first-page": "27864", "DOI": "10.1074/jbc.M201519200", "volume": "277", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Small GW, Shi YY: Evidence that inhibition of p44/42 mitogen activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem. 2002, 277: 27864-27871. 10.1074/jbc.M201519200.", "journal-title": "J Biol Chem"}, {"key": "551_CR28", "doi-asserted-by": "publisher", "first-page": "559", "DOI": "10.1210/edrv-16-5-559", "volume": "16", "author": "RB Dickson", "year": "1995", "unstructured": "Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev. 1995, 16: 559-589. 10.1210/er.16.5.559.", "journal-title": "Endocr Rev"}, {"key": "551_CR29", "first-page": "2638", "volume": "5", "author": "BA Teicher", "year": "1999", "unstructured": "Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999, 5: 2638-2645.", "journal-title": "Clin Cancer Res"}, {"key": "551_CR30", "first-page": "85a", "volume": "20", "author": "C Aghajanian", "year": "2001", "unstructured": "Aghajanian C, Soignet S, Dizon DS, Pezzulli S, Daud A, Spriggs DR, Adams J, Elliott P, Pien C: A Phase I trial of the novel proteasome inhibitor PS-341 in advanced solid tumor malignancies [abstract]. Proc Am Soc Clin Oncol. 2001, 20: 85a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR31", "first-page": "11a", "volume": "21", "author": "PG Richardson", "year": "2002", "unstructured": "Richardson PG, Barlogie B, Berenson J, Traynor A, Singhal S, Jagannath S, Irwin D, Rajkumar V, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani S, Esseltine D, Kauffman M, Adams J, Schenkein D, Anderson KC: Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients with relapsed/refractory disease [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 11a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR32", "first-page": "93a", "volume": "21", "author": "JP Thomas", "year": "2002", "unstructured": "Thomas JP, Arzoomanian R, Alberti D, Geiger P, Marnocha R, Tutsch K, Dresen A, Volkman J, Binger K, Kolb M, Feierabend C, Black S, Hampton K, Wilding G: A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 93a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR33", "first-page": "93a", "volume": "21", "author": "S Iqbal", "year": "2002", "unstructured": "Iqbal S, Lenz HJ, Groshen S, Wei Y, Gandara DR, Lara PN, Gumerlock P, Doroshow JH, Twardowski P, Synold T: Phase I study of PS-341 in combination with 5-FU/LV in solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 93a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR34", "first-page": "93a", "volume": "21", "author": "JW Clark", "year": "2002", "unstructured": "Clark JW, Ryan D, Dees C, Eder JP, Winkelmann J, Lynch T, Supko J, Appleman LJ, Fidias P, O'Neil B, Orlowski RZ, Baldwin A, Kinchla N, Zhu A, Esseltine D, Elliott P, Adams J, Kauffman M, Schenkein D, Cusack J: Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 93a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR35", "first-page": "95a", "volume": "21", "author": "DP Ryan", "year": "2002", "unstructured": "Ryan DP, Eder JP, Winkelmann J, Lynch T, Supko J, Appleman LJ, Fidias P, Enzinger P, Zhu A, Kinchla N, Esseltine D, Baldwin A, Elliott P, Adams J, Kauffman M, Schenkein D, Cusack J: Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 2002, 21: 95a-", "journal-title": "Proc Am Soc Clin Oncol"}, {"key": "551_CR36", "doi-asserted-by": "publisher", "first-page": "179", "DOI": "10.1007/BF01806499", "volume": "37", "author": "CE Bueso-Ramos", "year": "1996", "unstructured": "Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown P, Ordonez N, Glassman A, Sneige N, Albitar M: Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996, 37: 179-188.", "journal-title": "Breast Cancer Res Treat"}, {"key": "551_CR37", "doi-asserted-by": "publisher", "first-page": "28169", "DOI": "10.1074/jbc.274.40.28169", "volume": "274", "author": "M Shirane", "year": "1999", "unstructured": "Shirane M, Hatakeyama S, Hattori K, Nakayama K: Common pathway for the ubiquitination of I\u03baB\u03b1, I\u03baB\u03b2, and I\u03baB\u03b5 mediated by the F-box protein FWD1. J Biol Chem. 1999, 274: 28169-28174. 10.1074/jbc.274.40.28169.", "journal-title": "J Biol Chem"}, {"key": "551_CR38", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1186/bcr277", "volume": "3", "author": "R Chiarle", "year": "2001", "unstructured": "Chiarle R, Pagano M, Inghirami G: The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res. 2001, 3: 91-94. 10.1186/bcr277.", "journal-title": "Breast Cancer Res"}, {"key": "551_CR39", "doi-asserted-by": "publisher", "first-page": "4579", "DOI": "10.1073/pnas.090465597", "volume": "97", "author": "VN Podust", "year": "2000", "unstructured": "Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB, Pierce JW, Lightcap ES, Chau V: A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA. 2000, 97: 4579-4584. 10.1073/pnas.090465597.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "551_CR40", "doi-asserted-by": "publisher", "first-page": "48937", "DOI": "10.1074/jbc.M107274200", "volume": "276", "author": "T Hara", "year": "2001", "unstructured": "Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S: Degradation of p27(Kip1) at the G 0-G1 transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem. 2001, 276: 48937-48943. 10.1074/jbc.M107274200.", "journal-title": "J Biol Chem"}, {"key": "551_CR41", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1016/S1097-2765(00)80133-1", "volume": "2", "author": "JM Desterro", "year": "1998", "unstructured": "Desterro JM, Rodriguez MS, Hay RT: SUMO-1 modification of I\u03baB\u03b1 inhibits NF-\u03baB activation. Mol Cell. 1998, 2: 233-239.", "journal-title": "Mol Cell"}, {"key": "551_CR42", "doi-asserted-by": "publisher", "first-page": "4046", "DOI": "10.1073/pnas.080536597", "volume": "97", "author": "Y Mao", "year": "2000", "unstructured": "Mao Y, Sun M, Desai SD, Liu LF: SUMO-1 conjugation to topoisomerase I: A possible repair response to topoisomerase-mediated DNA damage. Proc Natl Acad Sci USA. 2000, 97: 4046-4051. 10.1073/pnas.080536597.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "551_CR43", "doi-asserted-by": "publisher", "first-page": "373", "DOI": "10.1152/physrev.00027.2001", "volume": "82", "author": "MH Glickman", "year": "2002", "unstructured": "Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002, 82: 373-428.", "journal-title": "Physiol Rev"}, {"key": "551_CR44", "doi-asserted-by": "publisher", "first-page": "112", "DOI": "10.1038/nrm731", "volume": "3", "author": "V Jesenberger", "year": "2002", "unstructured": "Jesenberger V, Jentsch S: Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002, 3: 112-121. 10.1038/nrm731.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "551_CR45", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1177/002215540104900311", "volume": "49", "author": "OS Frankfurt", "year": "2001", "unstructured": "Frankfurt OS, Krishan A: Identification of apoptotic cells by formamide-induced DNA denaturation in condensed chromatin. J Histochem Cytochem. 2001, 49: 369-378.", "journal-title": "J Histochem Cytochem"}], "container-title": ["Breast Cancer Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/bcr460.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1186/bcr460/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1186/bcr460.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 1, 12]], "date-time": "2018-01-12T17:42:45Z", "timestamp": 1515778965000}, "score": 37.087788, "issued": {"date-parts": [[2002, 2]]}, "references-count": 45, "journal-issue": {"published-print": {"date-parts": [[2002, 2]]}, "issue": "1"}, "alternative-id": ["551"], "URL": "http://dx.doi.org/10.1186/bcr460", "relation": {"cites": []}, "ISSN": ["1465-542X"], "issn-type": [{"value": "1465-542X", "type": "electronic"}], "article-number": "1"}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T21:24:38Z", "timestamp": 1576790678051}, "reference-count": 140, "publisher": "Future Medicine Ltd", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Future Oncology"], "published-print": {"date-parts": [[2006, 2]]}, "DOI": "10.2217/14796694.2.1.121", "type": "journal-article", "created": {"date-parts": [[2006, 1, 23]], "date-time": "2006-01-23T16:38:06Z", "timestamp": 1138034286000}, "page": "121-135", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Targeting the ubiquitin\u2013proteasome pathway in breast cancer therapy"], "prefix": "10.2217", "volume": "2", "author": [{"given": "E Claire", "family": "Dees", "sequence": "first", "affiliation": []}, {"given": "Robert Z", "family": "Orlowski", "sequence": "additional", "affiliation": []}], "member": "1057", "reference": [{"key": "ref-1", "author": "Goldberg", "volume": "378", "first-page": "131", "year": "1997", "journal-title": "Biol.\u00a0Chem."}, {"key": "ref-2", "DOI": "10.1074/jbc.274.32.22123", "doi-asserted-by": "publisher"}, {"key": "ref-3", "DOI": "10.1023/A:1006909522731", "doi-asserted-by": "publisher"}, {"key": "ref-4", "DOI": "10.1016/S0959-440X(00)00075-0", "doi-asserted-by": "publisher"}, {"key": "ref-5", "DOI": "10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q", "doi-asserted-by": "publisher"}, {"key": "ref-6", "DOI": "10.1006/abbi.2000.2036", "doi-asserted-by": "publisher"}, {"key": "ref-7", "DOI": "10.1016/S0955-0674(97)80079-8", "doi-asserted-by": "publisher"}, {"key": "ref-8", "DOI": "10.1038/35056572", "doi-asserted-by": "publisher"}, {"key": "ref-9", "DOI": "10.1006/bbrc.1998.8604", "doi-asserted-by": "publisher"}, {"key": "ref-10", "DOI": "10.1158/0008-5472.CAN-05-0201", "doi-asserted-by": "publisher"}, {"key": "ref-11", "DOI": "10.1158/1078-0432.CCR-04-1989", "doi-asserted-by": "publisher"}, {"key": "ref-12", "author": "Gobbi", "volume": "25", "first-page": "1625", "year": "2004", "journal-title": "Int.\u00a0J. Oncol."}, {"key": "ref-13", "DOI": "10.1016/S0959-437X(01)00269-6", "doi-asserted-by": "publisher"}, {"key": "ref-14", "DOI": "10.1073/pnas.0836054100", "doi-asserted-by": "publisher"}, {"key": "ref-15", "DOI": "10.1128/MCB.24.19.8457-8466.2004", "doi-asserted-by": "publisher"}, {"key": "ref-16", "author": "Hayami", "volume": "65", "first-page": "6", "year": "2005", "journal-title": "Cancer Res."}, {"key": "ref-17", "DOI": "10.1038/nature03445", "doi-asserted-by": "publisher"}, {"key": "ref-18", "DOI": "10.1038/nature03443", "doi-asserted-by": "publisher"}, {"key": "ref-19", "DOI": "10.1053/j.seminoncol.2003.08.006", "doi-asserted-by": "publisher"}, {"key": "ref-20", "DOI": "10.1038/sj.onc.1206779", "doi-asserted-by": "publisher"}, {"key": "ref-21", "DOI": "10.1158/0008-5472.CAN-2522-2", "doi-asserted-by": "publisher"}, {"key": "ref-22", "DOI": "10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X", "doi-asserted-by": "publisher"}, {"key": "ref-23", "DOI": "10.3816/CBC.2003.n.038", "doi-asserted-by": "publisher"}, {"key": "ref-24", "DOI": "10.1074/jbc.M300848200", "doi-asserted-by": "publisher"}, {"key": "ref-25", "DOI": "10.1002/ijc.11445", "doi-asserted-by": "publisher"}, {"key": "ref-26", "DOI": "10.1186/bcr722", "doi-asserted-by": "publisher"}, {"key": "ref-27", "DOI": "10.1677/erc.0.0100179", "doi-asserted-by": "publisher"}, {"key": "ref-28", "DOI": "10.1074/jbc.M302830200", "doi-asserted-by": "publisher"}, {"key": "ref-29", "DOI": "10.1016/j.semcdb.2005.02.010", "doi-asserted-by": "publisher"}, {"key": "ref-30", "DOI": "10.1172/JCI200215795", "doi-asserted-by": "publisher"}, {"key": "ref-31", "DOI": "10.1023/A:1006382320697", "doi-asserted-by": "publisher"}, {"key": "ref-32", "DOI": "10.1074/jbc.271.9.4974", "doi-asserted-by": "publisher"}, {"key": "ref-33", "DOI": "10.1517/14712598.2.1.3", "doi-asserted-by": "publisher"}, {"key": "ref-34", "DOI": "10.1016/S1471-4914(02)02316-X", "doi-asserted-by": "publisher"}, {"key": "ref-35", "author": "Beliakoff", "volume": "9", "first-page": "4961", "year": "2003", "journal-title": "Clin. Cancer Res."}, {"key": "ref-36", "author": "Srethapakdi", "volume": "60", "first-page": "3940", "year": "2000", "journal-title": "Cancer Res."}, {"key": "ref-37", "author": "Munster", "volume": "61", "first-page": "2945", "year": "2001", "journal-title": "Cancer Res."}, {"key": "ref-38", "DOI": "10.1074/jbc.M106736200", "doi-asserted-by": "publisher"}, {"key": "ref-39", "DOI": "10.1074/jbc.270.41.24585", "doi-asserted-by": "publisher"}, {"key": "ref-40", "author": "Munster", "volume": "7", "first-page": "2228", "year": "2001", "journal-title": "Clin. Cancer Res."}, {"key": "ref-41", "DOI": "10.1038/sj.leu.2402257", "doi-asserted-by": "publisher"}, {"key": "ref-42", "author": "Bisht", "volume": "63", "first-page": "8984", "year": "2003", "journal-title": "Cancer Res."}, {"key": "ref-43", "DOI": "10.1080/09553000310001626135", "doi-asserted-by": "publisher"}, {"key": "ref-44", "author": "Adams", "volume": "59", "first-page": "2615", "year": "1999", "journal-title": "Cancer Res."}, {"key": "ref-45", "DOI": "10.1200/JCO.2002.01.133", "doi-asserted-by": "publisher"}, {"key": "ref-46", "DOI": "10.1056/NEJMoa030288", "doi-asserted-by": "publisher"}, {"key": "ref-47", "DOI": "10.1056/NEJMoa043445", "doi-asserted-by": "publisher"}, {"key": "ref-48", "author": "Teicher", "volume": "5", "first-page": "2638", "year": "1999", "journal-title": "Clin. Cancer Res."}, {"key": "ref-49", "DOI": "10.1186/bcr460", "doi-asserted-by": "publisher"}, {"key": "ref-50", "DOI": "10.1016/S1471-4914(02)02375-4", "doi-asserted-by": "publisher"}, {"key": "ref-51", "DOI": "10.1074/jbc.M201519200", "doi-asserted-by": "publisher"}, {"key": "ref-52", "DOI": "10.1159/000068621", "doi-asserted-by": "publisher"}, {"key": "ref-53", "author": "Voorhees", "volume": "9", "first-page": "6316", "year": "2003", "journal-title": "Clin. Cancer Res."}, {"key": "ref-54", "DOI": "10.1042/0264-6021:3400127", "doi-asserted-by": "publisher"}, {"key": "ref-55", "DOI": "10.1006/bbrc.1999.1291", "doi-asserted-by": "publisher"}, {"key": "ref-56", "DOI": "10.1074/jbc.273.24.14671", "doi-asserted-by": "publisher"}, {"key": "ref-57", "author": "Loo", "volume": "13", "first-page": "1724", "year": "1999", "journal-title": "FASEB\u00a0J.", "DOI": "10.1096/fasebj.13.13.1724", "doi-asserted-by": "crossref"}, {"key": "ref-58", "DOI": "10.1002/ijc.21063", "doi-asserted-by": "publisher"}, {"key": "ref-59", "DOI": "10.1124/mol.104.003400", "doi-asserted-by": "publisher"}, {"key": "ref-60", "DOI": "10.1056/NEJMoa052306", "doi-asserted-by": "publisher"}, {"key": "ref-61", "author": "Miller", "year": "2005", "journal-title": "Proc.\u00a0Am. Soc. Clin. Oncol."}, {"key": "ref-62", "DOI": "10.3322/canjclin.55.1.10", "doi-asserted-by": "publisher"}, {"key": "ref-63", "author": "Erlichman", "volume": "23", "year": "2004", "journal-title": "Proc.\u00a0Am. Soc. Clin. Oncol."}, {"key": "ref-64", "author": "Ramanathan", "volume": "23", "year": "2005", "journal-title": "J.\u00a0Clin. Oncol.", "DOI": "10.1200/jco.2005.23.16_suppl.3050", "doi-asserted-by": "crossref"}, {"key": "ref-65", "DOI": "10.1200/JCO.2005.09.119", "doi-asserted-by": "publisher"}, {"key": "ref-66", "author": "Aghajanian", "volume": "8", "first-page": "2505", "year": "2002", "journal-title": "Clin. Cancer Res."}, {"key": "ref-67", "DOI": "10.1200/JCO.2005.09.051", "doi-asserted-by": "publisher"}, {"key": "ref-68", "author": "Cristofanilli", "volume": "22", "year": "2004", "journal-title": "J.\u00a0Clin. Oncol.", "DOI": "10.1200/jco.2004.22.14_suppl.3102", "doi-asserted-by": "crossref"}, {"key": "ref-69", "author": "Dees", "volume": "22", "year": "2003", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-70", "DOI": "10.1182/blood-2004-07-2911", "doi-asserted-by": "publisher"}, {"key": "ref-71", "author": "Thomas", "volume": "21", "year": "2002", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-72", "author": "Albanell", "volume": "22", "year": "2003", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-73", "DOI": "10.1358/dot.2005.41.5.893706", "doi-asserted-by": "publisher"}, {"key": "ref-74", "author": "Messersmith", "volume": "23", "year": "2004", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-75", "DOI": "10.1200/JCO.2005.03.903", "doi-asserted-by": "publisher"}, {"key": "ref-76", "author": "Ma", "volume": "45", "year": "2004", "journal-title": "Proc. Am. Assoc. Cancer Res."}, {"key": "ref-77", "author": "Iqbal", "volume": "23", "year": "2004", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-78", "author": "Clark", "volume": "21", "year": "2002", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-79", "author": "Ryan", "volume": "22", "year": "2003", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-80", "author": "Appleman", "volume": "22", "year": "2003", "journal-title": "J.\u00a0Clin. Oncol."}, {"key": "ref-81", "author": "Voortman", "volume": "23", "year": "2005", "journal-title": "J.\u00a0Clin. Oncol.", "DOI": "10.1200/jco.2005.23.16_suppl.2103", "doi-asserted-by": "crossref"}, {"key": "ref-82", "author": "Possinger", "volume": "23", "year": "2005", "journal-title": "J.\u00a0Clin. Oncol.", "DOI": "10.1200/jco.2005.23.16_suppl.755", "doi-asserted-by": "crossref"}, {"key": "ref-83", "DOI": "10.3816/CBC.2004.n.020", "doi-asserted-by": "publisher"}, {"key": "ref-84", "DOI": "10.1126/science.1092472", "doi-asserted-by": "publisher"}, {"key": "ref-85", "DOI": "10.1038/sj.onc.1206203", "doi-asserted-by": "publisher"}, {"key": "ref-86", "DOI": "10.1002/cncr.20304", "doi-asserted-by": "publisher"}, {"key": "ref-87", "DOI": "10.1074/jbc.M413382200", "doi-asserted-by": "publisher"}, {"key": "ref-88", "DOI": "10.1186/bcr1116", "doi-asserted-by": "publisher"}, {"key": "ref-89", "author": "Townsend", "volume": "63", "first-page": "4150", "year": "2003", "journal-title": "Cancer Res."}, {"key": "ref-90", "DOI": "10.1074/jbc.M209682200", "doi-asserted-by": "publisher"}, {"key": "ref-91", "DOI": "10.1016/j.biocel.2004.03.016", "doi-asserted-by": "publisher"}, {"key": "ref-92", "DOI": "10.1038/sj.onc.1206880", "doi-asserted-by": "publisher"}, {"key": "ref-93", "DOI": "10.1016/j.yexcr.2004.05.004", "doi-asserted-by": "publisher"}, {"key": "ref-94", "DOI": "10.1038/sj.onc.1207302", "doi-asserted-by": "publisher"}, {"key": "ref-95", "DOI": "10.1016/S1097-2765(03)00424-6", "doi-asserted-by": "publisher"}, {"key": "ref-96", "author": "Lee", "volume": "65", "first-page": "3072", "year": "2005", "journal-title": "Cancer Res.", "DOI": "10.1158/0008-5472.CAN-04-2865", "doi-asserted-by": "crossref"}, {"key": "ref-97", "DOI": "10.1006/mcbr.1999.0157", "doi-asserted-by": "publisher"}, {"key": "ref-98", "DOI": "10.1074/jbc.M212260200", "doi-asserted-by": "publisher"}, {"key": "ref-99", "author": "Romieu", "volume": "62", "first-page": "6770", "year": "2002", "journal-title": "Cancer Res."}, {"key": "ref-100", "DOI": "10.1158/0008-5472.CAN-04-2601", "doi-asserted-by": "publisher"}, {"key": "ref-101", "author": "Chen", "volume": "58", "first-page": "3677", "year": "1998", "journal-title": "Cancer Res."}, {"key": "ref-102", "DOI": "10.1210/en.2004-1198", "doi-asserted-by": "publisher"}, {"key": "ref-103", "DOI": "10.1016/S0960-0760(03)00209-7", "doi-asserted-by": "publisher"}, {"key": "ref-104", "DOI": "10.1038/sj.onc.1206436", "doi-asserted-by": "publisher"}, {"key": "ref-105", "DOI": "10.1128/MCB.23.17.5979-5988.2003", "doi-asserted-by": "publisher"}, {"key": "ref-106", "DOI": "10.1158/0008-5472.CAN-03-3650", "doi-asserted-by": "publisher"}, {"key": "ref-107", "DOI": "10.1038/35095076", "doi-asserted-by": "publisher"}, {"key": "ref-108", "DOI": "10.1038/sj.onc.1205847", "doi-asserted-by": "publisher"}, {"key": "ref-109", "DOI": "10.1038/sj.onc.1203462", "doi-asserted-by": "publisher"}, {"key": "ref-110", "DOI": "10.3109/02841869609109917", "doi-asserted-by": "publisher"}, {"key": "ref-111", "DOI": "10.1074/jbc.M413387200", "doi-asserted-by": "publisher"}, {"key": "ref-112", "DOI": "10.1083/jcb.200406140", "doi-asserted-by": "publisher"}, {"key": "ref-113", "DOI": "10.1016/j.ccr.2005.01.009", "doi-asserted-by": "publisher"}, {"key": "ref-114", "author": "Shekhar", "volume": "62", "first-page": "2115", "year": "2002", "journal-title": "Cancer Res."}, {"key": "ref-115", "DOI": "10.1128/MCB.23.7.2463-2475.2003", "doi-asserted-by": "publisher"}, {"key": "ref-116", "DOI": "10.1038/sj.bjc.6601301", "doi-asserted-by": "publisher"}, {"key": "ref-117", "author": "Li", "volume": "11", "first-page": "1801", "journal-title": "Oncogene"}, {"key": "ref-118", "DOI": "10.1002/ijc.20261", "doi-asserted-by": "publisher"}, {"key": "ref-119", "DOI": "10.1074/jbc.M207604200", "doi-asserted-by": "publisher"}, {"key": "ref-120", "DOI": "10.1002/jcb.10727", "doi-asserted-by": "publisher"}, {"key": "ref-121", "DOI": "10.1093/carcin/bgh231", "doi-asserted-by": "publisher"}, {"key": "ref-122", "DOI": "10.1002/jcb.10353", "doi-asserted-by": "publisher"}, {"key": "ref-123", "DOI": "10.1016/j.yexcr.2004.01.019", "doi-asserted-by": "publisher"}, {"key": "ref-124", "DOI": "10.1074/jbc.M305529200", "doi-asserted-by": "publisher"}, {"key": "ref-125", "DOI": "10.1074/jbc.M103593200", "doi-asserted-by": "publisher"}, {"key": "ref-126", "author": "Qin", "volume": "63", "first-page": "958", "year": "2003", "journal-title": "Cancer Res."}, {"key": "ref-127", "DOI": "10.1128/MCB.23.16.5867-5881.2003", "doi-asserted-by": "publisher"}, {"key": "ref-128", "DOI": "10.1016/S0014-5793(99)00343-9", "doi-asserted-by": "publisher"}, {"key": "ref-129", "DOI": "10.1677/jme.0.0320987", "doi-asserted-by": "publisher"}, {"key": "ref-130", "DOI": "10.1016/S1368-8375(03)00131-3", "doi-asserted-by": "publisher"}, {"key": "ref-131", "DOI": "10.1158/0008-5472.CAN-04-4458", "doi-asserted-by": "publisher"}, {"key": "ref-132", "DOI": "10.1016/j.jsbmb.2005.01.018", "doi-asserted-by": "publisher"}, {"key": "ref-133", "DOI": "10.1016/S0014-5793(97)01612-8", "doi-asserted-by": "publisher"}, {"key": "ref-134", "author": "Fuino", "volume": "2", "first-page": "971", "year": "2003", "journal-title": "Mol. Cancer Ther."}, {"key": "ref-135", "DOI": "10.1128/MCB.24.17.7444-7455.2004", "doi-asserted-by": "publisher"}, {"key": "ref-136", "DOI": "10.1073/pnas.97.3.1032", "doi-asserted-by": "publisher"}, {"key": "ref-137", "DOI": "10.1158/0008-5472.CAN-04-2501", "doi-asserted-by": "publisher"}, {"key": "ref-138", "DOI": "10.1038/sj.onc.1208458", "doi-asserted-by": "publisher"}, {"key": "ref-139", "DOI": "10.1002/ijc.11720", "doi-asserted-by": "publisher"}, {"key": "ref-140", "DOI": "10.1158/1078-0432.CCR-04-1023", "doi-asserted-by": "publisher"}], "container-title": ["Future Oncology"], "language": "en", "link": [{"URL": "https://www.futuremedicine.com/doi/pdf/10.2217/14796694.2.1.121", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:04:02Z", "timestamp": 1574244242000}, "score": 32.63057, "issued": {"date-parts": [[2006, 2]]}, "references-count": 140, "journal-issue": {"published-print": {"date-parts": [[2006, 2]]}, "issue": "1"}, "alternative-id": ["10.2217/14796694.2.1.121"], "URL": "http://dx.doi.org/10.2217/14796694.2.1.121", "relation": {"cites": []}, "ISSN": ["1479-6694", "1744-8301"], "issn-type": [{"value": "1479-6694", "type": "print"}, {"value": "1744-8301", "type": "electronic"}], "subject": ["Cancer Research", "Oncology", "General Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T11:44:28Z", "timestamp": 1574163868332}, "reference-count": 59, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 7, 1]], "date-time": "2003-07-01T00:00:00Z", "timestamp": 1057017600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Archives of Biochemistry and Biophysics"], "published-print": {"date-parts": [[2003, 7]]}, "DOI": "10.1016/s0003-9861(03)00197-8", "type": "journal-article", "created": {"date-parts": [[2003, 6, 2]], "date-time": "2003-06-02T23:03:18Z", "timestamp": 1054594998000}, "page": "1-5", "source": "Crossref", "is-referenced-by-count": 138, "title": ["Ubiquitin-independent proteolytic functions of the proteasome"], "prefix": "10.1016", "volume": "415", "author": [{"given": "Marian", "family": "Orlowski", "sequence": "first", "affiliation": []}, {"given": "Sherwin", "family": "Wilk", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Archives of Biochemistry and Biophysics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0003986103001978?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0003986103001978?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 21]], "date-time": "2019-03-21T01:25:01Z", "timestamp": 1553131501000}, "score": 29.023737, "issued": {"date-parts": [[2003, 7]]}, "references-count": 59, "journal-issue": {"published-print": {"date-parts": [[2003, 7]]}, "issue": "1"}, "alternative-id": ["S0003986103001978"], "URL": "http://dx.doi.org/10.1016/s0003-9861(03)00197-8", "ISSN": ["0003-9861"], "issn-type": [{"value": "0003-9861", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:53:54Z", "timestamp": 1574110434627}, "reference-count": 0, "publisher": "American Chemical Society (ACS)", "issue": "50", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Biochemistry"], "published-print": {"date-parts": [[2001, 12]]}, "DOI": "10.1021/bi0116240", "type": "journal-article", "created": {"date-parts": [[2002, 7, 26]], "date-time": "2002-07-26T04:37:30Z", "timestamp": 1027658250000}, "page": "15318-15326", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Selective Activation of the 20 S Proteasome (Multicatalytic Proteinase Complex) by Histone H3\u2020"], "prefix": "10.1021", "volume": "40", "author": [{"given": "Marian", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "316", "container-title": ["Biochemistry"], "language": "en", "link": [{"URL": "https://pubs.acs.org/doi/pdf/10.1021/bi0116240", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 9]], "date-time": "2019-10-09T00:41:25Z", "timestamp": 1570581685000}, "score": 23.901592, "issued": {"date-parts": [[2001, 12]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2001, 12]]}, "issue": "50"}, "alternative-id": ["10.1021/bi0116240"], "URL": "http://dx.doi.org/10.1021/bi0116240", "ISSN": ["0006-2960", "1520-4995"], "issn-type": [{"value": "0006-2960", "type": "print"}, {"value": "1520-4995", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T14:49:48Z", "timestamp": 1574520588371}, "publisher-location": "New York, NY", "reference-count": 78, "publisher": "Springer New York", "isbn-type": [{"value": "9781461452591", "type": "print"}, {"value": "9781461452607", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013]]}, "DOI": "10.1007/978-1-4614-5260-7_7", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 6]], "date-time": "2012-12-06T00:01:03Z", "timestamp": 1354752063000}, "page": "157-180", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Novel Proteasome Inhibitors"], "prefix": "10.1007", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 11, 1]]}, "reference": [{"issue": "22", "key": "7_CR00071", "doi-asserted-by": "publisher", "first-page": "4420", "DOI": "10.1200/JCO.2002.01.133", "volume": "20", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420\u20137", "journal-title": "J Clin Oncol"}, {"issue": "26", "key": "7_CR00072", "doi-asserted-by": "publisher", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609\u201317", "journal-title": "N Engl J Med"}, {"issue": "24", "key": "7_CR00073", "doi-asserted-by": "publisher", "first-page": "2487", "DOI": "10.1056/NEJMoa043445", "volume": "352", "author": "PG Richardson", "year": "2005", "unstructured": "Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u201398", "journal-title": "N Engl J Med"}, {"issue": "25", "key": "7_CR00074", "doi-asserted-by": "publisher", "first-page": "3892", "DOI": "10.1200/JCO.2006.10.5460", "volume": "25", "author": "RZ Orlowski", "year": "2007", "unstructured": "Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892\u2013901", "journal-title": "J Clin Oncol"}, {"issue": "9", "key": "7_CR00075", "doi-asserted-by": "publisher", "first-page": "906", "DOI": "10.1056/NEJMoa0801479", "volume": "359", "author": "JF San Miguel", "year": "2008", "unstructured": "San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906\u201317", "journal-title": "N Engl J Med"}, {"key": "7_CR00076", "doi-asserted-by": "publisher", "first-page": "761", "DOI": "10.1016/S0092-8674(94)90462-6", "volume": "78", "author": "KL Rock", "year": "1994", "unstructured": "Rock KL, Gramm C, Rothstein L et al (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761\u201371", "journal-title": "Cell"}, {"issue": "6", "key": "7_CR00077", "doi-asserted-by": "publisher", "first-page": "1649", "DOI": "10.1158/1078-0432.CCR-07-2218", "volume": "14", "author": "RZ Orlowski", "year": "2008", "unstructured": "Orlowski RZ, Kuhn DJ (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14(6):1649\u201357", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "7_CR00078", "doi-asserted-by": "publisher", "first-page": "1964", "DOI": "10.1038/leu.2009.173", "volume": "23", "author": "JJ Shah", "year": "2009", "unstructured": "Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23(11):1964\u201379", "journal-title": "Leukemia"}, {"issue": "5\u20136", "key": "7_CR00079", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1016/j.drudis.2010.01.008", "volume": "15", "author": "LR Dick", "year": "2010", "unstructured": "Dick LR, Fleming PE (2010) Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 15(5\u20136):243\u20139", "journal-title": "Drug Discov Today"}, {"issue": "4", "key": "7_CR000710", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1016/S0960-894X(98)00029-8", "volume": "8", "author": "J Adams", "year": "1998", "unstructured": "Adams J, Behnke M, Chen S et al (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8(4):333\u20138", "journal-title": "Bioorg Med Chem Lett"}, {"issue": "11", "key": "7_CR000711", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615\u201322", "journal-title": "Cancer Res"}, {"issue": "11", "key": "7_CR000712", "doi-asserted-by": "publisher", "first-page": "1746", "DOI": "10.7164/antibiotics.45.1746", "volume": "45", "author": "M Hanada", "year": "1992", "unstructured": "Hanada M, Sugawara K, Kaneta K et al (1992) Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 45(11):1746\u201352", "journal-title": "J Antibiot"}, {"key": "7_CR000713", "doi-asserted-by": "publisher", "first-page": "2283", "DOI": "10.1016/S0960-894X(99)00376-5", "volume": "9", "author": "N Sin", "year": "1999", "unstructured": "Sin N, Kim KB, Elofsson M et al (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9:2283\u20138", "journal-title": "Bioorg Med Chem Lett"}, {"issue": "18", "key": "7_CR000714", "doi-asserted-by": "publisher", "first-page": "10403", "DOI": "10.1073/pnas.96.18.10403", "volume": "96", "author": "L Meng", "year": "1999", "unstructured": "Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96(18):10403\u20138", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "23", "key": "7_CR000715", "doi-asserted-by": "publisher", "first-page": "3335", "DOI": "10.1016/S0960-894X(99)00612-5", "volume": "9", "author": "KB Kim", "year": "1999", "unstructured": "Kim KB, Myung J, Sin N, Crews CM (1999) Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett 9(23):3335\u201340", "journal-title": "Bioorg Med Chem Lett"}, {"issue": "9", "key": "7_CR000716", "doi-asserted-by": "publisher", "first-page": "3281", "DOI": "10.1182/blood-2007-01-065888", "volume": "110", "author": "DJ Kuhn", "year": "2007", "unstructured": "Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110(9):3281\u201390", "journal-title": "Blood"}, {"issue": "13", "key": "7_CR000717", "doi-asserted-by": "publisher", "first-page": "6383", "DOI": "10.1158/0008-5472.CAN-06-4086", "volume": "67", "author": "SD Demo", "year": "2007", "unstructured": "Demo SD, Kirk CJ, Aujay MA et al (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67(13):6383\u201391", "journal-title": "Cancer Res"}, {"issue": "16", "key": "7_CR000718", "doi-asserted-by": "publisher", "first-page": "3439", "DOI": "10.1182/blood-2009-05-223677", "volume": "114", "author": "F Parlati", "year": "2009", "unstructured": "Parlati F, Lee SJ, Aujay M et al (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114(16):3439\u201347", "journal-title": "Blood"}, {"issue": "7", "key": "7_CR000719", "doi-asserted-by": "publisher", "first-page": "2906", "DOI": "10.1182/blood-2007-12-130781", "volume": "112", "author": "L Paoluzzi", "year": "2008", "unstructured": "Paoluzzi L, Gonen M, Bhagat G et al (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112(7): 2906\u201316", "journal-title": "Blood"}, {"issue": "11", "key": "7_CR000720", "doi-asserted-by": "publisher", "first-page": "5350", "DOI": "10.1182/blood-2007-12-129833", "volume": "111", "author": "L Paoluzzi", "year": "2008", "unstructured": "Paoluzzi L, Gonen M, Gardner JR et al (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111(11):5350\u20138", "journal-title": "Blood"}, {"issue": "22", "key": "7_CR000721", "doi-asserted-by": "publisher", "first-page": "4478", "DOI": "10.1182/blood-2009-12-257261", "volume": "115", "author": "G Dasmahapatra", "year": "2010", "unstructured": "Dasmahapatra G, Lembersky D, Kramer L et al (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115(22):4478\u201387", "journal-title": "Blood"}, {"key": "7_CR000722", "first-page": "2854", "volume": "114", "author": "M DiLiberto", "year": "2009", "unstructured": "DiLiberto M, Huang X, Zewdu R et al (2009) Selective inhibition of CDK4/CDK6 sensitizes bone marrow myeloma cells for killing by proteasome inhibitors carfilzomib and PR-047 through cell cycle-dependent expression of pro-apoptotic Noxa and Bim. Blood (ASH Annual Meeting Abstract) 114:2854", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"key": "7_CR000723", "first-page": "299", "volume": "114", "author": "X Huang", "year": "2009", "unstructured": "Huang X, Di Liberto M, Ely S et al (2009) Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4. Blood (ASH Annual Meeting Abstract) 114:299", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "22", "key": "7_CR000724", "doi-asserted-by": "publisher", "first-page": "7085", "DOI": "10.1158/1078-0432.CCR-09-0822", "volume": "15", "author": "OA O\u2019Connor", "year": "2009", "unstructured": "O\u2019Connor OA, Stewart AK, Vallone M et al (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085\u201391", "journal-title": "Clin Cancer Res"}, {"key": "7_CR000725", "first-page": "2657", "volume": "112", "author": "S Arastu-Kapur", "year": "2008", "unstructured": "Arastu-Kapur S, Shenk K, Parlati F, Bennett MK (2008) Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib. Blood (ASH Annual Meeting Abstract) 112:2657", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"key": "7_CR000726", "first-page": "411", "volume": "110", "author": "M Alsina", "year": "2007", "unstructured": "Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A (2007) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstract ) 110:411", "journal-title": "Blood (ASH Annual Meeting Abstract )"}, {"key": "7_CR000727", "unstructured": "Jagannath S, Vij R, Stewart K et al (2009) Final results of PX-171\u2013003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 27(15s), ASCO Annual Meeting Abstract 8504"}, {"key": "7_CR000728", "unstructured": "http://www.onyx-pharm.com/view.cfm/690/Onyx-Pharmaceuticals-Announces-Positive-Top-Line-Carfilzomib-Data-from-Phase-2b-Study\n                  \n                ; 2010."}, {"key": "7_CR000729", "first-page": "303", "volume": "114", "author": "D Siegel", "year": "2009", "unstructured": "Siegel D, Wang L, Orlowski RZ et al (2009) PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM); updated results from the bortezomib-treated cohort. Blood (ASH Annual Meeting Abstract) 114:303", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"key": "7_CR000730", "first-page": "302", "volume": "114", "author": "L Wang", "year": "2009", "unstructured": "Wang L, Siegel D, Kaufman JL et al (2009) Updated results of bortezomib-na\u00efve patients in PX-171-004, an ongoing open-label, phase II study of single-agent carfilzomib (CFZ) in patients with relapsed or refractory myeloma (MM). Blood (ASH Annual Meeting Abstract) 114:302", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "34", "key": "7_CR000731", "doi-asserted-by": "publisher", "first-page": "5713", "DOI": "10.1200/JCO.2009.22.2679", "volume": "27", "author": "PG Richardson", "year": "2009", "unstructured": "Richardson PG, Weller E, Jagannath S et al (2009) Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 27(34):5713\u20139", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "7_CR000732", "doi-asserted-by": "publisher", "first-page": "679", "DOI": "10.1182/blood-2010-02-268862", "volume": "116", "author": "PG Richardson", "year": "2010", "unstructured": "Richardson PG, Weller E, Lonial S et al (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679\u201386", "journal-title": "Blood"}, {"key": "7_CR000733", "unstructured": "Bensinger W, Wang M, Orlowski RZ et al (2010) Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM). J Clin Oncol 28(15s), ASCO Annual Meeting Abstract 8029", "DOI": "10.1200/jco.2010.28.15_suppl.8029", "doi-asserted-by": "crossref"}, {"key": "7_CR000734", "first-page": "3671", "volume": "112", "author": "T Muchamuel", "year": "2008", "unstructured": "Muchamuel T, Aujay M, Bennett MK et al (2008) Preclinical pharmacology and in vitro characterization of PR-047, an oral inhibitor of the 20S proteasome. Blood (ASH Annual Meeting Abstract) 112:3671", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "9", "key": "7_CR000735", "doi-asserted-by": "publisher", "first-page": "3028", "DOI": "10.1021/jm801329v", "volume": "52", "author": "HJ Zhou", "year": "2009", "unstructured": "Zhou HJ, Aujay MA, Bennett MK et al (2009) Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 52(9):3028\u201338", "journal-title": "J Med Chem"}, {"key": "7_CR000736", "first-page": "4910", "volume": "114", "author": "T Muchamuel", "year": "2009", "unstructured": "Muchamuel T, Kapur S, Kirk CJ et al (2009) Dose intensive administration of PR-047, a novel orally bioavailable inhibitor of the 20S proteasome, is well tolerated in experimental animals. Blood (ASH Annual Meeting Abstract) 114:4910", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "20", "key": "7_CR000737", "doi-asserted-by": "publisher", "first-page": "4051", "DOI": "10.1182/blood-2009-09-243402", "volume": "115", "author": "AM Roccaro", "year": "2010", "unstructured": "Roccaro AM, Sacco A, Aujay M et al (2010) Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 115(20):4051\u201360", "journal-title": "Blood"}, {"key": "7_CR000738", "first-page": "3670", "volume": "112", "author": "X Huang", "year": "2008", "unstructured": "Huang X, Bailey K, Di Liberto M et al (2008) Induction of sustained early G1 arrest by selective inhibition of CDK4 and CDK6 primes myeloma cells for synergistic killing by proteasome inhibitors carfilzomib and PR-047. Blood (ASH Annual Meeting Abstract) 112:3670", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "3", "key": "7_CR000739", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1002/anie.200390115", "volume": "42", "author": "RH Feling", "year": "2003", "unstructured": "Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W (2003) Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42(3):355\u20137", "journal-title": "Angew Chem Int Ed Engl"}, {"issue": "15", "key": "7_CR000740", "doi-asserted-by": "publisher", "first-page": "8545", "DOI": "10.1074/jbc.273.15.8545", "volume": "273", "author": "G Fenteany", "year": "1998", "unstructured": "Fenteany G, Schreiber SL (1998) Lactacystin, proteasome function, and cell fate. J Biol Chem 273(15):8545\u20138", "journal-title": "J Biol Chem"}, {"issue": "11", "key": "7_CR000741", "doi-asserted-by": "publisher", "first-page": "3882", "DOI": "10.1021/jo100432g", "volume": "75", "author": "T Ling", "year": "2010", "unstructured": "Ling T, Potts BC, Macherla VR (2010) Concise formal synthesis of (\u2212)-salinosporamide A (marizomib) using a regio- and stereoselective epoxidation and reductive oxirane ring-opening strategy. J Org Chem 75(11):3882\u20135", "journal-title": "J Org Chem"}, {"issue": "5", "key": "7_CR000742", "doi-asserted-by": "publisher", "first-page": "407", "DOI": "10.1016/j.ccr.2005.10.013", "volume": "8", "author": "D Chauhan", "year": "2005", "unstructured": "Chauhan D, Catley L, Li G et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8(5):407\u201319", "journal-title": "Cancer Cell"}, {"issue": "4", "key": "7_CR000743", "doi-asserted-by": "publisher", "first-page": "550", "DOI": "10.1111/j.1365-2141.2010.08144.x", "volume": "149", "author": "AV Singh", "year": "2010", "unstructured": "Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC (2010) Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol 149(4):550\u20139", "journal-title": "Br J Haematol"}, {"issue": "7", "key": "7_CR000744", "doi-asserted-by": "publisher", "first-page": "2286", "DOI": "10.1182/blood-2007-04-084996", "volume": "110", "author": "KS Ahn", "year": "2007", "unstructured": "Ahn KS, Sethi G, Chao TH et al (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood 110(7):2286\u201395", "journal-title": "Blood"}, {"issue": "3", "key": "7_CR000745", "doi-asserted-by": "publisher", "first-page": "1654", "DOI": "10.1182/blood-2007-08-105601", "volume": "111", "author": "D Chauhan", "year": "2008", "unstructured": "Chauhan D, Singh A, Brahmandam M et al (2008) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 111(3):1654\u201364", "journal-title": "Blood"}, {"issue": "9", "key": "7_CR000746", "doi-asserted-by": "publisher", "first-page": "4752", "DOI": "10.1182/blood-2007-11-120972", "volume": "111", "author": "AM Roccaro", "year": "2008", "unstructured": "Roccaro AM, Leleu X, Sacco A et al (2008) Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 111(9):4752\u201363", "journal-title": "Blood"}, {"issue": "4", "key": "7_CR000747", "doi-asserted-by": "publisher", "first-page": "834", "DOI": "10.1182/blood-2009-03-213009", "volume": "115", "author": "D Chauhan", "year": "2010", "unstructured": "Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC (2010) Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 115(4):834\u201345", "journal-title": "Blood"}, {"key": "7_CR000748", "first-page": "667", "volume": "110", "author": "X Huang", "year": "2007", "unstructured": "Huang X, Louie T, Di Liberto M et al (2007) Targeting cdk4/6 in combination therapy overcomes proteasome inhibitor resistance in multiple myeloma through synergistic mitochondria depolarization. Blood (ASH Annual Meeting Abstracts) 110:667", "journal-title": "Blood (ASH Annual Meeting Abstracts)"}, {"key": "7_CR000749", "first-page": "4504", "volume": "110", "author": "R Kurzrock", "year": "2007", "unstructured": "Kurzrock R, Hamlin P, Younes A et al (2007) Phase 1 clinical trial of a novel proteasome inhibitor (NPI-0052) in patients with lymphomas and solid tumors. Blood (ASH Annual Meeting Abstract) 110:4504", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"key": "7_CR000750", "first-page": "4939", "volume": "112", "author": "PA Hamlin", "year": "2008", "unstructured": "Hamlin PA, Aghajanian C, Hong D et al (2008) First-in-human phase 1 dose escalation study of NPI-0052, a novel proteasome inhibitor, in patients with lymphoma and solid tumor. Blood (ASH Annual Meeting Abstracts) 112:4939", "journal-title": "Blood (ASH Annual Meeting Abstracts)"}, {"issue": "15s", "key": "7_CR000751", "first-page": "3516", "volume": "27", "author": "PA Hamlin", "year": "2009", "unstructured": "Hamlin PA, Aghajanian C, Younes A et al (2009) First-in-human phase I study of the novel structure proteasome inhibitor NPI-0052. J Clin Oncol 27(15s):3516, ASCO Annual Meeting Abstract", "journal-title": "J Clin Oncol"}, {"key": "7_CR000752", "first-page": "4934", "volume": "112", "author": "T Price", "year": "2008", "unstructured": "Price T, Padrik P, Townsend A et al (2008) Clinical trial of NPI-0052 (2nd generation proteasome inhibitor) in patients having advanced malignancies with expanded RP2D cohorts in lymphoma and CLL. Blood 112:4934, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"issue": "15s", "key": "7_CR000753", "first-page": "3582", "volume": "27", "author": "AR Townsend", "year": "2009", "unstructured": "Townsend AR, Millward M, Price T et al (2009) Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol 27(15s):3582, ASCO Annual Meeting Abstract", "journal-title": "J Clin Oncol"}, {"key": "7_CR000754", "first-page": "2693", "volume": "114", "author": "A Spencer", "year": "2009", "unstructured": "Spencer A, Millward M, Mainwaring P et al (2009) Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052. Blood 114:2693, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"key": "7_CR000755", "first-page": "431", "volume": "114", "author": "P Richardson", "year": "2009", "unstructured": "Richardson P, Hofmeister C, Jakubowiak A et al (2009) Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstract) 114:431", "journal-title": "Blood (ASH Annual Meeting Abstract)"}, {"issue": "4", "key": "7_CR000756", "doi-asserted-by": "publisher", "first-page": "1068", "DOI": "10.1021/jm7010589", "volume": "51", "author": "BD Dorsey", "year": "2008", "unstructured": "Dorsey BD, Iqbal M, Chatterjee S et al (2008) Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 51(4):1068\u201372", "journal-title": "J Med Chem"}, {"issue": "5", "key": "7_CR000757", "doi-asserted-by": "publisher", "first-page": "2765", "DOI": "10.1182/blood-2007-07-100651", "volume": "111", "author": "R Piva", "year": "2008", "unstructured": "Piva R, Ruggeri B, Williams M et al (2008) CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111(5):2765\u201375", "journal-title": "Blood"}, {"issue": "6", "key": "7_CR000758", "doi-asserted-by": "crossref", "first-page": "249", "DOI": "10.3851/IMP1632", "volume": "20", "author": "PC Trippier", "year": "2010", "unstructured": "Trippier PC, McGuigan C, Balzarini J (2010) Phenylboronic-acid-based carbohydrate binders as antiviral therapeutics: monophenylboronic acids. Antivir Chem Chemother 20(6):249\u201357", "journal-title": "Antivir Chem Chemother"}, {"issue": "4", "key": "7_CR000759", "doi-asserted-by": "publisher", "first-page": "569", "DOI": "10.1111/j.1365-2141.2009.08008.x", "volume": "148", "author": "E Sanchez", "year": "2010", "unstructured": "Sanchez E, Li M, Steinberg JA et al (2010) The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 148(4):569\u201381", "journal-title": "Br J Haematol"}, {"key": "7_CR000760", "unstructured": "Marangon E, Sala F, Sessa C, et al. Pharmacokinetics and pharmacodynamics of the new proteasome inhibitor CEP-18770 Preliminary results from a phase I study. J Am Soc Mass Spectrom 2009;20(5, Supplement 1):Annual ASMS Meeting Abstract 452"}, {"issue": "5", "key": "7_CR000761", "doi-asserted-by": "publisher", "first-page": "1970", "DOI": "10.1158/0008-5472.CAN-09-2766", "volume": "70", "author": "E Kupperman", "year": "2010", "unstructured": "Kupperman E, Lee EC, Cao Y et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 70(5):1970\u201380", "journal-title": "Cancer Res"}, {"key": "7_CR000762", "doi-asserted-by": "publisher", "first-page": "3724", "DOI": "10.1182/blood-2009-08-238139", "volume": "114", "author": "J Donelan", "year": "2009", "unstructured": "Donelan J, Bannerman B, Bano K et al (2009) Antitumor activity of MLN9708, a second-generation proteasome inhibitor, in preclinical models of lymphoma. Blood 114:3724, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"key": "7_CR000763", "first-page": "1834", "volume": "114", "author": "E Lee", "year": "2009", "unstructured": "Lee E, Bannerman B, Fitzgerald M et al (2009) MLN9708 elicits pharmacodynamic response in the bone marrow compartment and has strong antitumor activity in a preclinical intraosseous model of plasma cell malignancy. Blood 114:1834, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"key": "7_CR000764", "first-page": "3835", "volume": "114", "author": "M Fitzgerald", "year": "2009", "unstructured": "Fitzgerald M, Cao Y, Bannerman B et al (2009) Evaluating the antitumor activity of MLN9708 in a disseminated mouse model of double transgenic iMyc Ca/Bcl-XL plasma cell malignancy. Blood 114:3835, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"key": "7_CR000765", "first-page": "3849", "volume": "114", "author": "S Janz", "year": "2009", "unstructured": "Janz S, Van Ness BG, Neppalli V et al (2009) The novel proteasome inhibitor MLN9708 demonstrates efficacy in a genetically-engineered mouse model of denovo plasma cell malignancy. Blood 114:3849, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"key": "7_CR000766", "doi-asserted-by": "crossref", "first-page": "3071", "DOI": "10.1200/jco.2010.28.15_suppl.3071", "volume": "28", "author": "ET Rodler", "year": "2010", "unstructured": "Rodler ET, Infante JR, Siu LL et al (2010) First-in-human, phase I dose-escalation study of investigational drug MLN9708, a second-generation proteasome inhibitor, in advanced nonhematologic malignancies. J Clin Oncol 28:3071, ASCO Annual Meeting Abstract", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "7_CR000767", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1016/j.coi.2003.11.004", "volume": "16", "author": "PM Kloetzel", "year": "2004", "unstructured": "Kloetzel PM, Ossendorp F (2004) Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 16(1):76\u201381", "journal-title": "Curr Opin Immunol"}, {"issue": "19", "key": "7_CR000768", "doi-asserted-by": "publisher", "first-page": "4667", "DOI": "10.1182/blood-2008-07-171637", "volume": "113", "author": "DJ Kuhn", "year": "2009", "unstructured": "Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ (2009) Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113(19):4667\u201376", "journal-title": "Blood"}, {"issue": "7", "key": "7_CR000769", "doi-asserted-by": "publisher", "first-page": "781", "DOI": "10.1038/nm.1978", "volume": "15", "author": "T Muchamuel", "year": "2009", "unstructured": "Muchamuel T, Basler M, Aujay MA et al (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781\u20137", "journal-title": "Nat Med"}, {"issue": "13", "key": "7_CR000770", "first-page": "4653", "volume": "9", "author": "M Trikha", "year": "2003", "unstructured": "Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9(13):4653\u201365", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "7_CR000771", "first-page": "385", "volume": "132", "author": "H Yasui", "year": "2006", "unstructured": "Yasui H, Hideshima T, Richardson PG, Anderson KC (2006) Novel therapeutic strategies \u00adtargeting growth factor signalling cascades in multiple myeloma. Br J Haematol 132(4): 385\u201397", "journal-title": "Br J Haematol"}, {"issue": "9", "key": "7_CR000772", "doi-asserted-by": "publisher", "first-page": "1911", "DOI": "10.1002/cncr.22999", "volume": "110", "author": "DS Hong", "year": "2007", "unstructured": "Hong DS, Angelo LS, Kurzrock R (2007) Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics. Cancer 110(9):1911\u201328", "journal-title": "Cancer"}, {"issue": "21", "key": "7_CR000773", "doi-asserted-by": "publisher", "first-page": "6469", "DOI": "10.1158/1078-0432.CCR-07-1293", "volume": "13", "author": "PM Voorhees", "year": "2007", "unstructured": "Voorhees PM, Chen Q, Kuhn DJ et al (2007) Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 13(21):6469\u201378", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "7_CR000774", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1111/j.1365-2141.2009.07647.x", "volume": "145", "author": "PM Voorhees", "year": "2009", "unstructured": "Voorhees PM, Chen Q, Small GW et al (2009) Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 145(4):481\u201390", "journal-title": "Br J Haematol"}, {"key": "7_CR000775", "doi-asserted-by": "publisher", "first-page": "612", "DOI": "10.1182/blood-2009-05-221267", "volume": "114", "author": "AV Singh", "year": "2009", "unstructured": "Singh AV, Bandi M, Aujay M et al (2009) PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7 blocks multiple myeloma cell growth both in vitro and In vivo. Blood 114:612, ASH Annual Meeting Abstract", "journal-title": "Blood"}, {"issue": "6", "key": "7_CR000776", "doi-asserted-by": "publisher", "first-page": "1195", "DOI": "10.1002/cncr.20888", "volume": "103", "author": "S Jagannath", "year": "2005", "unstructured": "Jagannath S, Barlogie B, Berenson JR et al (2005) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 103(6):1195\u2013200", "journal-title": "Cancer"}, {"issue": "6", "key": "7_CR000777", "doi-asserted-by": "publisher", "first-page": "2604", "DOI": "10.1182/blood-2006-09-046409", "volume": "109", "author": "AA Chanan-Khan", "year": "2007", "unstructured": "Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109(6):2604\u20136", "journal-title": "Blood"}, {"issue": "6", "key": "7_CR000778", "doi-asserted-by": "publisher", "first-page": "352", "DOI": "10.3816/CLM.2008.n.051", "volume": "8", "author": "J Blade", "year": "2008", "unstructured": "Blade J, Sonneveld P, SanMiguel F et al (2008) Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8(6):352\u20135", "journal-title": "Clin Lymphoma Myeloma"}], "container-title": ["Advances in Biology and Therapy of Multiple Myeloma"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4614-5260-7_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T19:40:07Z", "timestamp": 1557430807000}, "score": 23.623716, "issued": {"date-parts": [[2012, 11, 1]]}, "ISBN": ["9781461452591", "9781461452607"], "references-count": 78, "URL": "http://dx.doi.org/10.1007/978-1-4614-5260-7_7", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:57:50Z", "timestamp": 1574524670885}, "publisher-location": "Totowa, NJ", "reference-count": 59, "publisher": "Humana Press", "isbn-type": [{"value": "9781617374524", "type": "print"}, {"value": "9781592597949", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2004]]}, "DOI": "10.1007/978-1-59259-794-9_14", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 28]], "date-time": "2012-12-28T15:58:01Z", "timestamp": 1356710281000}, "page": "171-180", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Anthracyclines and Bortezomib"], "prefix": "10.1007", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "14_CR1", "author": "CEJ Riggs", "first-page": "345", "year": "1997", "unstructured": "Riggs CEJ. Antitumor antibiotics and related compounds. In: The Chemotherapy Source Book. (Perry MC, ed). Williams & Wilkins, Baltimore, 1997:345\u2013386.", "volume-title": "The Chemotherapy Source Book"}, {"key": "14_CR2", "first-page": "2467", "volume": "61", "author": "K Kiyomiya", "year": "2001", "unstructured": "Kiyomiya K, et al. Mechanism of specific nuclear transport of Adriamycin: the mode of nuclear translocation of Adriamycin-proteasome complex. Cancer Res 2001;61:2467\u20132471.", "journal-title": "Cancer Res"}, {"key": "14_CR3", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.1016/S0024-3205(98)00151-9", "volume": "62", "author": "K Kiyomiya", "year": "1998", "unstructured": "Kiyomiya K, et al. Proteasome is a carrier to translocate doxorubicin from cytoplasm into nucleus. Life Sci 1998;62:1853\u20131860.", "journal-title": "Life Sci"}, {"key": "14_CR4", "doi-asserted-by": "publisher", "first-page": "7071", "DOI": "10.1073/pnas.87.18.7071", "volume": "87", "author": "A Kumatori", "year": "1990", "unstructured": "Kumatori A, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990;87:7071\u20137075.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "14_CR5", "first-page": "6677", "volume": "51", "author": "H Kanayama", "year": "1991", "unstructured": "Kanayama H, et al. Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Res 1991;51:6677\u20136685.", "journal-title": "Cancer Res"}, {"key": "14_CR6", "first-page": "18100", "volume": "267", "author": "N Shimbara", "year": "1992", "unstructured": "Shimbara N, et al. Regulation of gene expression of proteasomes (multi-protease complexes) during growth and differentiation of human hematopoietic cells. J Biol Chem 1992;267:18100\u201318109.", "journal-title": "J Biol Chem"}, {"key": "14_CR7", "doi-asserted-by": "publisher", "first-page": "2830", "DOI": "10.1182/blood.V97.9.2830", "volume": "97", "author": "O Ciftci", "year": "2001", "unstructured": "Ciftci O, et al. Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after Adriamycin treatment. Blood 2001;97:2830\u20132838.", "journal-title": "Blood"}, {"key": "14_CR8", "doi-asserted-by": "publisher", "first-page": "8643", "DOI": "10.1128/MCB.20.23.8643-8654.2000", "volume": "20", "author": "C Poizat", "year": "2000", "unstructured": "Poizat C, et al. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 2000;20:8643\u20138654.", "journal-title": "Mol Cell Biol"}, {"key": "14_CR9", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.1016/0304-4165(92)90070-B", "volume": "1117", "author": "T Isoe", "year": "1992", "unstructured": "Isoe T, et al. Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin. Biochim Biophys Acta 1992;1117:131\u2013135.", "journal-title": "Biochim Biophys Acta"}, {"key": "14_CR10", "doi-asserted-by": "publisher", "first-page": "16455", "DOI": "10.1074/jbc.271.28.16455", "volume": "271", "author": "ME Figueiredo-Pereira", "year": "1996", "unstructured": "Figueiredo-Pereira ME, et al. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome [published erratum appears in J Biol Chem 1996;271:23602]. J Biol Chem 1996;271:16455\u201316459.", "journal-title": "J Biol Chem"}, {"key": "14_CR11", "doi-asserted-by": "publisher", "first-page": "173", "DOI": "10.1007/BF00172077", "volume": "1", "author": "C Karanes", "year": "1983", "unstructured": "Karanes C, et al. Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. Invest New Drugs 1983;1:173\u2013179.", "journal-title": "Invest New Drugs"}, {"key": "14_CR12", "doi-asserted-by": "publisher", "first-page": "30470", "DOI": "10.1074/jbc.272.48.30470", "volume": "272", "author": "V Spataro", "year": "1997", "unstructured": "Spataro V, et al. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit. J Biol Chem 1997;272:30470\u201330475.", "journal-title": "J Biol Chem"}, {"key": "14_CR13", "doi-asserted-by": "publisher", "first-page": "241", "DOI": "10.1172/JCI11991", "volume": "107", "author": "AS Baldwin", "year": "2001", "unstructured": "Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001;107:241\u2013246.", "journal-title": "J Clin Invest"}, {"key": "14_CR14", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1038/10577", "volume": "5", "author": "CY Wang", "year": "1999", "unstructured": "Wang CY, et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412\u2013417.", "journal-title": "Nat Med"}, {"key": "14_CR15", "doi-asserted-by": "publisher", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "VJ Palombella", "year": "1994", "unstructured": "Palombella VJ, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773\u2013785.", "journal-title": "Cell"}, {"key": "14_CR16", "first-page": "3535", "volume": "61", "author": "JC Cusack Jr", "year": "2001", "unstructured": "Cusack JC, Jr., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535\u20133540.", "journal-title": "Cancer Res"}, {"key": "14_CR17", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1016/S0360-3016(01)01446-8", "volume": "50", "author": "SM Russo", "year": "2001", "unstructured": "Russo SM, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001;50:183\u2013193.", "journal-title": "Int J Radiat Oncol Biol Phys"}, {"key": "14_CR18", "doi-asserted-by": "publisher", "first-page": "14914", "DOI": "10.1074/jbc.272.23.14914", "volume": "272", "author": "KC Das", "year": "1997", "unstructured": "Das KC, et al. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J Biol Chem 1997;272:14914\u201314920.", "journal-title": "J Biol Chem"}, {"key": "14_CR19", "doi-asserted-by": "publisher", "first-page": "27864", "DOI": "10.1074/jbc.M201519200", "volume": "277", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, et al. Evidence that inhibition of p44/42 mitogen activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002;277:27864\u201327871.", "journal-title": "J Biol Chem"}, {"key": "14_CR20", "doi-asserted-by": "publisher", "first-page": "1843", "DOI": "10.1038/sj.leu.2401222", "volume": "12", "author": "P Dent", "year": "1998", "unstructured": "Dent P, et al. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998;12:1843\u20131850.", "journal-title": "Leukemia"}, {"key": "14_CR21", "doi-asserted-by": "crossref", "first-page": "2435", "DOI": "10.1128/MCB.19.4.2435", "volume": "19", "author": "HJ Schaeffer", "year": "1999", "unstructured": "Schaeffer HJ, et al. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999;19:2435\u20132444.", "journal-title": "Mol Cell Biol"}, {"key": "14_CR22", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1006/excr.2000.4836", "volume": "256", "author": "TG Cross", "year": "2000", "unstructured": "Cross TG, et al. Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000;256:34\u201341.", "journal-title": "Exp Cell Res"}, {"key": "14_CR23", "doi-asserted-by": "publisher", "first-page": "1358", "DOI": "10.1126/science.286.5443.1358", "volume": "286", "author": "A Bonni", "year": "1999", "unstructured": "Bonni A, et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms [see comments]. Science 1999;286:1358\u20131362.", "journal-title": "Science"}, {"key": "14_CR24", "doi-asserted-by": "publisher", "first-page": "6635", "DOI": "10.1038/sj.onc.1203076", "volume": "18", "author": "X Fang", "year": "1999", "unstructured": "Fang X, et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999;18:6635\u20136640.", "journal-title": "Oncogene"}, {"key": "14_CR25", "doi-asserted-by": "publisher", "first-page": "724", "DOI": "10.1006/bbrc.1999.1475", "volume": "264", "author": "MS Jan", "year": "1999", "unstructured": "Jan MS, et al. Bad overexpression sensitizes NIH/3T3 cells to undergo apoptosis which involves caspase activation and ERK inactivation. Biochem Biophys Res Commun 1999;264:724\u2013729.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "14_CR26", "doi-asserted-by": "publisher", "first-page": "5418", "DOI": "10.1093/emboj/19.20.5418", "volume": "19", "author": "TH Holmstrom", "year": "2000", "unstructured": "Holmstrom TH, et al. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J 2000;19:5418\u20135428.", "journal-title": "EMBO J"}, {"key": "14_CR27", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1161/01.RES.86.1.8", "volume": "86", "author": "M Arai", "year": "2000", "unstructured": "Arai M, et al. Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca (2+)-ATPase gene transcription. Circ Res 2000;86:8\u201314.", "journal-title": "Circ Res"}, {"key": "14_CR28", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1016/0306-3623(95)02013-6", "volume": "27", "author": "D Nielsen", "year": "1996", "unstructured": "Nielsen D, et al. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27:251\u2013255.", "journal-title": "Gen Pharmacol"}, {"key": "14_CR29", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1046/j.1365-2362.1999.00495.x", "volume": "29", "author": "J Robert", "year": "1999", "unstructured": "Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 1999;29:536\u2013545.", "journal-title": "Eur J Clin Invest"}, {"key": "14_CR30", "doi-asserted-by": "crossref", "first-page": "835", "DOI": "10.1200/JCO.1994.12.4.835", "volume": "12", "author": "NL Bartlett", "year": "1994", "unstructured": "Bartlett NL, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835\u2013842.", "journal-title": "J Clin Oncol"}, {"key": "14_CR31", "first-page": "1451", "volume": "4", "author": "E Warner", "year": "1998", "unstructured": "Warner E, et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 1998;4:1451\u20131457.", "journal-title": "Clin Cancer Res"}, {"key": "14_CR32", "doi-asserted-by": "publisher", "first-page": "14671", "DOI": "10.1074/jbc.273.24.14671", "volume": "273", "author": "TW Loo", "year": "1998", "unstructured": "Loo TW, et al. Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 1998;273:14671\u201314674.", "journal-title": "J Biol Chem"}, {"key": "14_CR33", "doi-asserted-by": "crossref", "first-page": "1724", "DOI": "10.1096/fasebj.13.13.1724", "volume": "13", "author": "TW Loo", "year": "1999", "unstructured": "Loo TW, et al. The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 1999;13:1724\u20131732.", "journal-title": "FASEB J"}, {"key": "14_CR34", "first-page": "235", "volume": "2", "author": "WT Beck", "year": "1991", "unstructured": "Beck WT, et al. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 1991;2:235\u2013244.", "journal-title": "Semin Cancer Biol"}, {"key": "14_CR35", "first-page": "169", "volume": "14", "author": "A Tomida", "year": "1999", "unstructured": "Tomida A, et al. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999;14:169\u2013177.", "journal-title": "Anticancer Drug Des"}, {"key": "14_CR36", "doi-asserted-by": "publisher", "first-page": "24842", "DOI": "10.1074/jbc.271.40.24842", "volume": "271", "author": "T Nakajima", "year": "1996", "unstructured": "Nakajima T, et al. Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996;271:24842\u201324849.", "journal-title": "J Biol Chem"}, {"key": "14_CR37", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1002/(SICI)1097-4652(199907)180:1<97::AID-JCP11>3.0.CO;2-Y", "volume": "180", "author": "HD Kim", "year": "1999", "unstructured": "Kim HD, et al. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999;180:97\u2013104.", "journal-title": "J Cell Physiol"}, {"key": "14_CR38", "first-page": "2429", "volume": "60", "author": "Y Ogiso", "year": "2000", "unstructured": "Ogiso Y, et al. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 2000;60:2429\u20132434.", "journal-title": "Cancer Res"}, {"key": "14_CR39", "first-page": "S47", "volume": "23", "author": "PJ Smith", "year": "1994", "unstructured": "Smith PJ, et al. Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer Suppl 1994;23:S47\u2013S51.", "journal-title": "Br J Cancer Suppl"}, {"key": "14_CR40", "doi-asserted-by": "publisher", "first-page": "40652", "DOI": "10.1074/jbc.M104009200", "volume": "276", "author": "Y Mao", "year": "2001", "unstructured": "Mao Y, et al. 26 S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem 2001;276:40652\u201340658.", "journal-title": "J Biol Chem"}, {"key": "14_CR41", "doi-asserted-by": "publisher", "first-page": "913", "DOI": "10.1182/blood.V98.4.913", "volume": "98", "author": "G Laurent", "year": "2001", "unstructured": "Laurent G, et al. Signaling pathways activated by daunorubicin. Blood 2001;98:913\u2013924.", "journal-title": "Blood"}, {"key": "14_CR42", "doi-asserted-by": "publisher", "first-page": "6373", "DOI": "10.1074/jbc.273.11.6373", "volume": "273", "author": "AB Meriin", "year": "1998", "unstructured": "Meriin AB, et al. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis. J Biol Chem 1998;273:6373\u20136379.", "journal-title": "J Biol Chem"}, {"key": "14_CR43", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "14_CR44", "doi-asserted-by": "publisher", "first-page": "8545", "DOI": "10.1074/jbc.273.15.8545", "volume": "273", "author": "G Fenteany", "year": "1998", "unstructured": "Fenteany G, et al. Lactacystin, proteasome function, and cell fate. J Biol Chem 1998;273:8545\u20138548", "journal-title": "J Biol Chem"}, {"key": "14_CR45", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.1007/s002800000196", "volume": "47", "author": "R Yuan", "year": "2001", "unstructured": "Yuan R, et al. P53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemother Pharmacol 2001;47:161\u2013169.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "14_CR46", "first-page": "3059", "volume": "58", "author": "ZP Lin", "year": "1998", "unstructured": "Lin ZP, et al. Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res 1998;58:3059\u20133065.", "journal-title": "Cancer Res"}, {"key": "14_CR47", "doi-asserted-by": "publisher", "first-page": "8029", "DOI": "10.1074/jbc.M009831200", "volume": "276", "author": "M Tabata", "year": "2001", "unstructured": "Tabata M, et al. Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma. J Biol Chem 2001;276:8029\u20138036.", "journal-title": "J Biol Chem"}, {"key": "14_CR48", "first-page": "559", "volume": "60", "author": "LM Brandes", "year": "2001", "unstructured": "Brandes LM, et al. Reversal of physiological stress-induced resistance to topoisomerase II inhibitors using an inducible phosphorylation site-deficient mutant of I kappa B alpha. Mol Pharmacol 2001;60:559\u2013567.", "journal-title": "Mol Pharmacol"}, {"key": "14_CR49", "doi-asserted-by": "crossref", "first-page": "559", "DOI": "10.1210/edrv-16-5-559", "volume": "16", "author": "RB Dickson", "year": "1995", "unstructured": "Dickson RB, et al. Growth factors in breast cancer. Endocr Rev 1995;16:559\u2013589.", "journal-title": "Endocr Rev"}, {"key": "14_CR50", "doi-asserted-by": "publisher", "first-page": "384", "DOI": "10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R", "volume": "89", "author": "H Mueller", "year": "2000", "unstructured": "Mueller H, et al. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000;89:384\u2013388.", "journal-title": "Int J Cancer"}, {"key": "14_CR51", "first-page": "2638", "volume": "5", "author": "BA Teicher", "year": "1999", "unstructured": "Teicher BA, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin CancerRes 1999;5:2638\u20132645.", "journal-title": "Clin CancerRes"}, {"key": "14_CR52", "author": "JP Thomas", "year": "2002", "unstructured": "Thomas JP, et al. A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin. In: Proceedings of the American Society of Clinical Oncology, Orlando, FL, 2002, vol 21.", "volume-title": "Proceedings of the American Society of Clinical Oncology"}, {"key": "14_CR53", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1053/sonc.2001.26436", "volume": "28", "author": "JA Sparano", "year": "2001", "unstructured": "Sparano JA, et al. Liposomal anthracyclines for breast cancer. Semin Oncol 2001;28:32\u201340.", "journal-title": "Semin Oncol"}, {"issue": "suppl 9", "key": "14_CR54", "doi-asserted-by": "publisher", "first-page": "S15", "DOI": "10.1016/S0959-8049(01)00330-6", "volume": "37", "author": "F Muggia", "year": "2001", "unstructured": "Muggia F, et al. Phase III data on Caelyx in ovarian cancer. Eur J Cancer 2001;37(suppl 9):S15\u2013S18", "journal-title": "Eur J Cancer"}, {"key": "14_CR55", "doi-asserted-by": "publisher", "first-page": "156", "DOI": "10.1007/s11912-001-0016-5", "volume": "3", "author": "FM Muggia", "year": "2001", "unstructured": "Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001;3:156\u2013162.", "journal-title": "Curr Oncol Rep"}, {"key": "14_CR56", "doi-asserted-by": "publisher", "first-page": "1037", "DOI": "10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z", "volume": "89", "author": "O Lyass", "year": "2000", "unstructured": "Lyass O, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000 89:1037\u20131047.", "journal-title": "Cancer"}, {"key": "14_CR57", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1023/A:1008216430806", "volume": "9", "author": "G Berry", "year": "1998", "unstructured": "Berry G, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998;9:711\u2013716.", "journal-title": "Ann Oncol"}, {"key": "14_CR58", "doi-asserted-by": "publisher", "first-page": "900", "DOI": "10.1056/NEJM199809243391307", "volume": "339", "author": "PK Singal", "year": "1998", "unstructured": "Singal PK, et al. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900\u2013905.", "journal-title": "N Engl J Med"}, {"key": "14_CR59", "author": "TE Stinchcombe", "year": "2000", "unstructured": "Stinchcombe TE, et al. PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies. In: Proceedings of the American Society of Hematology, San Francisco, CA, 2000, vol 96.", "volume-title": "Proceedings of the American Society of Hematology"}], "container-title": ["Proteasome Inhibitors in Cancer Therapy"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-59259-794-9_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 10]], "date-time": "2019-05-10T02:20:12Z", "timestamp": 1557454812000}, "score": 23.623716, "issued": {"date-parts": [[2004]]}, "ISBN": ["9781617374524", "9781592597949"], "references-count": 59, "URL": "http://dx.doi.org/10.1007/978-1-59259-794-9_14", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T01:58:38Z", "timestamp": 1574215118682}, "publisher-location": "New York", "reference-count": 178, "publisher": "Springer-Verlag", "isbn-type": [{"value": "0387233849", "type": "print"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1007/0-387-23695-3_12", "type": "book-chapter", "created": {"date-parts": [[2006, 6, 19]], "date-time": "2006-06-19T09:49:02Z", "timestamp": 1150710542000}, "page": "243-274", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Targeting the Proteasome in Cancer Therapy"], "prefix": "10.1007", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "297", "reference": [{"key": "12_CR1", "doi-asserted-by": "crossref", "first-page": "3797", "DOI": "10.1093/emboj/16.13.3797", "volume": "16", "author": "H. Aberle", "year": "1997", "unstructured": "Aberle H, Bauer A, Stappert J, et al., (1997). Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J, 16:3797\u2013804.", "journal-title": "EMBO J"}, {"key": "12_CR2", "doi-asserted-by": "crossref", "first-page": "628", "DOI": "10.1097/00001622-200211000-00007", "volume": "14", "author": "J. Adams", "year": "2002", "unstructured": "Adams J. (2002). Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol, 14:628\u201334.", "journal-title": "Curr Opin Oncol"}, {"key": "12_CR3", "first-page": "2615", "volume": "59", "author": "J. Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, et al., (1999). Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res, 59:2615\u201322.", "journal-title": "Cancer Res"}, {"key": "12_CR4", "first-page": "452", "volume": "22", "author": "C. Aghajanian", "year": "2003", "unstructured": "Aghajanian C, Dizon D, Yan XJ, et al., (2003). Phase I trial of PS-341 and carboplatin in recurrent ovarian cancer. Proc Amer Soc Clin Oncol, 22:452, Abstract 1815.", "journal-title": "Proc Amer Soc Clin Oncol"}, {"key": "12_CR5", "first-page": "2505", "volume": "8", "author": "C. Aghajanian", "year": "2002", "unstructured": "Aghajanian C, Soignet S, Dizon DS, et al., (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res, 8:2505\u201311.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR6", "doi-asserted-by": "crossref", "first-page": "1062", "DOI": "10.1038/sj.cdd.4400436", "volume": "5", "author": "B. An", "year": "1998", "unstructured": "An B, Goldfarb RH, Siman R & Dou QP. (1998). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ, 5:1062\u201375.", "journal-title": "Cell Death Differ"}, {"key": "12_CR7", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1182/blood-2003-04-1045", "volume": "103", "author": "B. Barlogie", "year": "2004", "unstructured": "Barlogie B, Shaughnessy JD, Tricot G, et al., (2004). Treatment of multiple myeloma. Blood, 103:20\u201332.", "journal-title": "Blood"}, {"key": "12_CR8", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1038/sj.neo.7900233", "volume": "4", "author": "A. Basu", "year": "2002", "unstructured": "Basu A, Das M, Qanungo S, et al., (2002). Proteasomal degradation of human peptidyl-prolyl-isomerase Pin-1-pointing phospho-Bcl-2 toward dephosphorylation. Neoplasia, 4:218\u201327.", "journal-title": "Neoplasia"}, {"key": "12_CR9", "first-page": "1563", "volume": "1", "author": "W.T. Bellamy", "year": "1995", "unstructured": "Bellamy WT, Odeleye A, Huizenga E, et al., (1995). Severe combined immunodeficiency mouse modeling of P-glycoprotein chemosensitization in multi-drug-resistant human myeloma xenografts. Clin Cancer Res, 1:1563\u201370.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR10", "doi-asserted-by": "crossref", "first-page": "505", "DOI": "10.1007/BF03033160", "volume": "5", "author": "R. Berti", "year": "2003", "unstructured": "Berti R, Williams AJ, Velarde LC, et al., (2003). Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res, 5:505\u201314.", "journal-title": "Neurotox Res"}, {"key": "12_CR11", "doi-asserted-by": "crossref", "first-page": "1115", "DOI": "10.1046/j.1365-2141.1998.00930.x", "volume": "102", "author": "J. Blad\u00e9", "year": "1998", "unstructured": "Blad\u00e9 J, Samson D, Reece D, et al., (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the European Group for Blood and Marrow Transplant. Br J Haematol, 102:1115\u201323.", "journal-title": "Br J Haematol"}, {"key": "12_CR12", "doi-asserted-by": "crossref", "first-page": "564", "DOI": "10.1006/bbrc.1996.1546", "volume": "227", "author": "M.V. Blagosklonny", "year": "1996", "unstructured": "Blagosklonny MV, Wu GS, Omura S & el-Deiry WS. (1996). Proteasome-dependent regulation of p21Wafl/Cipl expression. Biochem Biophys Res Commun, 227:564\u20139.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR13", "doi-asserted-by": "crossref", "first-page": "41", "DOI": "10.1016/S1044-579X(02)00098-6", "volume": "13", "author": "J. Bloom", "year": "2003", "unstructured": "Bloom J & Pagano M. (2003). Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol, 13:41\u20137.", "journal-title": "Semin Cancer Biol"}, {"key": "12_CR14", "doi-asserted-by": "crossref", "first-page": "1358", "DOI": "10.1126/science.286.5443.1358", "volume": "286", "author": "A. Bonni", "year": "1999", "unstructured": "Bonni A, Brunet A, West AE, et al., (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science, 286:1358\u201362.", "journal-title": "Science"}, {"key": "12_CR15", "first-page": "415", "volume": "21", "author": "M. Bosland", "year": "2003", "unstructured": "Bosland M. (2003). Bombesin stimulates nuclear factor kappa B activation and expression of pro-angiogenic factors in prostate cancer cells. Urol Oncol, 21:415.", "journal-title": "Urol Oncol"}, {"key": "12_CR16", "doi-asserted-by": "crossref", "first-page": "21648", "DOI": "10.1074/jbc.M001083200", "volume": "275", "author": "K. Breitschopf", "year": "2000", "unstructured": "Breitschopf K, Zeiher AM & Dimmeler S. (2000). Ubiquitin-mediated degradation of the pro-apoptotic active form of Bid. A functional consequence on apoptosis induction. J Biol Chem, 275:21648\u201352.", "journal-title": "J Biol Chem"}, {"key": "12_CR17", "doi-asserted-by": "crossref", "first-page": "467", "DOI": "10.1006/jmcc.1998.0880", "volume": "31", "author": "B. Campbell", "year": "1999", "unstructured": "Campbell B, Adams J, Shin YK & Lefer AM. (1999). Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol, 31:467\u201376.", "journal-title": "J Mol Cell Cardiol"}, {"key": "12_CR18", "doi-asserted-by": "crossref", "first-page": "2437", "DOI": "10.1038/sj.onc.1202189", "volume": "17", "author": "C. Cayrol", "year": "1998", "unstructured": "Cayrol C & Ducommun B. (1998). Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene, 17:2437\u201344.", "journal-title": "Oncogene"}, {"key": "12_CR19", "first-page": "469", "volume": "22", "author": "F. Chang", "year": "2003", "unstructured": "Chang F, Steelman LS, Shelton JG, et al., (2003). Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol, 22:469\u201380.", "journal-title": "Int J Oncol"}, {"key": "12_CR20", "first-page": "79", "volume": "9", "author": "Y.C. Chang", "year": "1998", "unstructured": "Chang YC, Lee YS, Tejima T, et al., (1998). Mdm2 and Bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ, 9:79\u201384.", "journal-title": "Cell Growth Differ"}, {"key": "12_CR21", "doi-asserted-by": "crossref", "first-page": "3379", "DOI": "10.1182/blood-2003-05-1417", "volume": "102", "author": "D. Chauhan", "year": "2003", "unstructured": "Chauhan D, Li G, Hideshima T, et al., (2003a). HSP-27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 102:3379\u201386.", "journal-title": "Blood"}, {"key": "12_CR22", "doi-asserted-by": "crossref", "first-page": "17593", "DOI": "10.1074/jbc.C300076200", "volume": "278", "author": "D. Chauhan", "year": "2003", "unstructured": "Chauhan D, Li G, Hideshima T, et al., (2003b). JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma cells. J Biol Chem, 278:17593\u20136.", "journal-title": "J Biol Chem"}, {"key": "12_CR23", "first-page": "6174", "volume": "63", "author": "D. Chauhan", "year": "2003", "unstructured": "Chauhan D, Li G, Shringarpure R, Podar K, et al., (2003c). Blockade of HSP-27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res, 63:6174\u20137.", "journal-title": "Cancer Res"}, {"key": "12_CR24", "first-page": "1104", "volume": "87", "author": "D. Chauhan", "year": "1996", "unstructured": "Chauhan D, Uchiyama H, Akbarali Y, et al., (1996). Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87:1104\u201312.", "journal-title": "Blood"}, {"key": "12_CR25", "first-page": "619", "volume": "95", "author": "R. Chiarle", "year": "2000", "unstructured": "Chiarle R, Budel LM, Skolnik J, et al., (2000). Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95:619\u201326.", "journal-title": "Blood"}, {"key": "12_CR26", "doi-asserted-by": "crossref", "first-page": "442", "DOI": "10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q", "volume": "22", "author": "A. Ciechanover", "year": "2000", "unstructured": "Ciechanover A, Orian A & Schwartz AL. (2000). Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays, 22:442\u201351.", "journal-title": "Bioessays"}, {"key": "12_CR27", "doi-asserted-by": "crossref", "first-page": "839", "DOI": "10.1002/eji.1830260417", "volume": "26", "author": "R.R. Cobb", "year": "1996", "unstructured": "Cobb RR, Felts KA, Parry GC, et al., (1996). Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Eur J Immunol, 26:839\u201345.", "journal-title": "Eur J Immunol"}, {"key": "12_CR28", "first-page": "3535", "volume": "61", "author": "J.C. Cusack Jr", "year": "2001", "unstructured": "Cusack JC Jr, Liu R, Houston M, et al., (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res, 61:3535\u201340.", "journal-title": "Cancer Res"}, {"key": "12_CR29", "doi-asserted-by": "crossref", "first-page": "C813", "DOI": "10.1152/ajpcell.00102.2003", "volume": "285", "author": "N.M. Dagia", "year": "2003", "unstructured": "Dagia NM and Goetz DJ. (2003). A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1 beta-and TNF-alpha-induced ECAM expression and adhesion. Am J Physiol Cell Physiol, 285:C813\u2013C822.", "journal-title": "Am J Physiol Cell Physiol"}, {"key": "12_CR30", "doi-asserted-by": "crossref", "first-page": "301", "DOI": "10.1016/S0300-9084(01)01250-0", "volume": "83", "author": "K.J. Davies", "year": "2001", "unstructured": "Davies KJ. (2001). Degradation of oxidized proteins by the 20S proteasome. Biochimie, 83:301\u201310.", "journal-title": "Biochimie"}, {"key": "12_CR31", "doi-asserted-by": "crossref", "first-page": "115", "DOI": "10.1200/JCO.2004.07.165", "volume": "22", "author": "N.B. Davis", "year": "2004", "unstructured": "Davis NB, Taber DA, Ansari RH, et al., (2004). Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol, 22:115\u201319.", "journal-title": "J Clin Oncol"}, {"key": "12_CR32", "first-page": "217", "volume": "22", "author": "E.C. Dees", "year": "2003", "unstructured": "Dees EC, O\u2019Neil B, Humes E, et al., (2003). Phase I trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. Proc American Soc Clin Oncol, 22:217, Abstract 868.", "journal-title": "Proc American Soc Clin Oncol"}, {"key": "12_CR33", "doi-asserted-by": "crossref", "first-page": "22123", "DOI": "10.1074/jbc.274.32.22123", "volume": "274", "author": "G.N. DeMartino", "year": "1999", "unstructured": "DeMartino GN & Slaughter CA. (1999). The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem, 274:22123\u20136.", "journal-title": "J Biol Chem"}, {"key": "12_CR34", "first-page": "5926", "volume": "61", "author": "S.D. Desai", "year": "2001", "unstructured": "Desai SD, Li TK, Rodriguez-Bauman A, et al., (2001). Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res, 61:5926\u201332.", "journal-title": "Cancer Res"}, {"key": "12_CR35", "doi-asserted-by": "crossref", "first-page": "24159", "DOI": "10.1074/jbc.272.39.24159", "volume": "272", "author": "S.D. Desai", "year": "1997", "unstructured": "Desai SD, Liu LF, Vazquez-Abad D, et al., (1997). Ubiquitin-dependent destruction of topoisomerase I is stimulated by the anti-tumor drug camptothecin. J Biol Chem, 272:24159\u201364.", "journal-title": "J Biol Chem"}, {"key": "12_CR36", "first-page": "1333", "volume": "4", "author": "M. Napoli Di", "year": "2003", "unstructured": "Di Napoli M & Papa F. (2003). The proteasome system and proteasome inhibitors in stroke: Controlling the inflammatory response. Curr Opin Investig Drugs, 4:1333\u201342.", "journal-title": "Curr Opin Investig Drugs"}, {"key": "12_CR37", "doi-asserted-by": "crossref", "first-page": "855", "DOI": "10.1073/pnas.94.3.855", "volume": "94", "author": "H.C. Drexler", "year": "1997", "unstructured": "Drexler HC. (1997). Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA, 94:855\u201360.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR38", "doi-asserted-by": "crossref", "first-page": "438", "DOI": "10.4161/cc.2.5.461", "volume": "2", "author": "H.C. Drexler", "year": "2003", "unstructured": "Drexler HC. (2003). The role of p27Kipl in proteasome inhibitor induced apoptosis. Cell Cycle, 2:438\u201341.", "journal-title": "Cell Cycle"}, {"key": "12_CR39", "doi-asserted-by": "crossref", "first-page": "290", "DOI": "10.1038/sj.cdd.4401159", "volume": "10", "author": "H.C. Drexler", "year": "2003", "unstructured": "Drexler HC & Pebler S. (2003). Inducible p27Kipl expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ, 10:290\u2013301.", "journal-title": "Cell Death Differ"}, {"key": "12_CR40", "doi-asserted-by": "crossref", "first-page": "236", "DOI": "10.1002/(SICI)1097-0215(20000115)85:2%3C236::AID-IJC14%3E3.0.CO;2-5", "volume": "85", "author": "K.M. El-Shami", "year": "2000", "unstructured": "El-Shami KM, Tirosh B, Popovic D, et al., (2000). Induction of anti-tumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer, 85:236\u201342.", "journal-title": "Int J Cancer"}, {"key": "12_CR41", "doi-asserted-by": "crossref", "first-page": "235", "DOI": "10.1007/s00109-003-0422-2", "volume": "81", "author": "P.J. Elliott", "year": "2003", "unstructured": "Elliott PJ, Zollner TM & Boehncke WH. (2003). Proteasome inhibition: A new anti-inflammatory strategy. J Mol Med, 81:235\u201345.", "journal-title": "J Mol Med"}, {"key": "12_CR42", "first-page": "820", "volume": "9", "author": "M. Filipits", "year": "2003", "unstructured": "Filipits M, Pohl G, Stranzl T, et al., (2003). Low p27Kipl expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res, 9:820\u20136.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR43", "first-page": "3719", "volume": "6", "author": "A. Frankel", "year": "2000", "unstructured": "Frankel A, Man S, Elliott P, et al., (2000). Lack of multi-cellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res, 6:3719\u201328.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR44", "doi-asserted-by": "crossref", "first-page": "6380", "DOI": "10.1073/pnas.94.12.6380", "volume": "94", "author": "S. Fredersdorf", "year": "1997", "unstructured": "Fredersdorf S, Burns J, Milne AM, et al., (1997). High level expression of p27Kipl and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kipl and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA, 94:6380\u20135.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR45", "doi-asserted-by": "crossref", "first-page": "2061", "DOI": "10.1096/fasebj.13.14.2061", "volume": "13", "author": "C. Garrido", "year": "1999", "unstructured": "Garrido C, Bruey JM, Fromentin A, et al., (1999). HSP-27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J, 13:2061\u201370.", "journal-title": "FASEB J"}, {"key": "12_CR46", "doi-asserted-by": "crossref", "first-page": "628", "DOI": "10.1038/sj.leu.2403269", "volume": "18", "author": "N. Giuliani", "year": "2004", "unstructured": "Giuliani N, Lunghi P, Morandi F, et al., (2004). Down-modulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia, 18:628\u201335.", "journal-title": "Leukemia"}, {"key": "12_CR47", "first-page": "1717", "volume": "20", "author": "J. Golab", "year": "2000", "unstructured": "Golab J, Stoklosa T, Czajka A, et al., (2000). Synergistic anti-tumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res, 20:1717\u201321.", "journal-title": "Anticancer Res"}, {"key": "12_CR48", "doi-asserted-by": "crossref", "first-page": "17", "DOI": "10.1016/S0014-5793(97)00225-1", "volume": "406", "author": "H. Gonen", "year": "1997", "unstructured": "Gonen H, Shkedy D, Barnoy S, et al., (1997). On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett, 406:17\u201322.", "journal-title": "FEBS Lett"}, {"key": "12_CR49", "doi-asserted-by": "crossref", "first-page": "180a", "DOI": "10.1182/blood-2002-10-3034", "volume": "102", "author": "A. Goy", "year": "2003", "unstructured": "Goy A, Hart S, Pro B, et al., (2003). Report of a phase II study of proteasome inhibitor bortezomib (VELCADE\u00ae) in patients with relapsed or refractory indolent or aggressive lymphomas. Blood, 102:180a, Abstract 627.", "journal-title": "Blood"}, {"key": "12_CR50", "doi-asserted-by": "crossref", "first-page": "77", "DOI": "10.1016/S1044-579X(02)00102-5", "volume": "13", "author": "R.C. Gregory", "year": "2003", "unstructured": "Gregory RC, Taniguchi T & D\u2019Andrea AD. (2003). Regulation of the Fanconi anemia pathway by monoubiquitination. Semin Cancer Biol, 13:77\u201382.", "journal-title": "Semin Cancer Biol"}, {"key": "12_CR51", "doi-asserted-by": "crossref", "first-page": "4027", "DOI": "10.1074/jbc.273.7.4027", "volume": "273", "author": "Y.L. Guo", "year": "1998", "unstructured": "Guo YL, Baysal K, Kang B, et al., (1998a). Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem, 273:4027\u201334.", "journal-title": "J Biol Chem"}, {"key": "12_CR52", "doi-asserted-by": "crossref", "first-page": "10362", "DOI": "10.1074/jbc.273.17.10362", "volume": "273", "author": "Y.L. Guo", "year": "1998", "unstructured": "Guo YL, Kang B & Williamson JR. (1998b). Inhibition of the expression of mitogen-activated protein kinase phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. J Biol Chem, 273:10362\u20136.", "journal-title": "J Biol Chem"}, {"key": "12_CR53", "doi-asserted-by": "crossref", "first-page": "16220", "DOI": "10.1073/pnas.252462599", "volume": "99", "author": "M.L. Guzman", "year": "2002", "unstructured": "Guzman ML, Swiderski CF, Howard DS, et al., (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA, 99:16220\u20135.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR54", "doi-asserted-by": "crossref", "first-page": "598", "DOI": "10.1016/j.tibs.2003.09.005", "volume": "28", "author": "K. Haglund", "year": "2003", "unstructured": "Haglund K, Di Fiore PP & Dikic I. (2003). Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci, 28:598\u2013603.", "journal-title": "Trends Biochem Sci"}, {"key": "12_CR55", "doi-asserted-by": "crossref", "first-page": "14537", "DOI": "10.1074/jbc.C000881200", "volume": "276", "author": "R. Hashizume", "year": "2001", "unstructured": "Hashizume R, Fukuda M, Maeda I, et al., (2001). The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem, 276:14537\u201340.", "journal-title": "J Biol Chem"}, {"key": "12_CR56", "doi-asserted-by": "crossref", "first-page": "2554", "DOI": "10.1038/sj.onc.1207351", "volume": "23", "author": "Q. He", "year": "2004", "unstructured": "He Q, Huang Y & Sheikh MS. (2004). Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and-deficient cells. Oncogene, 23:2554\u20138.", "journal-title": "Oncogene"}, {"key": "12_CR57", "doi-asserted-by": "crossref", "first-page": "2889", "DOI": "10.1038/sj.onc.1202221", "volume": "17", "author": "J.L. Herrmann", "year": "1998", "unstructured": "Herrmann JL, Briones F Jr., Brisbay S, et al., (1998). Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene, 17:2889\u201399.", "journal-title": "Oncogene"}, {"key": "12_CR58", "doi-asserted-by": "crossref", "first-page": "788", "DOI": "10.1016/S0955-0674(97)80079-8", "volume": "9", "author": "A. Hershko", "year": "1997", "unstructured": "Hershko A. (1997). Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol, 9:788\u201399.", "journal-title": "Curr Opin Cell Biol"}, {"key": "12_CR59", "doi-asserted-by": "crossref", "first-page": "8386", "DOI": "10.1038/sj.onc.1207170", "volume": "22", "author": "T. Hideshima", "year": "2003", "unstructured": "Hideshima T, Chauhan D, Hayashi T, et al., (2003). Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent down-regulation of gp130 in multiple myeloma. Oncogene, 22:8386\u201393.", "journal-title": "Oncogene"}, {"key": "12_CR60", "doi-asserted-by": "crossref", "first-page": "4519", "DOI": "10.1038/sj.onc.1204623", "volume": "20", "author": "T. Hideshima", "year": "2001", "unstructured": "Hideshima T, Chauhan D, Schlossman R, et al., (2001a). The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications. Oncogene, 20:4519\u201327.", "journal-title": "Oncogene"}, {"key": "12_CR61", "first-page": "3071", "volume": "61", "author": "T. Hideshima", "year": "2001", "unstructured": "Hideshima T, Richardson P, Chauhan D, et al., (2001b). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61:3071\u20133076.", "journal-title": "Cancer Res"}, {"key": "12_CR62", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1016/S0014-5793(97)01480-4", "volume": "420", "author": "R. Honda", "year": "1997", "unstructured": "Honda R, Tanaka H & Yasuda H. (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett, 420:25\u20137.", "journal-title": "FEBS Lett"}, {"key": "12_CR63", "doi-asserted-by": "crossref", "first-page": "1070", "DOI": "10.1006/bbrc.1995.2878", "volume": "217", "author": "K.T. Imajoh-Ohmi", "year": "1995", "unstructured": "Imajoh-Ohmi KT, Sugiyama S, Tanaka K, et al., (1995). Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun, 217:1070\u20137.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR64", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1016/S0006-8993(01)02386-1", "volume": "902", "author": "T. Ishibashi", "year": "2001", "unstructured": "Ishibashi T, Shinogami M, Ishimoto S, et al., (2001). Identification of dual specificity phosphatases induced by olfactory bulbectomy in rat olfactory neuroepithelium. Brain Res, 902:205\u201311.", "journal-title": "Brain Res"}, {"key": "12_CR65", "first-page": "452a", "volume": "102", "author": "S. Jagannath", "year": "2003", "unstructured": "Jagannath S, Durie BGM, Wolf J, et al., (2003). Bortezomib (VELCADE\u00ae, formerly PS-341) as first-line therapy in patients with multiple myeloma. Blood, 102:452a, Abstract 1650.", "journal-title": "Blood"}, {"key": "12_CR66", "doi-asserted-by": "crossref", "first-page": "724", "DOI": "10.1006/bbrc.1999.1475", "volume": "264", "author": "M.S. Jan", "year": "1999", "unstructured": "Jan MS, Liu HS & Lin YS. (1999). Bad overexpression sensitizes NIH/3T3 cells to undergo apoptosis which involves caspase activation and ERK inactivation. Biochem Biophys Res Commun, 264:724\u20139.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR67", "doi-asserted-by": "crossref", "first-page": "779", "DOI": "10.1136/gut.42.6.779", "volume": "42", "author": "C. Jobin", "year": "1998", "unstructured": "Jobin C, Hellerbrand C, Licato LL, et al., (1998). Mediation by NF-kappa B of cytokine induced expression of intercellular adhesion molecule 1 in an intestinal epithelial cell line, a process blocked by proteasome inhibitors. Gut, 42:779\u201387.", "journal-title": "Gut"}, {"key": "12_CR68", "doi-asserted-by": "crossref", "first-page": "1911", "DOI": "10.1126/science.1072682", "volume": "298", "author": "G.L. Johnson", "year": "2002", "unstructured": "Johnson GL & Lapadat R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298:1911\u20132.", "journal-title": "Science"}, {"key": "12_CR69", "doi-asserted-by": "crossref", "first-page": "4953", "DOI": "10.1038/sj.onc.1206656", "volume": "22", "author": "T.R. Johnson", "year": "2003", "unstructured": "Johnson TR, Stone K, Nikrad M, et al., (2003). The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-Xl overexpressing cells. Oncogene, 22:4953\u201363.", "journal-title": "Oncogene"}, {"key": "12_CR70", "doi-asserted-by": "crossref", "first-page": "L9", "DOI": "10.1152/ajpcell.1999.276.4.C856", "volume": "276", "author": "T.J. Kalogeris", "year": "1999", "unstructured": "Kalogeris TJ, Kevil CG, Laroux FS, et al., (1999). Differential monocyte adhesion and adhesion molecule expression in venous and arterial endothelial cells. Am J Physiol, 276:L9\u2013L19.", "journal-title": "Am J Physiol"}, {"key": "12_CR71", "doi-asserted-by": "crossref", "first-page": "778", "DOI": "10.1002/jlb.65.6.778", "volume": "65", "author": "K. Katagiri", "year": "1999", "unstructured": "Katagiri K, Yokosawa H, Kinashi T, et al., (1999). Ubiquitin-proteasome system is involved in induction of LFA-1/ICAM-1-dependent adhesion of HL-60 cells. J Leukoc Biol, 65:778\u201385.", "journal-title": "J Leukoc Biol"}, {"key": "12_CR72", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1016/j.bbamcr.2003.08.009", "volume": "1644", "author": "V. Kirkin", "year": "2004", "unstructured": "Kirkin V, Joos S & Zornig M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta, 1644:229\u201349.", "journal-title": "Biochim Biophys Acta"}, {"key": "12_CR73", "doi-asserted-by": "crossref", "first-page": "739", "DOI": "10.1016/S1074-5521(01)00056-4", "volume": "8", "author": "A.F. Kisselev", "year": "2001", "unstructured": "Kisselev AF & Goldberg AL. (2001). Proteasome inhibitors: From research tools to drug candidates. Chem Biol, 8:739\u201358.", "journal-title": "Chem Biol"}, {"key": "12_CR74", "doi-asserted-by": "crossref", "first-page": "179", "DOI": "10.1038/35056572", "volume": "2", "author": "P.M. Kloetzel", "year": "2001", "unstructured": "Kloetzel PM. (2001). Antigen processing by the proteasome. Nat Rev Mol Cell Biol, 2:179\u201387.", "journal-title": "Nat Rev Mol Cell Biol"}, {"key": "12_CR75", "doi-asserted-by": "crossref", "first-page": "460", "DOI": "10.1128/MCB.17.1.460", "volume": "17", "author": "M.H. Kubbutat", "year": "1997", "unstructured": "Kubbutat MH & Vousden KH. (1997). Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol, 17:460\u20138.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR76", "first-page": "916", "volume": "6", "author": "Y. Kudo", "year": "2000", "unstructured": "Kudo Y, Takata T, Ogawa I, et al., (2000). p27Kipl accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res, 6:916\u201323.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR77", "first-page": "3961", "volume": "19", "author": "S.I. Kumeda", "year": "1999", "unstructured": "Kumeda SI, Deguchi A, Toi M, et al., (1999). Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res, 19:3961\u20138.", "journal-title": "Anticancer Res"}, {"key": "12_CR78", "doi-asserted-by": "crossref", "first-page": "391", "DOI": "10.1080/07853890310014605", "volume": "35", "author": "M. Laiho", "year": "2003", "unstructured": "Laiho M & Latonen L. (2003). Cell cycle control, DNA damage checkpoints and cancer. Ann Med, 35:391\u20137.", "journal-title": "Ann Med"}, {"key": "12_CR79", "first-page": "4996", "volume": "62", "author": "R. LeBlanc", "year": "2002", "unstructured": "LeBlanc R, Catley LP, Hideshima T, et al., (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res, 62:4996\u20135000.", "journal-title": "Cancer Res"}, {"key": "12_CR80", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1634/theoncologist.8-5-411", "volume": "8", "author": "G.D. Leonard", "year": "2003", "unstructured": "Leonard GD, Fojo T & Bates SE. (2003). The role of ABC transporters in clinical practice. Oncologist, 8:411\u201324.", "journal-title": "Oncologist"}, {"key": "12_CR81", "first-page": "3495", "volume": "63", "author": "L. Levine", "year": "2003", "unstructured": "Levine L, Lucci JA, Pazdrak, B, et al., (2003). Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res, 63:3495\u2013502.", "journal-title": "Cancer Res"}, {"key": "12_CR82", "doi-asserted-by": "crossref", "first-page": "3850", "DOI": "10.1073/pnas.070047997", "volume": "97", "author": "B. Li", "year": "2000", "unstructured": "Li B & Dou QP. (2000). Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression. Proc Natl Acad Sci USA, 97:3850\u20135.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR83", "doi-asserted-by": "crossref", "first-page": "491", "DOI": "10.1016/S0092-8674(00)81590-1", "volume": "94", "author": "H. Li", "year": "1998", "unstructured": "Li H, Zhu H, Xu CJ, et al., (1998). Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94:491\u2013501.", "journal-title": "Cell"}, {"key": "12_CR84", "first-page": "673", "volume": "46", "author": "E.S. Lightcap", "year": "2000", "unstructured": "Lightcap ES, McCormack TA, Pien CS, et al., (2000). Proteasome inhibition measurements: Clinical application. Clin Chem, 46:673\u201383.", "journal-title": "Clin Chem"}, {"key": "12_CR85", "doi-asserted-by": "crossref", "first-page": "107", "DOI": "10.1016/S1044-579X(02)00128-1", "volume": "13", "author": "A. Lin", "year": "2003", "unstructured": "Lin A & Karin M. (2003). NF-kappaB in cancer: A marked target. Semin Cancer Biol, 13:107\u2013114.", "journal-title": "Semin Cancer Biol"}, {"key": "12_CR86", "doi-asserted-by": "crossref", "first-page": "417", "DOI": "10.1081/DMR-120026871", "volume": "35", "author": "J.H. Lin", "year": "2003", "unstructured": "Lin JH & Yamazaki M. (2003). Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev, 35:417\u201354.", "journal-title": "Drug Metab Rev"}, {"key": "12_CR87", "first-page": "841", "volume": "1", "author": "Y.H. Ling", "year": "2002", "unstructured": "Ling YH, Liebes L, Ng B, et al., (2002). PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther, 1:841\u20139.", "journal-title": "Mol Cancer Ther"}, {"key": "12_CR88", "doi-asserted-by": "crossref", "first-page": "14671", "DOI": "10.1074/jbc.273.24.14671", "volume": "273", "author": "T.W. Loo", "year": "1998", "unstructured": "Loo TW & Clarke DM. (1998). Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem, 273:14671\u20134.", "journal-title": "J Biol Chem"}, {"key": "12_CR89", "doi-asserted-by": "crossref", "first-page": "1724", "DOI": "10.1096/fasebj.13.13.1724", "volume": "13", "author": "T.W. Loo", "year": "1999", "unstructured": "Loo TW & Clarke DM. (1999). The human multi-drug resistance P-glycoprotein is inactive when its maturation is inhibited: Potential for a role in cancer chemotherapy. FASEB J, 13:1724\u201332.", "journal-title": "FASEB J"}, {"key": "12_CR90", "doi-asserted-by": "crossref", "first-page": "12893", "DOI": "10.1074/jbc.272.20.12893", "volume": "272", "author": "U.G. Lopes", "year": "1997", "unstructured": "Lopes UG, Erhardt P, Yao R, et al., (1997). p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem, 272:12893\u20136.", "journal-title": "J Biol Chem"}, {"key": "12_CR91", "doi-asserted-by": "crossref", "first-page": "6785", "DOI": "10.1038/sj.onc.1206792", "volume": "22", "author": "F. Luciano", "year": "2003", "unstructured": "Luciano F, Jacquel A, Colosetti P, et al., (2003). Phosphorylation of Bim-El by ERK-1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its pro-apoptotic function. Oncogene, 22:6785\u201393.", "journal-title": "Oncogene"}, {"key": "12_CR92", "first-page": "1136", "volume": "9", "author": "M.H. Ma", "year": "2003", "unstructured": "Ma MH, Yang HH, Parker K, et al., (2003). The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res, 9:1136\u201344.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR93", "doi-asserted-by": "crossref", "first-page": "36611", "DOI": "10.1074/jbc.M200317200", "volume": "277", "author": "M. MacFarlane", "year": "2002", "unstructured": "MacFarlane M, Merrison W, Bratton SB & Cohen GM. (2002). Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem, 277:36611\u201316.", "journal-title": "J Biol Chem"}, {"key": "12_CR94", "doi-asserted-by": "crossref", "first-page": "38953", "DOI": "10.1074/jbc.C000684200", "volume": "275", "author": "J.P. MacKeigan", "year": "2000", "unstructured": "MacKeigan JP, Collins TS & Ting JP. (2000). MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem, 275:38953\u20136.", "journal-title": "J Biol Chem"}, {"key": "12_CR95", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1517/14712598.2.1.3", "volume": "2", "author": "A. Maloney", "year": "2002", "unstructured": "Maloney A & Workman P. (2002). HSP-90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther, 2:3\u201324.", "journal-title": "Expert Opin Biol Ther"}, {"key": "12_CR96", "doi-asserted-by": "crossref", "first-page": "C1472", "DOI": "10.1152/ajpcell.2000.279.5.C1472", "volume": "279", "author": "I. Marschitz", "year": "2000", "unstructured": "Marschitz I, Lechner J, Mosser I, et al., (2000). Differential expression of cell-cell adhesion proteins and cyclin D in MEK 1-transdifferentiated MDCK cells. Am J Physiol Cell Physiol, 279:C1472\u2013C1482.", "journal-title": "Am J Physiol Cell Physiol"}, {"key": "12_CR97", "doi-asserted-by": "crossref", "first-page": "752", "DOI": "10.1046/j.1365-2141.1999.01388.x", "volume": "105", "author": "P. Masdehors", "year": "1999", "unstructured": "Masdehors P, Omura S, Merle-Beral H, et al., (1999). Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol, 105:752\u20137.", "journal-title": "Br J Haematol"}, {"key": "12_CR98", "doi-asserted-by": "crossref", "first-page": "16510", "DOI": "10.1074/jbc.271.28.16510", "volume": "271", "author": "P. Mehlen", "year": "1996", "unstructured": "Mehlen P, Schulze-Osthoff K & Arrigo AP. (1996). Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1-and staurosporine-induced cell death. J Biol Chem, 271:16510\u201314.", "journal-title": "J Biol Chem"}, {"key": "12_CR99", "doi-asserted-by": "crossref", "first-page": "6373", "DOI": "10.1074/jbc.273.11.6373", "volume": "273", "author": "A.B. Meriin", "year": "1998", "unstructured": "Meriin AB, Gabai VL, Yaglom J, et al., (1998). Proteasome inhibitors activate stress kinases and induce HSP-72. Diverse effects on apoptosis. J Biol Chem, 273:6373\u20139.", "journal-title": "J Biol Chem"}, {"key": "12_CR100", "doi-asserted-by": "crossref", "first-page": "1138", "DOI": "10.1002/jcb.10587", "volume": "89", "author": "J. Mezquita", "year": "2003", "unstructured": "Mezquita J, Mezquita B, Pau M & Mezquita C. (2003). Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem, 89:1138\u201347.", "journal-title": "J Cell Biochem"}, {"key": "12_CR101", "doi-asserted-by": "crossref", "first-page": "14374", "DOI": "10.1073/pnas.202445099", "volume": "99", "author": "N. Mitsiades", "year": "2002", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, et al., (2002a). Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA, 99:14374\u20139.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR102", "doi-asserted-by": "crossref", "first-page": "4079", "DOI": "10.1182/blood.V99.11.4079", "volume": "99", "author": "N. Mitsiades", "year": "2002", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V et al., (2002b). Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications. Blood, 99:4079\u201386.", "journal-title": "Blood"}, {"key": "12_CR103", "doi-asserted-by": "crossref", "first-page": "2377", "DOI": "10.1182/blood-2002-06-1768", "volume": "101", "author": "N. Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, et al., (2003). The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood, 101:2377\u201380.", "journal-title": "Blood"}, {"key": "12_CR104", "doi-asserted-by": "crossref", "first-page": "7146", "DOI": "10.1128/MCB.20.19.7146-7159.2000", "volume": "20", "author": "D.D. Mosser", "year": "2000", "unstructured": "Mosser DD, Caron AW, Bourget L, et al., (2000). The chaperone function of HSP-70 is required for protection against stress-induced apoptosis. Mol Cell Biol, 20:7146\u201359.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR105", "doi-asserted-by": "crossref", "first-page": "597", "DOI": "10.1038/360597a0", "volume": "360", "author": "Y. Murakami", "year": "1992", "unstructured": "Murakami Y, Matsufuji S, Kameji T, et al., (1992). Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature, 360:597\u20139.", "journal-title": "Nature"}, {"key": "12_CR106", "doi-asserted-by": "crossref", "first-page": "221", "DOI": "10.1016/S0092-8674(03)01080-8", "volume": "116", "author": "A.W. Murray", "year": "2004", "unstructured": "Murray AW. (2004). Recycling the cell cycle: Cyclins revisited. Cell, 116:221\u201334.", "journal-title": "Cell"}, {"key": "12_CR107", "doi-asserted-by": "crossref", "first-page": "683", "DOI": "10.1016/S1097-2765(01)00214-3", "volume": "7", "author": "K. Nakano", "year": "2001", "unstructured": "Nakano K & Vousden KH. (2001). PUMA, a novel pro-apoptotic gene, is induced by p53. Mol Cell, 7:683\u201394.", "journal-title": "Mol Cell"}, {"key": "12_CR108", "first-page": "1243", "volume": "1", "author": "S.T. Nawrocki", "year": "2002", "unstructured": "Nawrocki ST, Bruns CJ, Harbison MT, et al., (2002). Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther, 1:1243\u201353.", "journal-title": "Mol Cancer Ther"}, {"key": "12_CR109", "first-page": "59", "volume": "3", "author": "S.T. Nawrocki", "year": "2004", "unstructured": "Nawrocki ST, Sweeney-Gotsch B, Takamori R & McConkey DJ. (2004). The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther, 3:59\u201370.", "journal-title": "Mol Cancer Ther"}, {"key": "12_CR110", "doi-asserted-by": "crossref", "first-page": "S55", "DOI": "10.1016/S1471-4914(02)02316-X", "volume": "8", "author": "L. Neckers", "year": "2002", "unstructured": "Neckers L (2002). HSP-90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 8:S55\u2013S61.", "journal-title": "Trends Mol Med"}, {"key": "12_CR111", "first-page": "249", "volume": "5", "author": "R.S. Nho", "year": "2003", "unstructured": "Nho RS & Sheaff RJ. (2003). p27Kipl contributions to cancer. Prog Cell Cycle Res, 5:249\u201359.", "journal-title": "Prog Cell Cycle Res"}, {"key": "12_CR112", "first-page": "636a", "volume": "102", "author": "O. O\u2019Connor", "year": "2003", "unstructured": "O\u2019Connor O, Wright J, Moskowitz CH, et al., (2003). Promising activity of the proteasome inhibitor bortezomib (VELCADE\u00ae) in the treatment of indolent non-Hodgkins lymphoma and mantle cell lymphoma. Blood, 102:636a, Abstract 2346.", "journal-title": "Blood"}, {"key": "12_CR113", "doi-asserted-by": "crossref", "first-page": "1053", "DOI": "10.1126/science.288.5468.1053", "volume": "288", "author": "E. Oda", "year": "2000", "unstructured": "Oda E, Ohki R, Murasawa H, et al., (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science, 288:1053\u20138.", "journal-title": "Science"}, {"key": "12_CR114", "first-page": "2429", "volume": "60", "author": "Y. Ogiso", "year": "2000", "unstructured": "Ogiso Y, Tomida A, Lei S, et al.,(2000). Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res, 60:2429\u201334.", "journal-title": "Cancer Res"}, {"key": "12_CR115", "doi-asserted-by": "crossref", "first-page": "22627", "DOI": "10.1074/jbc.C000235200", "volume": "275", "author": "R. Ohki", "year": "2000", "unstructured": "Ohki R, Nemoto J, Murasawa H, et al., (2000). Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem, 275:22627\u201330.", "journal-title": "J Biol Chem"}, {"key": "12_CR116", "doi-asserted-by": "crossref", "first-page": "243", "DOI": "10.1006/bbrc.1998.8604", "volume": "246", "author": "T. Oikawa", "year": "1998", "unstructured": "Oikawa T, Sasaki T, Nakamura M, et al., (1998). The proteasome is involved in angiogenesis. Biochem Biophys Res Commun, 246:243\u20138.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "12_CR117", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1006/abbi.2000.2036", "volume": "383", "author": "M. Orlowski", "year": "2000", "unstructured": "Orlowski M & Wilk S. (2000). Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys, 383:1\u201316.", "journal-title": "Arch Biochem Biophys"}, {"key": "12_CR118", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1038/sj.cdd.4400505", "volume": "6", "author": "R.Z. Orlowski", "year": "1999", "unstructured": "Orlowski RZ. (1999). The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ, 6:303\u201313.", "journal-title": "Cell Death Differ"}, {"key": "12_CR119", "doi-asserted-by": "crossref", "first-page": "171", "DOI": "10.1586/14737140.4.2.171", "volume": "4", "author": "R.Z. Orlowski", "year": "2004", "unstructured": "Orlowski RZ. (2004). Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther, 4:171\u20139.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "12_CR120", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1016/S1471-4914(02)02375-4", "volume": "8", "author": "R.Z. Orlowski", "year": "2002", "unstructured": "Orlowski RZ & Baldwin AS. (2002). NF-kappaB as a therapeutic target in cancer. Trends Mol Med, 8:385\u20139.", "journal-title": "Trends Mol Med"}, {"key": "12_CR121", "first-page": "4342", "volume": "58", "author": "R.Z. Orlowski", "year": "1998", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, et al., (1998). Tumor growth inhibition induced in a murine model of human Burkitt\u2019s lymphoma by a proteasome inhibitor. Cancer Res, 58:4342\u20138.", "journal-title": "Cancer Res"}, {"key": "12_CR122", "doi-asserted-by": "crossref", "first-page": "27864", "DOI": "10.1074/jbc.M201519200", "volume": "277", "author": "R.Z. Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Small GW & Shi YY. (2002a). Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem, 277:27864\u201371.", "journal-title": "J Biol Chem"}, {"key": "12_CR123", "doi-asserted-by": "crossref", "first-page": "4420", "DOI": "10.1200/JCO.2002.01.133", "volume": "20", "author": "R.Z. Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, et al., (2002b). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 20:4420\u20137.", "journal-title": "J Clin Oncol"}, {"key": "12_CR124", "doi-asserted-by": "crossref", "first-page": "449a", "DOI": "10.1182/blood-2002-12-3882", "volume": "102", "author": "R.Z. Orlowski", "year": "2003", "unstructured": "Orlowski RZ, Voorhees PM, Garcia RA, et al., (2003). Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood, 102:449a, Abstract 1639.", "journal-title": "Blood"}, {"key": "12_CR125", "doi-asserted-by": "crossref", "first-page": "15671", "DOI": "10.1073/pnas.95.26.15671", "volume": "95", "author": "V.J. Palombella", "year": "1998", "unstructured": "Palombella VJ, Conner EM, Fuseler JW, et al., (1998). Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA, 95:15671\u20136.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR126", "doi-asserted-by": "crossref", "first-page": "773", "DOI": "10.1016/S0092-8674(94)90482-0", "volume": "78", "author": "V.J. Palombella", "year": "1994", "unstructured": "Palombella VJ, Rando OJ, Goldberg AL & Maniatis T. (1994). The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell, 78:773\u201385.", "journal-title": "Cell"}, {"key": "12_CR127", "doi-asserted-by": "crossref", "first-page": "2806", "DOI": "10.1128/MCB.17.5.2806", "volume": "17", "author": "M. Pariat", "year": "1997", "unstructured": "Pariat M, Carillo S, Molinari M, et al., (1997). Proteolysis by calpains: A possible contribution to degradation of p53. Mol Cell Biol, 17:2806\u201315.", "journal-title": "Mol Cell Biol"}, {"key": "12_CR128", "first-page": "7647", "volume": "61", "author": "B.K. Park", "year": "2001", "unstructured": "Park BK, Zeng X & Glazer RI. (2001). Aktl induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res, 61:7647\u201353.", "journal-title": "Cancer Res"}, {"key": "12_CR129", "doi-asserted-by": "crossref", "first-page": "2036", "DOI": "10.1038/sj.leu.2403109", "volume": "17", "author": "X.Y. Pei", "year": "2003", "unstructured": "Pei XY, Dai Y & Grant S. (2003). The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia, 17:2036\u201345.", "journal-title": "Leukemia"}, {"key": "12_CR130", "doi-asserted-by": "crossref", "first-page": "2934", "DOI": "10.1038/sj.onc.1207515", "volume": "23", "author": "Y. Pommier", "year": "2004", "unstructured": "Pommier Y, Sordet O, Antony S, et al., (2004). Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene, 23:2934\u201349.", "journal-title": "Oncogene"}, {"key": "12_CR131", "doi-asserted-by": "crossref", "first-page": "222", "DOI": "10.1038/nm0297-222", "volume": "3", "author": "P.L. Porter", "year": "1997", "unstructured": "Porter PL, Malone KE, Heagerty PJ, et al., (1997). Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med, 3:222\u20135.", "journal-title": "Nat Med"}, {"key": "12_CR132", "doi-asserted-by": "crossref", "first-page": "899", "DOI": "10.1016/S0896-6273(03)00355-6", "volume": "38", "author": "G.V. Putcha", "year": "2003", "unstructured": "Putcha GV, Le S, Frank S, et al., (2003). JNK-mediated Bim phosphorylation potentiates Bax-dependent apoptosis. Neuron, 38:899\u2013914.", "journal-title": "Neuron"}, {"key": "12_CR133", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1023/A:1023781114568", "volume": "22", "author": "K.B. Reddy", "year": "2003", "unstructured": "Reddy KB, Nabha SM & Atanaskova N. (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 22:395\u2013403.", "journal-title": "Cancer Metastasis Rev"}, {"key": "12_CR134", "doi-asserted-by": "crossref", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "P.G. Richardson", "year": "2003", "unstructured": "Richardson PG, Barlogie B, Berenson J, et al., (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348:2609\u201317.", "journal-title": "N Engl J Med"}, {"key": "12_CR135", "doi-asserted-by": "crossref", "first-page": "477", "DOI": "10.1042/bj3440477", "volume": "344", "author": "J.D. Robertson", "year": "1999", "unstructured": "Robertson JD, Datta K, Biswal SS & Kehrer JP. (1999). Heat-shock protein 70 antisense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J, 344 Pt 2:477\u201385.", "journal-title": "Biochem J"}, {"key": "12_CR136", "doi-asserted-by": "crossref", "first-page": "761", "DOI": "10.1016/S0092-8674(94)90462-6", "volume": "78", "author": "K.L. Rock", "year": "1994", "unstructured": "Rock KL, Gramm C, Rothstein L, et al., (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell, 78:761\u201371.", "journal-title": "Cell"}, {"key": "12_CR137", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S0065-2776(02)80012-8", "volume": "80", "author": "K.L. Rock", "year": "2002", "unstructured": "Rock KL, York IA, Saric T & Goldberg AL. (2002). Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol, 80:1\u201370.", "journal-title": "Adv Immunol"}, {"key": "12_CR138", "doi-asserted-by": "crossref", "first-page": "3264", "DOI": "10.1073/pnas.92.8.3264", "volume": "92", "author": "M. Rolfe", "year": "1995", "unstructured": "Rolfe M, Beer-Romero P, Glass, S, et al., (1995). Reconstitution of p53-ubiquitinylation reactions from purified components: The role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein. Proc Natl Acad Sci USA, 92:3264\u20138.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "12_CR139", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1023/A:1006960021281", "volume": "26", "author": "C. Salvat", "year": "1999", "unstructured": "Salvat C, Aquaviva C, Jariel-Encontre I, et al., (1999). Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep, 26:45\u201351.", "journal-title": "Mol Biol Rep"}, {"key": "12_CR140", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/S0960-0760(01)00189-3", "volume": "80", "author": "R.J. Santen", "year": "2002", "unstructured": "Santen RJ, Song RX, McPherson R, et al., (2002). The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol, 80:239\u201356.", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "12_CR141", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1182/blood-2002-09-2975", "volume": "102", "author": "T.J. Sayers", "year": "2003", "unstructured": "Sayers TJ, Brooks AD, Koh CY, et al., (2003). The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 102:303\u201310.", "journal-title": "Blood"}, {"key": "12_CR142", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1016/0092-8674(93)90384-3", "volume": "75", "author": "M. Scheffner", "year": "1993", "unstructured": "Scheffner M, Huibregtse JM, Vierstra RD & Howley PM. (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75:495\u2013505.", "journal-title": "Cell"}, {"key": "12_CR143", "doi-asserted-by": "crossref", "first-page": "31108", "DOI": "10.1074/jbc.274.43.31108", "volume": "274", "author": "M.P. Scheid", "year": "1999", "unstructured": "Scheid MP, Schubert KM & Duronio V. (1999). Regulation of Bad phosphorylation and association with Bcl-xl by the MAPK/ERK kinase. J Biol Chem, 274:31108\u201313.", "journal-title": "J Biol Chem"}, {"key": "12_CR144", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1023/A:1015872531675", "volume": "73", "author": "A. Shibata", "year": "2002", "unstructured": "Shibata A, Nagaya T, Imai T, et al., (2002). Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat, 73:237\u201343.", "journal-title": "Breast Cancer Res Treat"}, {"key": "12_CR145", "doi-asserted-by": "crossref", "first-page": "385", "DOI": "10.1042/bj3170385", "volume": "317", "author": "K. Shinohara", "year": "1996", "unstructured": "Shinohara K, Tomioka M, Nakano H, et al., (1996). Apoptosis induction resulting from proteasome inhibition. Biochem J, 317:385\u20138.", "journal-title": "Biochem J"}, {"key": "12_CR146", "doi-asserted-by": "crossref", "first-page": "13886", "DOI": "10.1074/jbc.274.20.13886", "volume": "274", "author": "M. Shirane", "year": "1999", "unstructured": "Shirane M, Harumiya Y, Ishida N, et al., (1999). Down-regulation of p27Kipl by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem, 274:13886\u201393.", "journal-title": "J Biol Chem"}, {"key": "12_CR147", "doi-asserted-by": "crossref", "first-page": "4", "DOI": "10.1016/S1097-2765(03)00529-X", "volume": "13", "author": "A. Shmueli", "year": "2004", "unstructured": "Shmueli A & Oren M. (2004). Regulation of p53 by Mdm2: Fate is in the numbers. Mol Cell, 13:4\u20135.", "journal-title": "Mol Cell"}, {"key": "12_CR148", "doi-asserted-by": "crossref", "first-page": "633", "DOI": "10.1172/JCI0215795", "volume": "110", "author": "S. Signoretti", "year": "2002", "unstructured": "Signoretti S, Di Marcotullio L, Richardson A, et al., (2002). Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest, 110:633\u201341.", "journal-title": "J Clin Invest"}, {"key": "12_CR149", "doi-asserted-by": "crossref", "first-page": "2809", "DOI": "10.1038/sj.onc.1207516", "volume": "23", "author": "E.A. Slee", "year": "2004", "unstructured": "Slee EA, O\u2019Connor DJ & Lu X. (2004). To die or not to die: How does p53 decide? Oncogene, 23:2809\u201318.", "journal-title": "Oncogene"}, {"key": "12_CR150", "doi-asserted-by": "crossref", "first-page": "861", "DOI": "10.1124/jpet.103.055806", "volume": "307", "author": "G.W. Small", "year": "2003", "unstructured": "Small GW, Somasundaram S, Moore DT, et al., (2003). Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their anti-apoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther, 307:861\u20139.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "12_CR151", "first-page": "631", "volume": "1", "author": "M.E. Stearns", "year": "2003", "unstructured": "Stearns ME, Wang M, Hu Y & Garcia FU. (2003). Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines. Mol Cancer Res, 1:631\u201342.", "journal-title": "Mol Cancer Res"}, {"key": "12_CR152", "doi-asserted-by": "crossref", "first-page": "193", "DOI": "10.1023/B:APPT.0000018801.59062.1d", "volume": "9", "author": "T. Stoklosa", "year": "2004", "unstructured": "Stoklosa T, Golacedil BJ, Wojcik C, et al., (2004). Increased local vascular endothelial growth factor expression associated with anti-tumor activity of proteasome inhibitor. Apoptosis, 9:193\u2013204.", "journal-title": "Apoptosis"}, {"key": "12_CR153", "first-page": "1419", "volume": "7", "author": "J.B. Sunwoo", "year": "2001", "unstructured": "Sunwoo JB, Chen Z, Dong G, et al., (2001). Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res, 7:1419\u201328.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR154", "first-page": "1259", "volume": "57", "author": "P. Tan", "year": "1997", "unstructured": "Tan P, Cady B, Wanner M, et al., (1997). The cell cycle inhibitor p27 is an independent prognostic marker in small (Tla,b) invasive breast carcinomas. Cancer Res, 57:1259\u201363.", "journal-title": "Cancer Res"}, {"key": "12_CR155", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1023/A:1006909522731", "volume": "26", "author": "N. Tanahashi", "year": "1999", "unstructured": "Tanahashi N, Kawahara H, Murakami Y & Tanaka K. (1999). The proteasome-dependent proteolytic system. Mol Biol Rep, 26:3\u20139.", "journal-title": "Mol Biol Rep"}, {"key": "12_CR156", "first-page": "2638", "volume": "5", "author": "B.A. Teicher", "year": "1999", "unstructured": "Teicher BA, Ara G, Herbst R, et al., (1999). The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res, 5:2638\u201345.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR157", "doi-asserted-by": "crossref", "first-page": "870", "DOI": "10.1126/science.288.5467.870", "volume": "288", "author": "C. Tournier", "year": "2000", "unstructured": "Tournier C, Hess P, Yang DD, et al., (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science, 288:870\u20134.", "journal-title": "Science"}, {"key": "12_CR158", "doi-asserted-by": "crossref", "first-page": "1889", "DOI": "10.1038/sj.emboj.7600194", "volume": "23", "author": "F. Tsuruta", "year": "2004", "unstructured": "Tsuruta F, Sunayama J, Mori Y, et al., (2004). JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J, 23:1889\u201399.", "journal-title": "EMBO J"}, {"key": "12_CR159", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.1016/S0960-9822(99)80290-5", "volume": "9", "author": "L.M. Tsvetkov", "year": "1999", "unstructured": "Tsvetkov LM, Yeh KH, Lee SJ, et al., (1999). p27Kipl ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thrl87 in p27. Curr Biol, 9:661\u20134.", "journal-title": "Curr Biol"}, {"key": "12_CR160", "doi-asserted-by": "crossref", "first-page": "9421", "DOI": "10.1021/bi00154a014", "volume": "31", "author": "A. Vinitsky", "year": "1992", "unstructured": "Vinitsky A, Michaud C, Powers JC & Orlowski M. (1992). Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 31:9421\u20138.", "journal-title": "Biochemistry"}, {"key": "12_CR161", "first-page": "6316", "volume": "9", "author": "P.M. Voorhees", "year": "2003", "unstructured": "Voorhees PM, Dees EC, O\u2019Neil B & Orlowski RZ. (2003). The proteasome as a target for cancer therapy. Clin Cancer Res, 9:6316\u201325.", "journal-title": "Clin Cancer Res"}, {"key": "12_CR162", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1159/000016308", "volume": "9", "author": "B. Wagenknecht", "year": "1999", "unstructured": "Wagenknecht B, Hermisson M, Eitel K & Weller M. (1999). Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell. Physiol Biochem., 9:117\u201325.", "journal-title": "Cell. Physiol Biochem."}, {"key": "12_CR163", "doi-asserted-by": "crossref", "first-page": "784", "DOI": "10.1126/science.274.5288.784", "volume": "274", "author": "C.Y. Wang", "year": "1996", "unstructured": "Wang CY, Mayo MW & Baldwin AS Jr. (1996). TNF-and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science, 274:784\u20137.", "journal-title": "Science"}, {"key": "12_CR164", "first-page": "835", "volume": "2", "author": "S. Williams", "year": "2003", "unstructured": "Williams S, Pettaway C, Song R, et al., (2003). Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther, 2:835\u201343.", "journal-title": "Mol Cancer Ther"}, {"key": "12_CR165", "first-page": "7338", "volume": "63", "author": "S.A. Williams", "year": "2003", "unstructured": "Williams SA & McConkey DJ. (2003). The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res, 63:7338\u201344.", "journal-title": "Cancer Res"}, {"key": "12_CR166", "doi-asserted-by": "crossref", "first-page": "32", "DOI": "10.1097/00002371-199801000-00004", "volume": "21", "author": "C. Wong", "year": "1998", "unstructured": "Wong C, Morse M & Nair SK. (1998). Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother, 21:32\u201340.", "journal-title": "J Immunother"}, {"key": "12_CR167", "first-page": "1625", "volume": "91", "author": "L. Xia", "year": "1998", "unstructured": "Xia L, Pan J, Yao L & McEver RP. (1998). A proteasome inhibitor, an antioxidant, or a salicylate, but not a glucocorticoid, blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood, 91:1625\u201332.", "journal-title": "Blood"}, {"key": "12_CR168", "doi-asserted-by": "crossref", "first-page": "315", "DOI": "10.1034/j.1600-0609.2000.90110.x", "volume": "64", "author": "Y. Yamada", "year": "2000", "unstructured": "Yamada Y, Sugahara K, Tsuruda K, et al., (2000). Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines. Eur J Haematol, 64:315\u201322.", "journal-title": "Eur J Haematol"}, {"key": "12_CR169", "doi-asserted-by": "crossref", "first-page": "4239", "DOI": "10.1200/JCO.2003.06.001", "volume": "21", "author": "H.H. Yang", "year": "2003", "unstructured": "Yang HH, Ma MH, Vescio RA & Berenson JR. (2003). Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J Clin Oncol, 21:4239\u201347.", "journal-title": "J Clin Oncol"}, {"key": "12_CR170", "first-page": "625", "volume": "15", "author": "S.A. You", "year": "1999", "unstructured": "You SA, Basu A & Haldar S. (1999). Potent anti-tumor agent proteasome inhibitors: A novel trigger for Bcl-2 phosphorylation to induce apoptosis. Int J Oncol, 15:625\u20138.", "journal-title": "Int J Oncol"}, {"key": "12_CR171", "doi-asserted-by": "crossref", "first-page": "555", "DOI": "10.1016/j.yexcr.2004.02.001", "volume": "295", "author": "C. Yu", "year": "2004", "unstructured": "Yu C, Rahmani M, Dent P & Grant S. (2004). The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res, 295:555\u201366.", "journal-title": "Exp Cell Res"}, {"key": "12_CR172", "first-page": "236a", "volume": "102", "author": "M. Zangari", "year": "2003", "unstructured": "Zangari M, Barlogie B, Jacobson J, et al., (2003). VTD regimen comprising VELCADE\u00ae (V) + thalidomide (T) and added dex (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma relapsing after autologous transplant. Blood, 102:236a, Abstract 830.", "journal-title": "Blood"}, {"key": "12_CR173", "doi-asserted-by": "crossref", "first-page": "24101", "DOI": "10.1074/jbc.272.39.24101", "volume": "272", "author": "J. Zha", "year": "1997", "unstructured": "Zha J, Harada H, Osipov K, et al., (1997). BH3 domain of Bad is required for heterodimerization with Bcl-xl and pro-apoptotic activity. J Biol Chem, 272:24101\u201304.", "journal-title": "J Biol Chem"}, {"key": "12_CR174", "doi-asserted-by": "crossref", "first-page": "2009", "DOI": "10.1038/sj.onc.1207373", "volume": "23", "author": "H.G. Zhang", "year": "2004", "unstructured": "Zhang HG, Wang J, Yang X, et al., (2004). Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene, 23:2009\u201315.", "journal-title": "Oncogene"}, {"key": "12_CR175", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1038/sj.onc.1200841", "volume": "14", "author": "W. Zhang", "year": "1997", "unstructured": "Zhang W, Lu Q, Xie ZJ & Mellgren RL. (1997). Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr-diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene, 14:255\u201363.", "journal-title": "Oncogene"}, {"key": "12_CR176", "doi-asserted-by": "crossref", "first-page": "127", "DOI": "10.1042/bj3400127", "volume": "340", "author": "X.M. Zhang", "year": "1999", "unstructured": "Zhang XM, Lin H, Chen C & Chen BD. (1999). Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J, 340(Pt 1):127\u201333.", "journal-title": "Biochem J"}, {"key": "12_CR177", "doi-asserted-by": "crossref", "first-page": "2100", "DOI": "10.1161/01.CIR.100.20.2100", "volume": "100", "author": "W. Zhu", "year": "1999", "unstructured": "Zhu W, Zou Y, Aikawa R, et al., (1999). MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation, 100:2100\u201307.", "journal-title": "Circulation"}, {"key": "12_CR178", "doi-asserted-by": "crossref", "first-page": "242", "DOI": "10.1016/S0959-440X(00)00075-0", "volume": "10", "author": "P. Zwickl", "year": "2000", "unstructured": "Zwickl P, Baumeister W & Steven A. (2000). Dis-assembly lines: The proteasome and related ATPase-assisted proteases. Curr Opin Struct Biol, 10:242\u201350.", "journal-title": "Curr Opin Struct Biol"}], "container-title": ["Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/0-387-23695-3_12", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 2, 11]], "date-time": "2019-02-11T01:23:34Z", "timestamp": 1549848214000}, "score": 22.555223, "issued": {"date-parts": [[null]]}, "ISBN": ["0387233849"], "references-count": 178, "URL": "http://dx.doi.org/10.1007/0-387-23695-3_12", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T08:09:03Z", "timestamp": 1575274143727}, "reference-count": 10, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2013, 9, 1]], "date-time": "2013-09-01T00:00:00Z", "timestamp": 1377993600000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "https://www.elsevier.com/open-access/userlicense/1.0/", "start": {"date-parts": [[2014, 9, 9]], "date-time": "2014-09-09T00:00:00Z", "timestamp": 1410220800000}, "delay-in-days": 373, "content-version": "vor"}], "content-domain": {"domain": ["cancercell.org", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Cancer Cell"], "published-print": {"date-parts": [[2013, 9]]}, "DOI": "10.1016/j.ccr.2013.08.014", "type": "journal-article", "created": {"date-parts": [[2013, 9, 10]], "date-time": "2013-09-10T12:40:28Z", "timestamp": 1378816828000}, "page": "275-277", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma"], "prefix": "10.1016", "volume": "24", "author": [{"given": "Robert\u00a0Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Cancer Cell"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1535610813003607?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1535610813003607?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 10, 13]], "date-time": "2018-10-13T06:24:16Z", "timestamp": 1539411856000}, "score": 22.555223, "issued": {"date-parts": [[2013, 9]]}, "references-count": 10, "journal-issue": {"published-print": {"date-parts": [[2013, 9]]}, "issue": "3"}, "alternative-id": ["S1535610813003607"], "URL": "http://dx.doi.org/10.1016/j.ccr.2013.08.014", "ISSN": ["1535-6108"], "issn-type": [{"value": "1535-6108", "type": "print"}], "subject": ["Cell Biology", "Cancer Research", "Oncology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma", "name": "articletitle", "label": "Article Title"}, {"value": "Cancer Cell", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ccr.2013.08.014", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "https://doi.org/10.1016/j.ccr.2013.08.009", "name": "associatedlink", "label": "CrossRef DOI link to the associated document"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "Copyright \u00a9 2013 Elsevier Inc. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:04:35Z", "timestamp": 1575173075509}, "reference-count": 125, "publisher": "Annual Reviews", "issue": "1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Annu. Rev. Pharmacol. Toxicol."], "published-print": {"date-parts": [[2006, 2]]}, "DOI": "10.1146/annurev.pharmtox.46.120604.141300", "type": "journal-article", "created": {"date-parts": [[2005, 8, 31]], "date-time": "2005-08-31T23:43:10Z", "timestamp": 1125531790000}, "page": "189-213", "source": "Crossref", "is-referenced-by-count": 162, "title": ["THE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY"], "prefix": "10.1146", "volume": "46", "author": [{"given": "Peter M.", "family": "Voorhees", "sequence": "first", "affiliation": [{"name": "Department of Medicine, Division of Hematology/Oncology, 2Lineberger Comprehensive Cancer Center, and 3Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295; email:"}]}, {"given": "Robert Z.", "family": "Orlowski", "sequence": "additional", "affiliation": [{"name": "Department of Medicine, Division of Hematology/Oncology, 2Lineberger Comprehensive Cancer Center, and 3Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295; email:"}]}], "member": "22", "container-title": ["Annual Review of Pharmacology and Toxicology"], "language": "en", "link": [{"URL": "http://www.annualreviews.org/doi/pdf/10.1146/annurev.pharmtox.46.120604.141300", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 19]], "date-time": "2019-03-19T01:21:15Z", "timestamp": 1552958475000}, "score": 22.42125, "issued": {"date-parts": [[2006, 2]]}, "references-count": 125, "journal-issue": {"published-print": {"date-parts": [[2006, 2]]}, "issue": "1"}, "alternative-id": ["10.1146/annurev.pharmtox.46.120604.141300"], "URL": "http://dx.doi.org/10.1146/annurev.pharmtox.46.120604.141300", "ISSN": ["0362-1642", "1545-4304"], "issn-type": [{"value": "0362-1642", "type": "print"}, {"value": "1545-4304", "type": "electronic"}], "subject": ["Toxicology", "Pharmacology"]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T07:38:45Z", "timestamp": 1575531525853}, "reference-count": 0, "publisher": "American Society of Hematology", "issue": "21", "content-domain": {"domain": ["ashpublications.org"], "crossmark-restriction": true}, "published-print": {"date-parts": [[2013, 11, 15]]}, "abstract": "<jats:title>Abstract</jats:title>\n               <jats:sec>\n                  <jats:title>Background</jats:title>\n                  <jats:p>Proteasome inhibition with bortezomib has revolutionized the treatment of multiple myeloma, but the vast majority of patients eventually develop clinical bortezomib resistance through poorly understood mechanisms. One of the most conserved cellular responses to proteasome inhibition is to up-regulate proteasome subunit expression, presumably with the goal of enhancing proteasome activity and restoring intracellular protein homeostasis. We therefore hypothesized that proteasome inhibitor resistance could be associated with enhanced proteasome assembly, and that suppression of this assembly process could help restore drug sensitivity. The current studies focused on POMP, which is involved in addition of catalytically active b subunits to the hemiproteasome ring initially formed by structural a subunits.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Methods</jats:title>\n                  <jats:p>We studied ANBL-6, KAS-6/1, OPM-2, and RPMI 8226 multiple myeloma cell lines which had acquired bortezomib resistance through prolonged exposure to increasing drug concentrations, and compared them to their drug-na\u00efve, vehicle-treated counterparts. In addition, we evaluated primary cells derived from patients with myeloma, and examined an in vivo murine xenograft model of human myeloma.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Results</jats:title>\n                  <jats:p>Bortezomib-resistant (V10R) ANBL-6, KAS-6/1, OPM-2, and RPMI 8226 cell lines showed enhanced levels of POMP mRNA by quantitative (q) PCR compared to their drug-sensitive counterparts, which was associated with higher POMP protein levels seen by immunoblotting. Exogenous over-expression of POMP in drug-na\u00efve OPM-2 and KAS-6/1 cells was sufficient by itself to induce resistance to both bortezomib and carfilzomib. Conversely, suppression of POMP with one of two different Lentiviral small hairpin (sh) RNAs restored sensitivity in OPM-2 and KAS-6/1 V10R cells to bortezomib and carfilzomib. Since no known pharmaceuticals directly target POMP, we examined its promoter region, and found a consensus binding site for nuclear factor (erythroid-derived 2)-like (NRF) 2. Consistent with a role of NRF2 in POMP expression, NRF2 mRNA and protein were increased in V10R myeloma cells, and in drug-na\u00efve cells treated with bortezomib. Moreover, transfection of cells with NRF2 cDNA activated a POMP promoter reporter, while chromatin immunoprecipitation with anti-NRF2 antibodies preferentially precipitated sequences near the POMP promoter. Also, NRF2 over-expression induced POMP and enhanced proteasome chymotrypsin-like activity, while its suppression had the opposite effects. All trans-retinoic acid (ATRA) blocked nuclear accumulation of NRF2 in OPM-2 and KAS-6/1 V10R cells, and reduced expression of POMP. Combinations of bortezomib with ATRA showed enhanced activity against these drug-resistant cell lines in association with greater proteasome inhibition, and were synergistic in drug-na\u00efve cells. In primary samples, ATRA with bortezomib induced a greater reduction in viability than did either treatment alone. Finally, in a murine xenograft model with OPM-2 V10R cells, neither ATRA nor bortezomib showed substantial activity, while the combination regimen, by comparison, retained efficacy.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions</jats:title>\n                  <jats:p>Taken together, our data support the hypotheses that NRF-2-influenced POMP over-expression contributes to proteasome inhibitor resistance in multiple myeloma, while approaches targeting POMP hold promise in overcoming resistance. Moreover, they provide a framework for translation of proteasome inhibitors with ATRA to the clinic to enhance activity, and to overcome resistance to this important class of anti-myeloma agents.</jats:p>\n               </jats:sec>\n               <jats:sec>\n                  <jats:title>Disclosures:</jats:title>\n                  <jats:p>No relevant conflicts of interest to declare.</jats:p>\n               </jats:sec>", "DOI": "10.1182/blood.v122.21.280.280", "type": "journal-article", "created": {"date-parts": [[2019, 10, 14]], "date-time": "2019-10-14T17:55:19Z", "timestamp": 1571075719000}, "page": "280-280", "update-policy": "http://dx.doi.org/10.1182/blood.2019cm0000", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Proteasome Maturation Protein (pomp) Is Associated With Proteasome Inhibitor Resistance In Myeloma, and Its Suppression Enhances The Activity Of Bortezomib and Carfilzomib"], "prefix": "10.1182", "volume": "122", "author": [{"given": "Bingzong", "family": "Li", "sequence": "first", "affiliation": [{"name": "Department of Hematology, 2nd Affiliated Hospital of Soochow University, Suzhou, China,"}]}, {"given": "Hua", "family": "Wang", "sequence": "additional", "affiliation": [{"name": "Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}]}, {"given": "Robert Z.", "family": "Orlowski", "sequence": "additional", "affiliation": [{"name": "Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}]}], "member": "234", "container-title": ["Blood"], "language": "en", "link": [{"URL": "https://ashpublications.org/blood/article/122/21/280/84881/Proteasome-Maturation-Protein-pomp-Is-Associated", "content-type": "application/pdf", "content-version": "vor", "intended-application": "syndication"}, {"URL": "https://ashpublications.org/blood/article/122/21/280/84881/Proteasome-Maturation-Protein-pomp-Is-Associated", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T00:43:20Z", "timestamp": 1574124200000}, "score": 22.42125, "issued": {"date-parts": [[2013, 11, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2013, 11, 15]]}, "issue": "21"}, "URL": "http://dx.doi.org/10.1182/blood.v122.21.280.280", "ISSN": ["0006-4971", "1528-0020"], "issn-type": [{"value": "0006-4971", "type": "print"}, {"value": "1528-0020", "type": "electronic"}], "subject": ["Immunology", "Cell Biology", "Biochemistry", "Hematology"]}, {"indexed": {"date-parts": [[2019, 12, 16]], "date-time": "2019-12-16T22:47:55Z", "timestamp": 1576536475026}, "reference-count": 145, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2000, 11, 1]], "date-time": "2000-11-01T00:00:00Z", "timestamp": 973036800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Archives of Biochemistry and Biophysics"], "published-print": {"date-parts": [[2000, 11]]}, "DOI": "10.1006/abbi.2000.2036", "type": "journal-article", "created": {"date-parts": [[2002, 9, 16]], "date-time": "2002-09-16T13:49:45Z", "timestamp": 1032184185000}, "page": "1-16", "source": "Crossref", "is-referenced-by-count": 191, "title": ["Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase Complex"], "prefix": "10.1006", "volume": "383", "author": [{"given": "Marian", "family": "Orlowski", "sequence": "first", "affiliation": []}, {"given": "Sherwin", "family": "Wilk", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Archives of Biochemistry and Biophysics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0003986100920368?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0003986100920368?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 12, 16]], "date-time": "2019-12-16T19:43:48Z", "timestamp": 1576525428000}, "score": 21.190872, "issued": {"date-parts": [[2000, 11]]}, "references-count": 145, "journal-issue": {"published-print": {"date-parts": [[2000, 11]]}, "issue": "1"}, "alternative-id": ["S0003986100920368"], "URL": "http://dx.doi.org/10.1006/abbi.2000.2036", "ISSN": ["0003-9861"], "issn-type": [{"value": "0003-9861", "type": "print"}], "subject": ["Biophysics", "Biochemistry", "Molecular Biology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T21:57:16Z", "timestamp": 1574546236481}, "publisher-location": "Cham", "reference-count": 65, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319067513", "type": "print"}, {"value": "9783319067520", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2014]]}, "DOI": "10.1007/978-3-319-06752-0_3", "type": "book-chapter", "created": {"date-parts": [[2014, 9, 16]], "date-time": "2014-09-16T06:02:17Z", "timestamp": 1410847337000}, "page": "81-98", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Overcoming Bortezomib Resistance: A Review of the Second-Generation Proteasome Inhibitor Carfilzomib in the Treatment of Multiple Myeloma"], "prefix": "10.1007", "author": [{"given": "Hans C.", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "Robert Z.", "family": "Orlowski", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2014, 8, 26]]}, "reference": [{"issue": "5", "key": "3_CR1", "doi-asserted-by": "publisher", "first-page": "2516", "DOI": "10.1182/blood-2007-10-116129", "volume": "111", "author": "SK Kumar", "year": "2008", "unstructured": "Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520", "journal-title": "Blood"}, {"issue": "26", "key": "3_CR2", "doi-asserted-by": "publisher", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26): 2609\u20132617", "journal-title": "N Engl J Med"}, {"issue": "3", "key": "3_CR3", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.2174/156800911794519752", "volume": "11", "author": "D Chen", "year": "2011", "unstructured": "Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP (2011) Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11(3):239\u2013253", "journal-title": "Curr Cancer Drug Targets"}, {"issue": "23", "key": "3_CR4", "doi-asserted-by": "publisher", "first-page": "10317", "DOI": "10.1021/jm300434z", "volume": "55", "author": "AJ Kale", "year": "2012", "unstructured": "Kale AJ, Moore BS (2012) Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem 55(23):10317\u201310327", "journal-title": "J Med Chem"}, {"issue": "4\u20135", "key": "3_CR5", "doi-asserted-by": "publisher", "first-page": "164", "DOI": "10.1016/j.drup.2008.08.002", "volume": "11", "author": "DJ McConkey", "year": "2008", "unstructured": "McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11(4\u20135):164\u2013179", "journal-title": "Drug Resist Updat"}, {"issue": "12", "key": "3_CR6", "doi-asserted-by": "publisher", "first-page": "3777", "DOI": "10.1182/blood-2005-03-1173", "volume": "106", "author": "S Lonial", "year": "2005", "unstructured": "Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 106(12):3777\u20133784", "journal-title": "Blood"}, {"issue": "5", "key": "3_CR7", "doi-asserted-by": "publisher", "first-page": "1593", "DOI": "10.1182/blood-2008-04-149385", "volume": "112", "author": "AA Argyriou", "year": "2008", "unstructured": "Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 112(5):1593\u20131599", "journal-title": "Blood"}, {"issue": "11", "key": "3_CR8", "doi-asserted-by": "publisher", "first-page": "1746", "DOI": "10.7164/antibiotics.45.1746", "volume": "45", "author": "M Hanada", "year": "1992", "unstructured": "Hanada M, Sugawara K, Kaneta K, Toda S, Nishiyama Y, Tomita K, Yamamoto H, Konishi M, Oki T (1992) Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) 45(11):1746\u20131752", "journal-title": "J Antibiot (Tokyo)"}, {"issue": "1", "key": "3_CR9", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.7164/antibiotics.43.8", "volume": "43", "author": "K Sugawara", "year": "1990", "unstructured": "Sugawara K, Hatori M, Nishiyama Y, Tomita K, Kamei H, Konishi M, Oki T (1990) Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J Antibiot (Tokyo) 43(1):8\u201318", "journal-title": "J Antibiot (Tokyo)"}, {"issue": "18", "key": "3_CR10", "doi-asserted-by": "publisher", "first-page": "10403", "DOI": "10.1073/pnas.96.18.10403", "volume": "96", "author": "L Meng", "year": "1999", "unstructured": "Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 96(18):10403\u201310408", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "6", "key": "3_CR11", "doi-asserted-by": "publisher", "first-page": "1237", "DOI": "10.1021/ja993588m", "volume": "122", "author": "M Groll", "year": "2000", "unstructured": "Groll M, Kim K, Kairies N, Huber R, Crews C (2000) Crystal structure of epoxomicin: 20s proteasome reveals a molecular basis for selectivity of \u03b1\u2032, \u03b2\u2032-epoxyketone proteasome inhibitors. J Am Chem Soc 122(6):1237\u20131238", "journal-title": "J Am Chem Soc"}, {"issue": "15", "key": "3_CR12", "doi-asserted-by": "publisher", "first-page": "2283", "DOI": "10.1016/S0960-894X(99)00376-5", "volume": "9", "author": "N Sin", "year": "1999", "unstructured": "Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH, Crews CM (1999) Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 9(15):2283\u20132288", "journal-title": "Bioorg Med Chem Lett"}, {"issue": "11", "key": "3_CR13", "doi-asserted-by": "publisher", "first-page": "811", "DOI": "10.1016/S1074-5521(99)80128-8", "volume": "6", "author": "M Elofsson", "year": "1999", "unstructured": "Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM (1999) Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha\u2032, beta\u2032-epoxyketones. Chem Biol 6(11):811\u2013822", "journal-title": "Chem Biol"}, {"issue": "9", "key": "3_CR14", "doi-asserted-by": "publisher", "first-page": "3281", "DOI": "10.1182/blood-2007-01-065888", "volume": "110", "author": "DJ Kuhn", "year": "2007", "unstructured": "Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110(9):3281\u20133290", "journal-title": "Blood"}, {"issue": "16", "key": "3_CR15", "doi-asserted-by": "publisher", "first-page": "3439", "DOI": "10.1182/blood-2009-05-223677", "volume": "114", "author": "F Parlati", "year": "2009", "unstructured": "Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, Shenk KD, Bennett MK (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114(16): 3439\u20133447", "journal-title": "Blood"}, {"issue": "8", "key": "3_CR16", "doi-asserted-by": "publisher", "first-page": "1889", "DOI": "10.1038/sj.emboj.7600194", "volume": "23", "author": "F Tsuruta", "year": "2004", "unstructured": "Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N, Gotoh Y (2004) JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23(8):1889\u20131899", "journal-title": "EMBO J"}, {"issue": "2", "key": "3_CR17", "doi-asserted-by": "publisher", "first-page": "176", "DOI": "10.1111/j.1349-7006.2004.tb03200.x", "volume": "95", "author": "Y Yang", "year": "2004", "unstructured": "Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 95(2):176\u2013180", "journal-title": "Cancer Sci"}, {"issue": "7", "key": "3_CR18", "doi-asserted-by": "publisher", "first-page": "1753", "DOI": "10.1158/1078-0432.CCR-10-2130", "volume": "17", "author": "A Sacco", "year": "2011", "unstructured": "Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, Roccaro AM, Ghobrial IM (2011) Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom\u2019s Macroglobulinemia. Clin Cancer Res 17(7):1753\u20131764", "journal-title": "Clin Cancer Res"}, {"issue": "13", "key": "3_CR19", "doi-asserted-by": "publisher", "first-page": "6383", "DOI": "10.1158/0008-5472.CAN-06-4086", "volume": "67", "author": "SD Demo", "year": "2007", "unstructured": "Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67(13):6383\u20136391", "journal-title": "Cancer Res"}, {"issue": "22", "key": "3_CR20", "doi-asserted-by": "publisher", "first-page": "14374", "DOI": "10.1073/pnas.202445099", "volume": "99", "author": "N Mitsiades", "year": "2002", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99(22):14374\u201314379", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "24", "key": "3_CR21", "doi-asserted-by": "publisher", "first-page": "21517", "DOI": "10.1074/jbc.M301032200", "volume": "278", "author": "S Meiners", "year": "2003", "unstructured": "Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Kruger E (2003) Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 278(24):21517\u201321525", "journal-title": "J Biol Chem"}, {"issue": "13", "key": "3_CR22", "doi-asserted-by": "publisher", "first-page": "3512", "DOI": "10.1182/blood-2010-12-328252", "volume": "118", "author": "JD Shaughnessy Jr", "year": "2011", "unstructured": "Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B (2011) Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 118(13):3512\u20133524", "journal-title": "Blood"}, {"issue": "6", "key": "3_CR23", "doi-asserted-by": "publisher", "first-page": "2489", "DOI": "10.1182/blood-2007-08-104950", "volume": "112", "author": "R Oerlemans", "year": "2008", "unstructured": "Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112(6):2489\u20132499", "journal-title": "Blood"}, {"issue": "10", "key": "3_CR24", "doi-asserted-by": "publisher", "first-page": "1278", "DOI": "10.1016/j.exphem.2008.04.013", "volume": "36", "author": "S Lu", "year": "2008", "unstructured": "Lu S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L, Wang J (2008) Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 36(10):1278\u20131284", "journal-title": "Exp Hematol"}, {"issue": "12", "key": "3_CR25", "doi-asserted-by": "publisher", "first-page": "e27996", "DOI": "10.1371/journal.pone.0027996", "volume": "6", "author": "E Suzuki", "year": "2011", "unstructured": "Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ (2011) Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS One 6(12):e27996", "journal-title": "PLoS One"}, {"issue": "4", "key": "3_CR26", "doi-asserted-by": "publisher", "first-page": "757", "DOI": "10.1038/leu.2011.256", "volume": "26", "author": "NE Franke", "year": "2012", "unstructured": "Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J (2012) Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 26(4):757\u2013768", "journal-title": "Leukemia"}, {"issue": "2", "key": "3_CR27", "doi-asserted-by": "publisher", "first-page": "240", "DOI": "10.1016/j.leukres.2005.06.014", "volume": "30", "author": "M Politou", "year": "2006", "unstructured": "Politou M, Karadimitris A, Terpos E, Kotsianidis I, Apperley JF, Rahemtulla A (2006) No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leuk Res 30(2):240\u2013241", "journal-title": "Leuk Res"}, {"issue": "23", "key": "3_CR28", "doi-asserted-by": "publisher", "first-page": "4513", "DOI": "10.1182/blood-2012-05-426924", "volume": "120", "author": "DI Lichter", "year": "2012", "unstructured": "Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Blade J, Facon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC (2012) Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood 120(23):4513\u20134516", "journal-title": "Blood"}, {"issue": "11", "key": "3_CR29", "doi-asserted-by": "publisher", "first-page": "3503", "DOI": "10.1158/1078-0432.CCR-07-5150", "volume": "14", "author": "L Wang", "year": "2008", "unstructured": "Wang L, Kumar S, Fridley BL, Kalari KR, Moon I, Pelleymounter LL, Hildebrandt MA, Batzler A, Eckloff BW, Wieben ED, Greipp PR (2008) Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics. Clin Cancer Res 14(11):3503\u20133513", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "3_CR30", "doi-asserted-by": "publisher", "first-page": "2108", "DOI": "10.1200/JCO.2004.02.106", "volume": "22", "author": "CN Papandreou", "year": "2004", "unstructured": "Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ (2004) Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108\u20132121", "journal-title": "J Clin Oncol"}, {"issue": "6", "key": "3_CR31", "doi-asserted-by": "publisher", "first-page": "777", "DOI": "10.1007/s00280-007-0424-9", "volume": "60", "author": "A Hemeryck", "year": "2007", "unstructured": "Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R (2007) Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 60(6):777\u2013787", "journal-title": "Cancer Chemother Pharmacol"}, {"issue": "10", "key": "3_CR32", "doi-asserted-by": "publisher", "first-page": "1873", "DOI": "10.1124/dmd.111.039164", "volume": "39", "author": "J Yang", "year": "2011", "unstructured": "Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ (2011) Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos 39(10):1873\u20131882", "journal-title": "Drug Metab Dispos"}, {"key": "3_CR33", "unstructured": "Rosen PJ, Gordon P, Lee E, Sausville K, Papadopoulous A, Wong M, Vallone L, Kunkel L, Infante J, Burris H (2012) Phase II results of study PX-171-007: a phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. J Clin Oncol 27(15S):(suppl; abstr 3515)"}, {"issue": "1", "key": "3_CR34", "doi-asserted-by": "publisher", "first-page": "230", "DOI": "10.1124/dmd.112.047662", "volume": "41", "author": "Z Wang", "year": "2013", "unstructured": "Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR (2013) Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 41(1):230\u2013237", "journal-title": "Drug Metab Dispos"}, {"issue": "22", "key": "3_CR35", "doi-asserted-by": "publisher", "first-page": "7085", "DOI": "10.1158/1078-0432.CCR-09-0822", "volume": "15", "author": "OA O\u2019Connor", "year": "2009", "unstructured": "O\u2019Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15(22):7085\u20137091", "journal-title": "Clin Cancer Res"}, {"issue": "17", "key": "3_CR36", "doi-asserted-by": "publisher", "first-page": "4830", "DOI": "10.1158/1078-0432.CCR-11-3007", "volume": "18", "author": "M Alsina", "year": "2012", "unstructured": "Alsina M, Trudel S, Furman RR, Rosen PJ, O\u2019Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A (2012) A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 18(17):4830\u20134840", "journal-title": "Clin Cancer Res"}, {"issue": "22", "key": "3_CR37", "doi-asserted-by": "publisher", "first-page": "4420", "DOI": "10.1200/JCO.2002.01.133", "volume": "20", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O\u2019Connor OA, Soignet SL (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420\u20134427", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "3_CR38", "doi-asserted-by": "publisher", "first-page": "310", "DOI": "10.1016/j.clml.2012.08.003", "volume": "12", "author": "S Jagannath", "year": "2012", "unstructured": "Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS (2012) An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 12(5):310\u2013318", "journal-title": "Clin Lymphoma Myeloma Leuk"}, {"issue": "9", "key": "3_CR39", "doi-asserted-by": "publisher", "first-page": "1467", "DOI": "10.1038/sj.leu.2404284", "volume": "20", "author": "BG Durie", "year": "2006", "unstructured": "Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467\u20131473", "journal-title": "Leukemia"}, {"issue": "5", "key": "3_CR40", "doi-asserted-by": "publisher", "first-page": "1115", "DOI": "10.1046/j.1365-2141.1998.00930.x", "volume": "102", "author": "J Blade", "year": "1998", "unstructured": "Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102(5):1115\u20131123", "journal-title": "Br J Haematol"}, {"issue": "14", "key": "3_CR41", "doi-asserted-by": "publisher", "first-page": "2817", "DOI": "10.1182/blood-2012-05-425934", "volume": "120", "author": "DS Siegel", "year": "2012", "unstructured": "Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817\u20132825", "journal-title": "Blood"}, {"issue": "12", "key": "3_CR42", "doi-asserted-by": "publisher", "first-page": "2351", "DOI": "10.1038/leu.2013.152", "volume": "27", "author": "AJ Jakubowiak", "year": "2013", "unstructured": "Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S (2013) Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12):2351\u20132356", "journal-title": "Leukemia"}, {"issue": "5", "key": "3_CR43", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1016/S1470-2045(11)70081-X", "volume": "12", "author": "P Moreau", "year": "2011", "unstructured": "Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431\u2013440. doi: 10.1016/S1470-2045(11)70081-X", "journal-title": "Lancet Oncol"}, {"issue": "9", "key": "3_CR44", "doi-asserted-by": "publisher", "first-page": "2734", "DOI": "10.1158/1078-0432.CCR-10-1950", "volume": "17", "author": "S Arastu-Kapur", "year": "2011", "unstructured": "Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, Kirk CJ (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 17(9): 2734\u20132743", "journal-title": "Clin Cancer Res"}, {"key": "3_CR45", "unstructured": "New Drug Application (NDA) 202714, carfilzomib (Kyprolis): Food and Drug Administration briefing document, Oncologic Drugs Advisory Committee Meeting, June 20, 2012."}, {"issue": "24", "key": "3_CR46", "doi-asserted-by": "publisher", "first-page": "5661", "DOI": "10.1182/blood-2012-03-414359", "volume": "119", "author": "R Vij", "year": "2012", "unstructured": "Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS (2012) An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 119(24): 5661\u20135670", "journal-title": "Blood"}, {"issue": "24", "key": "3_CR47", "doi-asserted-by": "publisher", "first-page": "2487", "DOI": "10.1056/NEJMoa043445", "volume": "352", "author": "PG Richardson", "year": "2005", "unstructured": "Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u20132498", "journal-title": "N Engl J Med"}, {"issue": "25", "key": "3_CR48", "doi-asserted-by": "publisher", "first-page": "3892", "DOI": "10.1200/JCO.2006.10.5460", "volume": "25", "author": "RZ Orlowski", "year": "2007", "unstructured": "Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25(25):3892\u20133901", "journal-title": "J Clin Oncol"}, {"issue": "21", "key": "3_CR49", "first-page": "2930", "volume": "118", "author": "K Papadopoulos", "year": "2011", "unstructured": "Papadopoulos K, Lee P, Singhal S, Holahan J, Vesole D, Rosen S, Kunkel L, Zojwalla N, Hannah A, Siegel D (2011) A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56mg/m2 expansion cohort of PX-171-007. Blood 118(21):2930", "journal-title": "Blood"}, {"issue": "8", "key": "3_CR50", "doi-asserted-by": "publisher", "first-page": "1707", "DOI": "10.1038/leu.2013.29", "volume": "27", "author": "AZ Badros", "year": "2013", "unstructured": "Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R (2013) Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 27(8):1707\u20131714", "journal-title": "Leukemia"}, {"key": "3_CR51", "unstructured": "Wang M, Martin T, Bensinger W, Alsina M, Siegel D, Kavalerchik E, Niesvizky R (2013) Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. J Clin Oncol 31:(suppl; abstr 8529)", "DOI": "10.1182/blood-2013-07-511170", "doi-asserted-by": "crossref"}, {"issue": "21", "key": "3_CR52", "doi-asserted-by": "publisher", "first-page": "2123", "DOI": "10.1056/NEJMoa070594", "volume": "357", "author": "M Dimopoulos", "year": "2007", "unstructured": "Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123\u20132132", "journal-title": "N Engl J Med"}, {"issue": "21", "key": "3_CR53", "doi-asserted-by": "publisher", "first-page": "2133", "DOI": "10.1056/NEJMoa070596", "volume": "357", "author": "DM Weber", "year": "2007", "unstructured": "Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357(21):2133\u20132142", "journal-title": "N Engl J Med"}, {"key": "3_CR54", "unstructured": "Anderson K, Jagannath S, Jakubowiak S, Lonial S, Raje N, Alsina M, Ghobrial I, Knight R, Esseltine D, Richardson P (2009) Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study J Clin Oncol 27 (15S):(suppl; abstr 8536)"}, {"issue": "9", "key": "3_CR55", "doi-asserted-by": "publisher", "first-page": "1801", "DOI": "10.1182/blood-2012-04-422683", "volume": "120", "author": "AJ Jakubowiak", "year": "2012", "unstructured": "Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120(9):1801\u20131809", "journal-title": "Blood"}, {"issue": "5", "key": "3_CR56", "doi-asserted-by": "publisher", "first-page": "679", "DOI": "10.1182/blood-2010-02-268862", "volume": "116", "author": "PG Richardson", "year": "2010", "unstructured": "Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC (2010) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116(5):679\u2013686", "journal-title": "Blood"}, {"issue": "21", "key": "3_CR57", "first-page": "4082", "volume": "120", "author": "JJ Shah", "year": "2012", "unstructured": "Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Parmar S, Shah N, Bashir Q, Popat UR, Hilder B, Orlowski RZ (2012) Phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520\u2009+\u2009carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21):4082", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR58", "first-page": "4048", "volume": "120", "author": "JG Berdeja", "year": "2012", "unstructured": "Berdeja JG, Hart L, Lamar R, Murphy P, Morgan S, Flinn IW (2012) Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase I safety analysis. ASH Annual Meeting Abstracts 120(21):4048", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR59", "first-page": "4081", "volume": "120", "author": "JJ Shah", "year": "2012", "unstructured": "Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH, Bashir Q, Parmar S, Shah N, Popat UR, Orlowski RZ (2012) Phase 1/1b study of the efficacy and safety of the combination of panobinostat\u2009+\u2009carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21):4081", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR60", "first-page": "74", "volume": "120", "author": "JJ Shah", "year": "2012", "unstructured": "Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Orlowski RZ, Kim EL, McKinley MB, Durie BGM (2012) A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 120(21):74", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR61", "first-page": "633", "volume": "118", "author": "P Sonneveld", "year": "2011", "unstructured": "Sonneveld P, Hacker E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk-Kooy M, de Weerdt O, Lonergan S, Palumbo A, Lokhorst HM (2011) Carfilzomib combined with thalidomide and dexamethasone (CARTHADEX) as induction treatment prior to high-dose melphalan (HDM) in newly diagnosed patients with multiple myeloma (MM). a trial of the European Myeloma Network EMN. ASH Annual Meeting Abstracts 118(21):633", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR62", "first-page": "445", "volume": "120", "author": "JR Mikhael", "year": "2012", "unstructured": "Mikhael JR, Reeder CB, Libby EN III, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Gano K, Wolf C, Dueck AC, Stewart AK (2012) Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts 120(21):445", "journal-title": "ASH Annual Meeting Abstracts"}, {"issue": "21", "key": "3_CR63", "first-page": "730", "volume": "120", "author": "A Palumbo", "year": "2012", "unstructured": "Palumbo A, Bringhen S, Villani O, Siniscalchi A, Russo E, Uccello G, Cerrato C, Gilestro M, Rossi D, Boccadoro M (2012) Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients. ASH Annual Meeting Abstracts 120(21):730", "journal-title": "ASH Annual Meeting Abstracts"}, {"key": "3_CR64", "unstructured": "Kolb B, Hulin C, Caillot D, Benboubker L, Tiab M, Blin M, Leleu X, Roussel M, Attal M, Facon T, Moreau P (2012) Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. J Clin Oncol 30:(suppl; abstr 8009)"}, {"issue": "S2", "key": "3_CR65", "first-page": "374", "volume": "96", "author": "K Papadopoulos", "year": "2011", "unstructured": "Papadopoulos K, Lee P, Singhal S, Holahan J, Tolcher A, Patnaik A, Vesole D, Rosen S, Rosen P, Bilotti E, Woo T, Lee S, Hannah A, Siegel D (2011) PX-171-007: a phase 1b study of evaluation the safety and efficacy of a 30-min IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM). Haematology 96(S2):374", "journal-title": "Haematology"}], "container-title": ["Resistance to Targeted Anti-Cancer Therapeutics", "Resistance to Proteasome Inhibitors in Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-06752-0_3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 15]], "date-time": "2019-08-15T01:06:46Z", "timestamp": 1565831206000}, "score": 20.59373, "issued": {"date-parts": [[2014]]}, "ISBN": ["9783319067513", "9783319067520"], "references-count": 65, "URL": "http://dx.doi.org/10.1007/978-3-319-06752-0_3", "relation": {"cites": []}, "ISSN": ["2196-5501", "2196-551X"], "issn-type": [{"value": "2196-5501", "type": "print"}, {"value": "2196-551X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T03:43:07Z", "timestamp": 1574134987141}, "reference-count": 72, "publisher": "American Society for Biochemistry & Molecular Biology (ASBMB)", "issue": "31", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["J. Biol. Chem."], "published-print": {"date-parts": [[2002, 8, 2]]}, "DOI": "10.1074/jbc.m201519200", "type": "journal-article", "created": {"date-parts": [[2002, 9, 18]], "date-time": "2002-09-18T17:58:01Z", "timestamp": 1032371881000}, "page": "27864-27871", "source": "Crossref", "is-referenced-by-count": 77, "title": ["Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis"], "prefix": "10.1074", "volume": "277", "author": [{"given": "Robert Z.", "family": "Orlowski", "sequence": "first", "affiliation": []}, {"given": "George W.", "family": "Small", "sequence": "additional", "affiliation": []}, {"given": "Yue Y.", "family": "Shi", "sequence": "additional", "affiliation": []}], "member": "28", "published-online": {"date-parts": [[2002, 5, 22]]}, "reference": [{"key": "2017062210223765000_277.31.27864.1", "author": "Goldberg", "volume": "378", "first-page": "131", "year": "1997", "journal-title": "Biol. Chem."}, {"key": "2017062210223765000_277.31.27864.2", "DOI": "10.1074/jbc.274.32.22123", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.3", "DOI": "10.1023/A:1006909522731", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.4", "DOI": "10.1016/S0959-440X(00)00075-0", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.5", "DOI": "10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.6", "DOI": "10.1006/abbi.2000.2036", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.7", "DOI": "10.1016/S0955-0674(97)80079-8", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.8", "DOI": "10.1038/35056572", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.9", "DOI": "10.1006/bbrc.1998.8604", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.10", "DOI": "10.1038/sj.cdd.4400505", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.11", "DOI": "10.1007/978-3-540-69184-6_10", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.12", "DOI": "10.2174/1389450003349056", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.13", "author": "Orlowski", "volume": "58", "first-page": "4342", "year": "1998", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.14", "DOI": "10.1038/bjc.1998.183", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.15", "DOI": "10.1038/sj.cdd.4400436", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.16", "author": "Adams", "volume": "59", "first-page": "2615", "year": "1999", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.17", "author": "Teicher", "volume": "5", "first-page": "2638", "year": "1999", "journal-title": "Clin. Cancer Res."}, {"key": "2017062210223765000_277.31.27864.18", "author": "Sun", "volume": "61", "first-page": "1280", "year": "2001", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.19", "author": "Stinchcombe", "volume": "96", "first-page": "516a", "year": "2000", "journal-title": "Am. Soc. Hematol."}, {"key": "2017062210223765000_277.31.27864.20", "author": "Hirsch", "volume": "161", "first-page": "35", "year": "1998", "journal-title": "J. Immunol."}, {"key": "2017062210223765000_277.31.27864.21", "DOI": "10.1074/jbc.272.20.12893", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.22", "DOI": "10.1074/jbc.273.11.6373", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.23", "author": "Kudo", "volume": "6", "first-page": "916", "year": "2000", "journal-title": "Clin. Cancer Res."}, {"key": "2017062210223765000_277.31.27864.24", "DOI": "10.1038/7410", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.25", "author": "Cusack", "volume": "61", "first-page": "3535", "year": "2001", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.26", "DOI": "10.1074/jbc.M001083200", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.27", "DOI": "10.1016/S0014-5793(01)02770-3", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.28", "DOI": "10.1038/sj.leu.2401222", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.29", "DOI": "10.1128/MCB.19.4.2435", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.30", "DOI": "10.1006/excr.2000.4836", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.31", "author": "Figueiredo-Pereira", "volume": "62", "first-page": "1989", "year": "1994", "journal-title": "J. Neurochem.", "DOI": "10.1046/j.1471-4159.1994.62051989.x", "doi-asserted-by": "crossref"}, {"key": "2017062210223765000_277.31.27864.32", "DOI": "10.1016/S0092-8674(94)90462-6", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.33", "DOI": "10.1093/oxfordjournals.jbchem.a021280", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.34", "DOI": "10.1083/jcb.142.3.625", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.35", "DOI": "10.1002/1097-4644(20010101)80:1<11::AID-JCB20>3.0.CO;2-W", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.36", "DOI": "10.1126/science.286.5449.2514", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.37", "author": "Hideshima", "volume": "61", "first-page": "3071", "year": "2001", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.38", "DOI": "10.1021/bi00154a014", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.39", "author": "Clark", "volume": "48", "first-page": "4689", "year": "1988", "journal-title": "Cancer Res."}, {"key": "2017062210223765000_277.31.27864.40", "DOI": "10.1093/jnci/53.3.661", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.41", "DOI": "10.1093/jnci/61.4.967", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.42", "DOI": "10.1038/227680a0", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.43", "DOI": "10.1074/jbc.271.11.6497", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.44", "author": "Robbins", "volume": "268", "first-page": "5097", "year": "1993", "journal-title": "J. Biol. Chem."}, {"key": "2017062210223765000_277.31.27864.45", "author": "Vinitsky", "volume": "269", "first-page": "29860", "year": "1994", "journal-title": "J. Biol. Chem."}, {"key": "2017062210223765000_277.31.27864.46", "DOI": "10.1074/jbc.273.15.8545", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.47", "DOI": "10.1006/excr.1999.4687", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.48", "author": "Camps", "volume": "14", "first-page": "6", "year": "2000", "journal-title": "FASEB J."}, {"key": "2017062210223765000_277.31.27864.49", "DOI": "10.1038/337078a0", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.50", "DOI": "10.1016/0014-5793(89)80803-8", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.51", "DOI": "10.1016/0968-0004(90)90192-E", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.52", "DOI": "10.1042/bj1810247", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.53", "author": "Swarup", "volume": "257", "first-page": "7298", "year": "1982", "journal-title": "J. Biol. Chem."}, {"key": "2017062210223765000_277.31.27864.54", "DOI": "10.1016/0006-291X(89)92189-X", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.55", "DOI": "10.1038/359644a0", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.56", "DOI": "10.1016/0092-8674(93)90383-2", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.57", "DOI": "10.1074/jbc.270.15.8377", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.58", "DOI": "10.1074/jbc.272.14.9086", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.59", "DOI": "10.1074/jbc.270.13.7161", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.60", "DOI": "10.1074/jbc.271.43.27018", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.61", "DOI": "10.1073/pnas.92.17.7686", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.62", "DOI": "10.1074/jbc.270.46.27489", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.63", "DOI": "10.1074/jbc.273.29.18623", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.64", "DOI": "10.1016/S0955-0674(99)80025-8", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.65", "DOI": "10.1016/S0955-0674(99)80024-6", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.66", "DOI": "10.1042/bj3520475", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.67", "DOI": "10.1016/S1074-5521(01)00056-4", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.68", "DOI": "10.1210/edrv-16-5-559", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.69", "DOI": "10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.70", "DOI": "10.1182/blood.V97.7.2105", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.71", "DOI": "10.1038/sj.onc.1203606", "doi-asserted-by": "publisher"}, {"key": "2017062210223765000_277.31.27864.72", "DOI": "10.1074/jbc.C000684200", "doi-asserted-by": "publisher"}], "container-title": ["Journal of Biological Chemistry"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1074/jbc.M201519200", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 23]], "date-time": "2017-06-23T11:52:59Z", "timestamp": 1498218779000}, "score": 20.549377, "issued": {"date-parts": [[2002, 5, 22]]}, "references-count": 72, "journal-issue": {"published-online": {"date-parts": [[2002, 7, 26]]}, "published-print": {"date-parts": [[2002, 8, 2]]}, "issue": "31"}, "alternative-id": ["10.1074/jbc.M201519200"], "URL": "http://dx.doi.org/10.1074/jbc.m201519200", "relation": {"cites": []}, "ISSN": ["0021-9258", "1083-351X"], "issn-type": [{"value": "0021-9258", "type": "print"}, {"value": "1083-351X", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T07:33:10Z", "timestamp": 1574321590910}, "reference-count": 224, "publisher": "Springer Science and Business Media LLC", "issue": "11", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2009, 9, 10]], "date-time": "2009-09-10T00:00:00Z", "timestamp": 1252540800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Leukemia"], "published-print": {"date-parts": [[2009, 11]]}, "DOI": "10.1038/leu.2009.173", "type": "journal-article", "created": {"date-parts": [[2009, 9, 10]], "date-time": "2009-09-10T10:29:38Z", "timestamp": 1252578578000}, "page": "1964-1979", "source": "Crossref", "is-referenced-by-count": 104, "title": ["Proteasome inhibitors in the treatment of multiple myeloma"], "prefix": "10.1038", "volume": "23", "author": [{"given": "J J", "family": "Shah", "sequence": "first", "affiliation": []}, {"given": "R Z", "family": "Orlowski", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2009, 9, 10]]}, "reference": [{"key": "BFleu2009173_CR1", "doi-asserted-by": "publisher", "first-page": "2962", "DOI": "10.1182/blood-2007-10-078022", "volume": "111", "author": "RA Kyle", "year": "2008", "unstructured": "Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962\u20132972.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR2", "doi-asserted-by": "publisher", "first-page": "339", "DOI": "10.1016/j.neuron.2005.01.019", "volume": "45", "author": "AL Goldberg", "year": "2005", "unstructured": "Goldberg AL . Nobel committee tags ubiquitin for distinction. Neuron 2005; 45: 339\u2013344.", "journal-title": "Neuron"}, {"key": "BFleu2009173_CR3", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1196/annals.1402.078", "volume": "1116", "author": "A Ciechanover", "year": "2007", "unstructured": "Ciechanover A . Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin\u2013proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann NY Acad Sci 2007; 1116: 1\u201328.", "journal-title": "Ann NY Acad Sci"}, {"key": "BFleu2009173_CR4", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1006/abbi.2000.2036", "volume": "383", "author": "M Orlowski", "year": "2000", "unstructured": "Orlowski M, Wilk S . Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 2000; 383: 1\u201316.", "journal-title": "Arch Biochem Biophys"}, {"key": "BFleu2009173_CR5", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1007/978-1-4419-8861-4_5", "volume": "547", "author": "MC Rechsteiner", "year": "2004", "unstructured": "Rechsteiner MC . Ubiquitin-mediated proteolysis: an ideal pathway for systems biology analysis. Adv Exp Med Biol 2004; 547: 49\u201359.", "journal-title": "Adv Exp Med Biol"}, {"issue": "Part 1", "key": "BFleu2009173_CR6", "doi-asserted-by": "publisher", "first-page": "12", "DOI": "10.1042/BST0350012", "volume": "35", "author": "AL Goldberg", "year": "2007", "unstructured": "Goldberg AL . Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007; 35 (Part 1): 12\u201317.", "journal-title": "Biochem Soc Trans"}, {"key": "BFleu2009173_CR7", "doi-asserted-by": "publisher", "first-page": "9421", "DOI": "10.1021/bi00154a014", "volume": "31", "author": "A Vinitsky", "year": "1992", "unstructured": "Vinitsky A, Michaud C, Powers JC, Orlowski M . Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992; 31: 9421\u20139428.", "journal-title": "Biochemistry"}, {"key": "BFleu2009173_CR8", "first-page": "29860", "volume": "269", "author": "A Vinitsky", "year": "1994", "unstructured": "Vinitsky A, Cardozo C, Sepp-Lorenzino L, Michaud C, Orlowski M . Inhibition of the proteolytic activity of the multicatalytic proteinase complex (proteasome) by substrate-related peptidyl aldehydes. J Biol Chem 1994; 269: 29860\u201329866.", "journal-title": "J Biol Chem"}, {"key": "BFleu2009173_CR9", "doi-asserted-by": "publisher", "first-page": "1070", "DOI": "10.1006/bbrc.1995.2878", "volume": "217", "author": "KT Imajoh-Ohmi", "year": "1995", "unstructured": "Imajoh-Ohmi KT, Sugiyama S, Tanaka K, Omura S, Kikuchi H . Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 1995; 217: 1070\u20131077.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "BFleu2009173_CR10", "doi-asserted-by": "publisher", "first-page": "385", "DOI": "10.1042/bj3170385", "volume": "317", "author": "K Shinohara", "year": "1996", "unstructured": "Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, Kawashima S . Apoptosis induction resulting from proteasome inhibition. Biochem J 1996; 317: 385\u2013388.", "journal-title": "Biochem J"}, {"key": "BFleu2009173_CR11", "first-page": "4342", "volume": "58", "author": "RZ Orlowski", "year": "1998", "unstructured": "Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV . Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58: 4342\u20134348.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR12", "doi-asserted-by": "publisher", "first-page": "1103", "DOI": "10.1038/bjc.1998.183", "volume": "77", "author": "J Delic", "year": "1998", "unstructured": "Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77: 1103\u20131107.", "journal-title": "Br J Cancer"}, {"key": "BFleu2009173_CR13", "doi-asserted-by": "publisher", "first-page": "686", "DOI": "10.1158/1535-7163.MCT-04-0338", "volume": "4", "author": "D Chauhan", "year": "2005", "unstructured": "Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC . Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005; 4: 686\u2013692.", "journal-title": "Mol Cancer Ther"}, {"key": "BFleu2009173_CR14", "doi-asserted-by": "publisher", "first-page": "391", "DOI": "10.1097/MOH.0b013e328302c7f4", "volume": "15", "author": "ZW Li", "year": "2008", "unstructured": "Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR . NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 2008; 15: 391\u2013399.", "journal-title": "Curr Opin Hematol"}, {"key": "BFleu2009173_CR15", "first-page": "3071", "volume": "61", "author": "T Hideshima", "year": "2001", "unstructured": "Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071\u20133076.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR16", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1016/j.ccr.2007.07.004", "volume": "12", "author": "CM Annunziata", "year": "2007", "unstructured": "Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12: 115\u2013130.", "journal-title": "Cancer Cell"}, {"key": "BFleu2009173_CR17", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.1016/j.ccr.2007.07.003", "volume": "12", "author": "JJ Keats", "year": "2007", "unstructured": "Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131\u2013144.", "journal-title": "Cancer Cell"}, {"key": "BFleu2009173_CR18", "doi-asserted-by": "publisher", "first-page": "761", "DOI": "10.1016/S0092-8674(94)90462-6", "volume": "78", "author": "KL Rock", "year": "1994", "unstructured": "Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761\u2013771.", "journal-title": "Cell"}, {"key": "BFleu2009173_CR19", "doi-asserted-by": "publisher", "first-page": "1783", "DOI": "10.1158/0008-5472.CAN-06-2258", "volume": "67", "author": "S Meister", "year": "2007", "unstructured": "Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783\u20131792.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR20", "doi-asserted-by": "publisher", "first-page": "1649", "DOI": "10.1158/1078-0432.CCR-07-2218", "volume": "14", "author": "RZ Orlowski", "year": "2008", "unstructured": "Orlowski RZ, Kuhn DJ . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649\u20131657.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR21", "doi-asserted-by": "publisher", "first-page": "4420", "DOI": "10.1200/JCO.2002.01.133", "volume": "20", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420\u20134427.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR22", "doi-asserted-by": "publisher", "first-page": "2609", "DOI": "10.1056/NEJMoa030288", "volume": "348", "author": "PG Richardson", "year": "2003", "unstructured": "Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609\u20132617.", "journal-title": "N Engl J Med"}, {"key": "BFleu2009173_CR23", "doi-asserted-by": "publisher", "first-page": "165", "DOI": "10.1111/j.1365-2141.2004.05188.x", "volume": "127", "author": "S Jagannath", "year": "2004", "unstructured": "Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165\u2013172.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR24", "first-page": "537", "volume": "143", "author": "S Jagannath", "year": "2008", "unstructured": "Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008; 143: 537\u2013540.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR25", "doi-asserted-by": "publisher", "first-page": "1316", "DOI": "10.1002/cncr.21740", "volume": "106", "author": "PG Richardson", "year": "2006", "unstructured": "Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316\u20131319.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR26", "doi-asserted-by": "publisher", "first-page": "867", "DOI": "10.4065/79.7.867", "volume": "79", "author": "SK Kumar", "year": "2004", "unstructured": "Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867\u2013874.", "journal-title": "Mayo Clin Proc"}, {"key": "BFleu2009173_CR27", "doi-asserted-by": "publisher", "first-page": "3777", "DOI": "10.1182/blood-2005-03-1173", "volume": "106", "author": "S Lonial", "year": "2005", "unstructured": "Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777\u20133784.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR28", "doi-asserted-by": "publisher", "first-page": "1042", "DOI": "10.1002/cncr.22921", "volume": "110", "author": "A Badros", "year": "2007", "unstructured": "Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042\u20131049.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR29", "doi-asserted-by": "publisher", "first-page": "3113", "DOI": "10.1200/JCO.2005.04.7779", "volume": "24", "author": "PG Richardson", "year": "2006", "unstructured": "Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113\u20133120.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR30", "doi-asserted-by": "publisher", "first-page": "895", "DOI": "10.1111/j.1365-2141.2008.07573.x", "volume": "144", "author": "PG Richardson", "year": "2009", "unstructured": "Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009; 144: 895\u2013903.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR31", "doi-asserted-by": "publisher", "first-page": "2487", "DOI": "10.1056/NEJMoa043445", "volume": "352", "author": "PG Richardson", "year": "2005", "unstructured": "Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.", "journal-title": "N Engl J Med"}, {"key": "BFleu2009173_CR32", "doi-asserted-by": "publisher", "first-page": "4784", "DOI": "10.1200/JCO.2007.14.9641", "volume": "26", "author": "A Chanan-Khan", "year": "2008", "unstructured": "Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784\u20134790.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR33", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.3816/CLM.2008.n.031", "volume": "8", "author": "SJ Kim", "year": "2008", "unstructured": "Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 237\u2013240.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR34", "doi-asserted-by": "publisher", "first-page": "229", "DOI": "10.1002/cncr.24006", "volume": "115", "author": "E Vickrey", "year": "2009", "unstructured": "Vickrey E, Allen S, Mehta J, Singhal S . Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009; 115: 229\u2013232.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR35", "doi-asserted-by": "publisher", "first-page": "3557", "DOI": "10.1182/blood-2006-08-036947", "volume": "110", "author": "PG Richardson", "year": "2007", "unstructured": "Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557\u20133560.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR36", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1002/cncr.23606", "volume": "113", "author": "JD Hainsworth", "year": "2008", "unstructured": "Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J et al. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008; 113: 765\u2013771.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR37", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.3816/CLM.2006.n.050", "volume": "7", "author": "A Suvannasankha", "year": "2006", "unstructured": "Suvannasankha A, Smith GG, Juliar BE, Abonour R . Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 131\u2013134.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR38", "doi-asserted-by": "publisher", "first-page": "623", "DOI": "10.1007/s00432-004-0593-4", "volume": "130", "author": "E Terpos", "year": "2004", "unstructured": "Terpos E, Politou M, Rahemtulla A . Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004; 130: 623\u2013625.", "journal-title": "J Cancer Res Clin Oncol"}, {"key": "BFleu2009173_CR39", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.3816/CLM.2006.n.064", "volume": "7", "author": "O Sezer", "year": "2006", "unstructured": "Sezer O, Vesole DH, Singhal S, Richardson P, Stadtmauer E, Jakob C et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 233\u2013235.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR40", "doi-asserted-by": "publisher", "first-page": "2380", "DOI": "10.1080/10428190802484099", "volume": "49", "author": "M Furtado", "year": "2008", "unstructured": "Furtado M, Rule S . Bortezomib-associated tumor lysis syndrome in multiple myeloma. Leuk Lymphoma 2008; 49: 2380\u20132382.", "journal-title": "Leuk Lymphoma"}, {"key": "BFleu2009173_CR41", "doi-asserted-by": "publisher", "first-page": "3492", "DOI": "10.1182/blood-2005-11-4541", "volume": "107", "author": "S Miyakoshi", "year": "2006", "unstructured": "Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006; 107: 3492\u20133494.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR42", "doi-asserted-by": "publisher", "first-page": "553", "DOI": "10.1097/01.mjt.0000245224.20913.0d", "volume": "13", "author": "A Ohri", "year": "2006", "unstructured": "Ohri A, Arena FP . Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther 2006; 13: 553\u2013555.", "journal-title": "Am J Ther"}, {"key": "BFleu2009173_CR43", "doi-asserted-by": "publisher", "first-page": "90", "DOI": "10.1532/IJH97.06062", "volume": "84", "author": "C Shimazaki", "year": "2006", "unstructured": "Shimazaki C, Kobayashi Y, Inaba T, Taniwaki M . Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients. Int J Hematol 2006; 84: 90\u201391.", "journal-title": "Int J Hematol"}, {"key": "BFleu2009173_CR44", "doi-asserted-by": "publisher", "first-page": "897", "DOI": "10.1016/j.jaad.2006.06.030", "volume": "55", "author": "KL Wu", "year": "2006", "unstructured": "Wu KL, Heule F, Lam K, Sonneveld P . Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol 2006; 55: 897\u2013900.", "journal-title": "J Am Acad Dermatol"}, {"key": "BFleu2009173_CR45", "doi-asserted-by": "publisher", "first-page": "464", "DOI": "10.1001/archinte.165.4.464", "volume": "165", "author": "L Rosinol", "year": "2005", "unstructured": "Rosinol L, Montoto S, Cibeira MT, Blade J . Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005; 165: 464\u2013465.", "journal-title": "Arch Intern Med"}, {"key": "BFleu2009173_CR46", "doi-asserted-by": "publisher", "first-page": "2141", "DOI": "10.1002/cncr.21427", "volume": "104", "author": "JR Berenson", "year": "2005", "unstructured": "Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104: 2141\u20132148.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR47", "doi-asserted-by": "publisher", "first-page": "317", "DOI": "10.1016/j.expneurol.2006.11.010", "volume": "204", "author": "G Cavaletti", "year": "2007", "unstructured": "Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317\u2013325.", "journal-title": "Exp Neurol"}, {"key": "BFleu2009173_CR48", "doi-asserted-by": "publisher", "first-page": "1593", "DOI": "10.1182/blood-2008-04-149385", "volume": "112", "author": "AA Argyriou", "year": "2008", "unstructured": "Argyriou AA, Iconomou G, Kalofonos HP . Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112: 1593\u20131599.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR49", "doi-asserted-by": "publisher", "first-page": "940", "DOI": "10.4161/cc.7.7.5625", "volume": "7", "author": "MS Poruchynsky", "year": "2008", "unstructured": "Poruchynsky MS, Sackett DL, Robey RW, Ward Y, Annunziata C, Fojo T . Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle 2008; 7: 940\u2013949.", "journal-title": "Cell Cycle"}, {"key": "BFleu2009173_CR50", "doi-asserted-by": "publisher", "first-page": "2507", "DOI": "10.1016/j.clinph.2008.08.007", "volume": "119", "author": "S Ravaglia", "year": "2008", "unstructured": "Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008; 119: 2507\u20132512.", "journal-title": "Clin Neurophysiol"}, {"key": "BFleu2009173_CR51", "doi-asserted-by": "publisher", "first-page": "429", "DOI": "10.1111/j.1365-2141.2007.06585.x", "volume": "137", "author": "PG Richardson", "year": "2007", "unstructured": "Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429\u2013435.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR52", "doi-asserted-by": "publisher", "first-page": "2977", "DOI": "10.1182/blood-2005-02-0691", "volume": "106", "author": "PG Richardson", "year": "2005", "unstructured": "Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106: 2977\u20132981.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR53", "doi-asserted-by": "publisher", "first-page": "1195", "DOI": "10.1002/cncr.20888", "volume": "103", "author": "S Jagannath", "year": "2005", "unstructured": "Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005; 103: 1195\u20131200.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR54", "doi-asserted-by": "publisher", "first-page": "2604", "DOI": "10.1182/blood-2006-09-046409", "volume": "109", "author": "AA Chanan-Khan", "year": "2007", "unstructured": "Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604\u20132606.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR55", "doi-asserted-by": "publisher", "first-page": "842", "DOI": "10.1038/sj.leu.2405087", "volume": "22", "author": "JF San-Miguel", "year": "2008", "unstructured": "San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008; 22: 842\u2013849.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR56", "doi-asserted-by": "publisher", "first-page": "255", "DOI": "10.1159/000095876", "volume": "116", "author": "AK Malani", "year": "2006", "unstructured": "Malani AK, Gupta V, Rangineni R . Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematologica 2006; 116: 255\u2013258.", "journal-title": "Acta Haematologica"}, {"key": "BFleu2009173_CR57", "doi-asserted-by": "publisher", "first-page": "546", "DOI": "10.3324/haematol.10759", "volume": "92", "author": "E Kastritis", "year": "2007", "unstructured": "Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546\u2013549.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR58", "doi-asserted-by": "publisher", "first-page": "1411", "DOI": "10.3324/haematol.11463", "volume": "92", "author": "H Ludwig", "year": "2007", "unstructured": "Ludwig H, Drach J, Graf H, Lang A, Meran JG . Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411\u20131414.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR59", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1038/sj.leu.2404442", "volume": "21", "author": "S Jagannath", "year": "2007", "unstructured": "Jagannath S, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151\u2013157.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR60", "doi-asserted-by": "publisher", "first-page": "164", "DOI": "10.1038/sj.leu.2404459", "volume": "21", "author": "V Sagaster", "year": "2007", "unstructured": "Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164\u2013168.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR61", "doi-asserted-by": "publisher", "first-page": "779", "DOI": "10.1016/j.leukres.2006.08.002", "volume": "31", "author": "H Chang", "year": "2007", "unstructured": "Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D . Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007; 31: 779\u2013782.", "journal-title": "Leuk Res"}, {"key": "BFleu2009173_CR62", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1111/j.1365-2141.2005.05733.x", "volume": "131", "author": "M Zangari", "year": "2005", "unstructured": "Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71\u201373.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR63", "doi-asserted-by": "publisher", "first-page": "233", "DOI": "10.1111/j.1600-0609.2006.00692.x", "volume": "77", "author": "U Heider", "year": "2006", "unstructured": "Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006; 77: 233\u2013238.", "journal-title": "Eur J Haematol"}, {"key": "BFleu2009173_CR64", "doi-asserted-by": "publisher", "first-page": "688", "DOI": "10.1111/j.1365-2141.2006.06356.x", "volume": "135", "author": "E Terpos", "year": "2006", "unstructured": "Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688\u2013692.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR65", "doi-asserted-by": "publisher", "first-page": "2247", "DOI": "10.1038/leu.2008.235", "volume": "22", "author": "E Terpos", "year": "2008", "unstructured": "Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247\u20132256.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR66", "doi-asserted-by": "publisher", "first-page": "180", "DOI": "10.1532/IJH97.07030", "volume": "86", "author": "S Ozaki", "year": "2007", "unstructured": "Ozaki S, Tanaka O, Fujii S, Shigekiyo Y, Miki H, Choraku M et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007; 86: 180\u2013185.", "journal-title": "Int J Hematol"}, {"key": "BFleu2009173_CR67", "doi-asserted-by": "publisher", "first-page": "831", "DOI": "10.1002/ajh.20961", "volume": "82", "author": "M Zangari", "year": "2007", "unstructured": "Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 2007; 82: 831\u2013833.", "journal-title": "Am J Hematol"}, {"key": "BFleu2009173_CR68", "doi-asserted-by": "publisher", "first-page": "630", "DOI": "10.1200/JCO.2005.11.030", "volume": "23", "author": "SV Rajkumar", "year": "2005", "unstructured": "Rajkumar SV, Richardson PG, Hideshima T, Anderson KC . Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630\u2013639.", "journal-title": "J Clin Oncol"}, {"issue": "Suppl 1", "key": "BFleu2009173_CR69", "doi-asserted-by": "publisher", "first-page": "S1", "DOI": "10.1186/1471-2091-9-S1-S1", "volume": "9", "author": "D Chauhan", "year": "2008", "unstructured": "Chauhan D, Bianchi G, Anderson KC . Targeting the UPS as therapy in multiple myeloma. BMC Biochem 2008; 9 (Suppl 1): S1; available online and pending publication.", "journal-title": "BMC Biochem"}, {"key": "BFleu2009173_CR70", "doi-asserted-by": "publisher", "first-page": "2377", "DOI": "10.1182/blood-2002-06-1768", "volume": "101", "author": "N Mitsiades", "year": "2003", "unstructured": "Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377\u20132380.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR71", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.1111/j.1365-2141.2008.07409.x", "volume": "144", "author": "JR Mikhael", "year": "2009", "unstructured": "Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009; 144: 169\u2013175.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR72", "first-page": "929", "volume": "91", "author": "S Jagannath", "year": "2006", "unstructured": "Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929\u2013934.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR73", "first-page": "837", "volume": "91", "author": "B Bruno", "year": "2006", "unstructured": "Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J et al. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica 2006; 91: 837\u2013839.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR74", "doi-asserted-by": "publisher", "first-page": "27864", "DOI": "10.1074/jbc.M201519200", "volume": "277", "author": "RZ Orlowski", "year": "2002", "unstructured": "Orlowski RZ, Small GW, Shi YY . Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 2002; 277: 27864\u201327871.", "journal-title": "J Biol Chem"}, {"key": "BFleu2009173_CR75", "doi-asserted-by": "publisher", "first-page": "861", "DOI": "10.1124/jpet.103.055806", "volume": "307", "author": "GW Small", "year": "2003", "unstructured": "Small GW, Somasundaram S, Moore DT, Shi YY, Orlowski RZ . Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 2003; 307: 861\u2013869.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "BFleu2009173_CR76", "doi-asserted-by": "publisher", "first-page": "1478", "DOI": "10.1124/mol.104.003400", "volume": "66", "author": "GW Small", "year": "2004", "unstructured": "Small GW, Shi YY, Edmund NA, Somasundaram S, Moore DT, Orlowski RZ . Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 2004; 66: 1478\u20131490.", "journal-title": "Mol Pharmacol"}, {"key": "BFleu2009173_CR77", "doi-asserted-by": "publisher", "first-page": "3058", "DOI": "10.1182/blood-2004-07-2911", "volume": "105", "author": "RZ Orlowski", "year": "2005", "unstructured": "Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058\u20133065.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR78", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1007/s00277-006-0220-3", "volume": "86", "author": "SE Biehn", "year": "2007", "unstructured": "Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007; 86: 211\u2013216.", "journal-title": "Ann Hematol"}, {"key": "BFleu2009173_CR79", "doi-asserted-by": "publisher", "first-page": "3892", "DOI": "10.1200/JCO.2006.10.5460", "volume": "25", "author": "RZ Orlowski", "year": "2007", "unstructured": "Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892\u20133901.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR80", "doi-asserted-by": "publisher", "first-page": "1529", "DOI": "10.1002/cncr.23326", "volume": "112", "author": "P Sonneveld", "year": "2008", "unstructured": "Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112: 1529\u20131537.", "journal-title": "Cancer"}, {"key": "BFleu2009173_CR81", "doi-asserted-by": "publisher", "first-page": "352", "DOI": "10.3816/CLM.2008.n.051", "volume": "8", "author": "J Blade", "year": "2008", "unstructured": "Blade J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A et al. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008; 8: 352\u2013355.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR82", "doi-asserted-by": "publisher", "first-page": "14374", "DOI": "10.1073/pnas.202445099", "volume": "99", "author": "N Mitsiades", "year": "2002", "unstructured": "Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374\u201314379.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFleu2009173_CR83", "doi-asserted-by": "publisher", "first-page": "6469", "DOI": "10.1158/1078-0432.CCR-07-1293", "volume": "13", "author": "PM Voorhees", "year": "2007", "unstructured": "Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007; 13: 6469\u20136478.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR84", "doi-asserted-by": "publisher", "first-page": "4053", "DOI": "10.1182/blood-2005-08-3434", "volume": "107", "author": "T Hideshima", "year": "2006", "unstructured": "Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053\u20134062.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR85", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1007/s10549-006-9232-x", "volume": "100", "author": "YY Shi", "year": "2006", "unstructured": "Shi YY, Small GW, Orlowski RZ . Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer. Breast Cancer Res Treat 2006; 100: 33\u201347.", "journal-title": "Breast Cancer Res Treat"}, {"key": "BFleu2009173_CR86", "doi-asserted-by": "publisher", "first-page": "8567", "DOI": "10.1073/pnas.0503221102", "volume": "102", "author": "T Hideshima", "year": "2005", "unstructured": "Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567\u20138572.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFleu2009173_CR87", "doi-asserted-by": "publisher", "first-page": "3773", "DOI": "10.1158/0008-5472.CAN-05-2961", "volume": "66", "author": "ST Nawrocki", "year": "2006", "unstructured": "Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner Jr K et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006; 66: 3773\u20133781.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR88", "doi-asserted-by": "publisher", "first-page": "3441", "DOI": "10.1182/blood-2006-04-016055", "volume": "108", "author": "L Catley", "year": "2006", "unstructured": "Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441\u20133449.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR89", "doi-asserted-by": "publisher", "first-page": "814", "DOI": "10.1111/j.1365-2141.2008.07147.x", "volume": "141", "author": "S Ciolli", "year": "2008", "unstructured": "Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A . The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008; 141: 814\u2013819.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR90", "doi-asserted-by": "publisher", "first-page": "4777", "DOI": "10.1200/JCO.2007.14.2372", "volume": "26", "author": "DE Reece", "year": "2008", "unstructured": "Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008; 26: 4777\u20134783.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR91", "first-page": "Abstract 870", "volume": "112", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin DH et al. Phase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed/refractory multiple myeloma who were previously relapsed from or refractory to bortezomib. Blood 2008; 112: Abstract 870.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR92", "first-page": "Abstract 406", "volume": "108", "author": "P Richardson", "year": "2006", "unstructured": "Richardson P, Chanan-Khan AA, Lonial S, Krishnan A, Alsina M, Carroll M et al. A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM). Blood 2006; 108: Abstract 406.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR93", "doi-asserted-by": "publisher", "first-page": "353a", "DOI": "10.1182/blood-2006-08-036947", "volume": "110", "author": "PG Richardson", "year": "2007", "unstructured": "Richardson PG, Chanan-Khan A, Lonial S, Krishman A, Carroll M, Cropp GF et al. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood 2007; 110: 353a, abstract 1165.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR94", "first-page": "Abstract 871", "volume": "112", "author": "D Weber", "year": "2008", "unstructured": "Weber D, Badros AZ, Jagannath S, Siegel D, Richon V, Rizvi S et al. Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience. Blood 2008; 112: Abstract 871.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR95", "first-page": "Abstract 1742", "volume": "112", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008; 112: Abstract 1742.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR96", "doi-asserted-by": "publisher", "first-page": "776", "DOI": "10.1111/j.1365-2141.2005.05540.x", "volume": "129", "author": "S Jagannath", "year": "2005", "unstructured": "Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776\u2013783.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR97", "first-page": "1498", "volume": "91", "author": "JL Harousseau", "year": "2006", "unstructured": "Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498\u20131505.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR98", "doi-asserted-by": "publisher", "first-page": "755", "DOI": "10.1111/j.1365-2141.2005.05519.x", "volume": "129", "author": "HE Oakervee", "year": "2005", "unstructured": "Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755\u2013762.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR99", "doi-asserted-by": "publisher", "first-page": "512", "DOI": "10.1111/j.1365-2141.2008.06997.x", "volume": "141", "author": "R Popat", "year": "2008", "unstructured": "Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008; 141: 512\u2013516.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR100", "first-page": "Abstract 1489", "volume": "110", "author": "M Hari", "year": "2007", "unstructured": "Hari M, MacDonald J, Friedman J, Kendall T, Mulligan G, Jakubowiak A . Gene expression profiles (GEP) to predict at least very good partial response to Velcade, Doxil, and dexamethasone in newly diagnosed patients with multiple myeloma. Blood 2007; 110: Abstract 1489.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR101", "doi-asserted-by": "publisher", "first-page": "Abstract 3713", "DOI": "10.1182/blood-2008-03-146290", "volume": "112", "author": "A Jakubowiak", "year": "2008", "unstructured": "Jakubowiak A, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Brozo C et al. Initial treatment with bortezomib (Velcade\u00ae), Doxil\u00ae, and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous stem cell transplantation (ASCT) for multiple myeloma (MM). Blood 2008; 112: Abstract 3713.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR102", "doi-asserted-by": "publisher", "first-page": "235", "DOI": "10.1080/10245330701214236", "volume": "12", "author": "M Wang", "year": "2007", "unstructured": "Wang M, Giralt S, Delasalle K, Handy B, Alexanian R . Bortezomib in combination with thalidomide\u2013dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235\u2013239.", "journal-title": "Hematology"}, {"key": "BFleu2009173_CR103", "first-page": "Abstract 92", "volume": "112", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Lonial S, Jakubowiak A, Jagannath S, Raje NS, Avigan D et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood 2008; 112: Abstract 92.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR104", "doi-asserted-by": "publisher", "first-page": "1337", "DOI": "10.1038/leu.2009.26", "volume": "23", "author": "CB Reeder", "year": "2009", "unstructured": "Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009; 23: 1337\u20131341.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR105", "unstructured": "Kropff M, Liebisch P, Knop S, Weisel K, Wand H, Gann CN et al. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 2009, March 10, e-pub ahead of print.", "DOI": "10.1007/s00277-009-0726-6", "doi-asserted-by": "crossref"}, {"key": "BFleu2009173_CR106", "doi-asserted-by": "publisher", "first-page": "210", "DOI": "10.3816/CLM.2006.n.061", "volume": "7", "author": "A Badros", "year": "2006", "unstructured": "Badros A, Goloubeva O, Fenton R, Rapoport AP, Akpek G, Harris C et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 210\u2013216.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR107", "doi-asserted-by": "publisher", "first-page": "176", "DOI": "10.1111/j.1365-2141.2007.06639.x", "volume": "138", "author": "B Barlogie", "year": "2007", "unstructured": "Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176\u2013185.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR108", "doi-asserted-by": "publisher", "first-page": "Abstract 450", "DOI": "10.1182/blood-2006-11-057935", "volume": "110", "author": "JL Harousseau", "year": "2007", "unstructured": "Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty MMM et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood 2007; 110: Abstract 450.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR109", "first-page": "Abstract 158", "volume": "112", "author": "M Cavo", "year": "2008", "unstructured": "Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Ceccolini M et al. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade\u2013thalidomide\u2013dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma. Blood 2008; 112: Abstract 158.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR110", "doi-asserted-by": "publisher", "first-page": "2165", "DOI": "10.1182/blood-2006-04-019778", "volume": "108", "author": "MV Mateos", "year": "2006", "unstructured": "Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165\u20132172.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR111", "doi-asserted-by": "publisher", "first-page": "560", "DOI": "10.3324/haematol.12106", "volume": "93", "author": "MV Mateos", "year": "2008", "unstructured": "Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93: 560\u2013565.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR112", "first-page": "Abstract 651", "volume": "112", "author": "M-V Mateos", "year": "2008", "unstructured": "Mateos M-V, Oriol A, Mart\u00ednez J, Cibeira MT, de Paz R, Terol MJ et al. Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade\u2013thalidomide\u2013prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for Velcade: an alkylating or an immunomodulator agent? Blood 2008; 112: Abstract 651.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR113", "doi-asserted-by": "publisher", "first-page": "Abstract 652", "DOI": "10.1182/blood-2008-04-149427", "volume": "112", "author": "A Palumbo", "year": "2008", "unstructured": "Palumbo A, Bringhen S, Rossi D, Magarotto V, Di Raimondo F, Ria R et al. A prospective, randomized, phase III study of bortezomib, melphalan, prednisone and thalidomide (VMPT) versus bortezomib, melphalan and prednisone (VMP) in elderly newly diagnosed myeloma patients. Blood 2008; 112: Abstract 652.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR114", "doi-asserted-by": "publisher", "first-page": "906", "DOI": "10.1056/NEJMoa0801479", "volume": "359", "author": "JF San Miguel", "year": "2008", "unstructured": "San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.", "journal-title": "N Engl J Med"}, {"key": "BFleu2009173_CR115", "first-page": "Abstract 2771", "volume": "112", "author": "G Benevolo", "year": "2008", "unstructured": "Benevolo G, Larocca A, Pregno P, Gay F, Botto B, Orsucci L et al. Bortezomib and dexamethasone as maintenance therapy in relapse/refractory multiple myeloma patients. Blood 2008; 112: Abstract 2771.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR116", "doi-asserted-by": "publisher", "first-page": "Abstract 1738", "DOI": "10.1182/blood-2008-06-160531", "volume": "112", "author": "A Dispenzieri", "year": "2008", "unstructured": "Dispenzieri A, Jacobus S, Vesole DH, Rajkumar SV, Greipp PR . Primary therapy with bortezomib\u2014the role of induction, maintenance, and re-induction in patients with high risk myeloma. Update of results from E2A02. Blood 2008; 112: Abstract 1738.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR117", "first-page": "Abstract 929", "volume": "104", "author": "K Hollmig", "year": "2004", "unstructured": "Hollmig K, Stover J, Talamo G, Zangari M, Thertulien R, van Rhee F et al. Addition of bortezomib (VelcadeTM) to high dose melphalan (Vel\u2013Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM). Blood 2004; 104: Abstract 929.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR118", "first-page": "Abstract 5131", "volume": "110", "author": "T Alekshun", "year": "2007", "unstructured": "Alekshun T, Mcisaac-Simonelli C, Kharfan-Dabaja M, Dalton W, Djulbegovic B, Fernandez H et al. Phase I study of bortezomib, (BTZ) followed by high-dose melphalan, (HD Mel) and BTZ as conditioning regimen for tandem peripheral blood stem cell transplants (TanPSCT) in patients with primary refractory multiple myeloma (MM) and plasma cell leukemia (PCL). Blood 2007; 110: Abstract 5131.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR119", "first-page": "Abstract 5117", "volume": "110", "author": "PR Scalzulli", "year": "2007", "unstructured": "Scalzulli PR, Valvano MR, Bodenizza CC, Carella AM, Dell\u2019Olio MM, Falcone AAP et al. Intermediate dose melphalan, bortezomib, thalidomide, dexametasone (MVTD) conditioning therapy and ASCT in relapsed multiple myeloma patients: a single center experience. Blood 2007; 110: Abstract 5117.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR120", "first-page": "Abstract 160", "volume": "112", "author": "M Roussel", "year": "2008", "unstructured": "Roussel M, Huynh A, Moreau P, Harousseau JL, Hulin C, Caillot D et al. Bortezomib (BOR) and high dose melphalan (HDM) as conditioning regimen before autologous stem cell transplantation (ASCT) for de novo multiple myeloma (MM): final results of the IFM phase II study VEL/MEL. Blood 2008; 112: Abstract 160.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR121", "first-page": "Abstract 3332", "volume": "112", "author": "S Lonial", "year": "2008", "unstructured": "Lonial S, Kaufman J, Torre C, Langston A, Lechowicz MJ, Flowers C et al. A randomized phase I trial of melphalan+bortezomib as conditioning for autologous transplant for myeloma: the effect of sequence of administration. Blood 2008; 112: Abstract 3332.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR122", "first-page": "Abstract 3237", "volume": "106", "author": "S Peles", "year": "2005", "unstructured": "Peles S, Fisher NM, Devine SM, Tomasson MH, DiPersio JF, Ravi Vij R . Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV). Blood 2005; 106: Abstract 3237.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR123", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.1038/bmt.2008.384", "volume": "43", "author": "GL Uy", "year": "2008", "unstructured": "Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K et al. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplant 2008; 43: 793\u2013800.", "journal-title": "Bone Marrow Transplant"}, {"key": "BFleu2009173_CR124", "first-page": "Abstract 5099", "volume": "108", "author": "S Knop", "year": "2006", "unstructured": "Knop S, Hebart H, Kunzmann V, Angermund R, Einsele H . Bortezomib once weekly is well tolerated as maintenance therapy after less than a complete response to high-dose melphalan in patients with multiple myeloma. Blood 2006; 108: Abstract 5099.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR125", "first-page": "Abstract 3710", "volume": "112", "author": "M Liao", "year": "2008", "unstructured": "Liao M, Malone R, Bartoni K, Habtemariam B, Paquette R, de Vos S et al. Updated results of a phase I/II trial of autologous peripheral blood progenitor cell transplantation with VelcadeTM maintenance as treatment for intermediate- and advanced-stage multiple myeloma. Blood 2008; 112: Abstract 3710.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR126", "doi-asserted-by": "publisher", "first-page": "770", "DOI": "10.1016/j.exphem.2006.02.020", "volume": "34", "author": "N Kroger", "year": "2006", "unstructured": "Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770\u2013775.", "journal-title": "Exp Hematol"}, {"key": "BFleu2009173_CR127", "doi-asserted-by": "publisher", "first-page": "Abstract 3330", "DOI": "10.1182/blood-2007-11-125203", "volume": "112", "author": "S-S Yoon", "year": "2008", "unstructured": "Yoon S-S, Kim HJ, Chung JS, Eom HS, Jang J-H, Kang HJ et al. Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (bortezomib, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with bortezomib for newly diagnosed multiple myeloma: final analysis of phase II trial. Blood 2008; 112: Abstract 3330.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR128", "first-page": "Abstract 3683", "volume": "112", "author": "M Ladetto", "year": "2008", "unstructured": "Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Boi M et al. Major shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-trasplant consolidation with bortezomib, thalidomide and dexamethasone: a qualitative and quantitative PCR study. Blood 2008; 112: Abstract 3683.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR129", "doi-asserted-by": "publisher", "first-page": "8120", "DOI": "10.1073/pnas.0401563101", "volume": "101", "author": "K Sun", "year": "2004", "unstructured": "Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120\u20138125.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "BFleu2009173_CR130", "doi-asserted-by": "publisher", "first-page": "3293", "DOI": "10.1182/blood-2004-11-4526", "volume": "106", "author": "K Sun", "year": "2005", "unstructured": "Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005; 106: 3293\u20133299.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR131", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.3324/haematol.12184", "volume": "93", "author": "J El-Cheikh", "year": "2008", "unstructured": "El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008; 93: 455\u2013458.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR132", "doi-asserted-by": "publisher", "first-page": "1295", "DOI": "10.3324/haematol.10820", "volume": "92", "author": "J Mateos-Mazon", "year": "2007", "unstructured": "Mateos-Mazon J, Perez-Simon JA, Lopez O, Hernandez E, Etxebarria J, San Miguel JF . Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007; 92: 1295\u20131296.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR133", "first-page": "755", "volume": "6", "author": "J Wolf", "year": "2008", "unstructured": "Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS . Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6: 755\u2013760.", "journal-title": "Clin Adv Hematol Oncol"}, {"key": "BFleu2009173_CR134", "doi-asserted-by": "publisher", "first-page": "140", "DOI": "10.3816/CLM.2008.n.016", "volume": "8", "author": "TM Conner", "year": "2008", "unstructured": "Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA . An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 140\u2013145.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR135", "doi-asserted-by": "publisher", "first-page": "Abstract 649", "DOI": "10.3324/haematol.12356", "volume": "93", "author": "A Rubio-Martinez", "year": "2008", "unstructured": "Rubio-Martinez A, Recasens V, Soria B, Monta\u00f1es MA, Rubio-Escuin R, Giraldo P . Response to re-treatment on relapse multiple myeloma patients previously treated with bortezomib. Haematologica 2008; 93: Abstract 649.", "journal-title": "Haematologica"}, {"key": "BFleu2009173_CR136", "doi-asserted-by": "publisher", "first-page": "270", "DOI": "10.1002/jcb.21405", "volume": "103", "author": "D Fuchs", "year": "2008", "unstructured": "Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C . Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem 2008; 103: 270\u2013283.", "journal-title": "J Cell Biochem"}, {"key": "BFleu2009173_CR137", "doi-asserted-by": "publisher", "first-page": "1098", "DOI": "10.1038/leu.2009.8", "volume": "23", "author": "T Ruckrich", "year": "2009", "unstructured": "Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M et al. Characterization of the ubiquitin\u2013proteasome system in bortezomib-adapted cells. Leukemia 2009; 23: 1098\u20131105.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR138", "doi-asserted-by": "publisher", "first-page": "1278", "DOI": "10.1016/j.exphem.2008.04.013", "volume": "36", "author": "S Lu", "year": "2008", "unstructured": "Lu S, Chen Z, Yang J, Chen L, Gong S, Zhou H et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol 2008; 36: 1278\u20131284.", "journal-title": "Exp Hematol"}, {"key": "BFleu2009173_CR139", "doi-asserted-by": "publisher", "first-page": "2489", "DOI": "10.1182/blood-2007-08-104950", "volume": "112", "author": "R Oerlemans", "year": "2008", "unstructured": "Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489\u20132499.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR140", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1124/jpet.108.138131", "volume": "326", "author": "S Lu", "year": "2008", "unstructured": "Lu S, Yang J, Song X, Gong S, Zhou H, Guo L et al. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther 2008; 326: 423\u2013431.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "BFleu2009173_CR141", "doi-asserted-by": "publisher", "first-page": "407", "DOI": "10.1016/j.ccr.2005.10.013", "volume": "8", "author": "D Chauhan", "year": "2005", "unstructured": "Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell 2005; 8: 407\u2013419.", "journal-title": "Cancer Cell"}, {"key": "BFleu2009173_CR142", "doi-asserted-by": "publisher", "first-page": "3281", "DOI": "10.1182/blood-2007-01-065888", "volume": "110", "author": "DJ Kuhn", "year": "2007", "unstructured": "Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin\u2013proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110: 3281\u20133290.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR143", "doi-asserted-by": "publisher", "first-page": "40", "DOI": "10.1186/1476-4598-7-40", "volume": "7", "author": "DT Yang", "year": "2008", "unstructured": "Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S . Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008; 7: 40; available online and pending publication.", "journal-title": "Mol Cancer"}, {"key": "BFleu2009173_CR144", "doi-asserted-by": "publisher", "first-page": "1356", "DOI": "10.1158/1541-7786.MCR-08-0108", "volume": "6", "author": "S Markovina", "year": "2008", "unstructured": "Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356\u20131364.", "journal-title": "Mol Cancer Res"}, {"key": "BFleu2009173_CR145", "doi-asserted-by": "publisher", "first-page": "16639", "DOI": "10.1074/jbc.M200360200", "volume": "277", "author": "T Hideshima", "year": "2002", "unstructured": "Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639\u201316647.", "journal-title": "J Biol Chem"}, {"key": "BFleu2009173_CR146", "doi-asserted-by": "publisher", "first-page": "549", "DOI": "10.1016/j.bbrc.2007.07.049", "volume": "361", "author": "H Rumpold", "year": "2007", "unstructured": "Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, Wolf D . Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun 2007; 361: 549\u2013554.", "journal-title": "Biochem Biophys Res Commun"}, {"key": "BFleu2009173_CR147", "doi-asserted-by": "publisher", "first-page": "2458", "DOI": "10.1182/blood-2004-02-0547", "volume": "104", "author": "D Chauhan", "year": "2004", "unstructured": "Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 104: 2458\u20132466.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR148", "doi-asserted-by": "publisher", "first-page": "333", "DOI": "10.1016/S0960-894X(98)00029-8", "volume": "8", "author": "J Adams", "year": "1998", "unstructured": "Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333\u2013338.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "BFleu2009173_CR149", "first-page": "2615", "volume": "59", "author": "J Adams", "year": "1999", "unstructured": "Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615\u20132622.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR150", "doi-asserted-by": "publisher", "first-page": "259", "DOI": "10.1006/bioo.2001.1217", "volume": "29", "author": "G Springsteen", "year": "2001", "unstructured": "Springsteen G, Ballard CE, Gao S, Wang W, Wang B . The development of photometric sensors for boronic acids. Bioorg Chem 2001; 29: 259\u2013270.", "journal-title": "Bioorg Chem"}, {"key": "BFleu2009173_CR151", "doi-asserted-by": "publisher", "first-page": "273", "DOI": "10.1158/1078-0432.CCR-05-0503", "volume": "12", "author": "W Zou", "year": "2006", "unstructured": "Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006; 12: 273\u2013280.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR152", "doi-asserted-by": "publisher", "first-page": "5927", "DOI": "10.1182/blood-2008-07-171389", "volume": "113", "author": "EB Golden", "year": "2009", "unstructured": "Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie SG et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009; 113: 5927\u20135937.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR153", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1097/CAD.0b013e3282f24031", "volume": "19", "author": "D Llobet", "year": "2008", "unstructured": "Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008; 19: 115\u2013124.", "journal-title": "Anticancer Drugs"}, {"key": "BFleu2009173_CR154", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1158/1078-0432.CCR-05-2272", "volume": "12", "author": "L Catley", "year": "2006", "unstructured": "Catley L, Anderson KC . Velcade and vitamin C: too much of a good thing? Clin Cancer Res 2006; 12: 3\u20134.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR155", "doi-asserted-by": "publisher", "first-page": "5695", "DOI": "10.1182/blood-2009-03-204776", "volume": "113", "author": "JJ Shah", "year": "2009", "unstructured": "Shah JJ, Kuhn DJ, Orlowski RZ . Bortezomib and EGCG: no green tea for you? Blood 2009; 113: 5695\u20135696.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR156", "doi-asserted-by": "publisher", "first-page": "539", "DOI": "10.1021/tx050313d", "volume": "19", "author": "J Labutti", "year": "2006", "unstructured": "Labutti J, Parsons I, Huang R, Miwa G, Gan LS, Daniels JS . Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction. Chem Res Toxicol 2006; 19: 539\u2013546.", "journal-title": "Chem Res Toxicol"}, {"key": "BFleu2009173_CR157", "doi-asserted-by": "publisher", "first-page": "2036", "DOI": "10.1038/sj.leu.2403109", "volume": "17", "author": "XY Pei", "year": "2003", "unstructured": "Pei XY, Dai Y, Grant S . The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003; 17: 2036\u20132045.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR158", "doi-asserted-by": "publisher", "first-page": "1654", "DOI": "10.1182/blood-2007-08-105601", "volume": "111", "author": "D Chauhan", "year": "2008", "unstructured": "Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P et al. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood 2008; 111: 1654\u20131664.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR159", "doi-asserted-by": "publisher", "first-page": "6383", "DOI": "10.1158/0008-5472.CAN-06-4086", "volume": "67", "author": "SD Demo", "year": "2007", "unstructured": "Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383\u20136391.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR160", "doi-asserted-by": "publisher", "first-page": "8545", "DOI": "10.1074/jbc.273.15.8545", "volume": "273", "author": "G Fenteany", "year": "1998", "unstructured": "Fenteany G, Schreiber SL . Lactacystin, proteasome function, and cell fate. J Biol Chem 1998; 273: 8545\u20138548.", "journal-title": "J Biol Chem"}, {"key": "BFleu2009173_CR161", "doi-asserted-by": "publisher", "first-page": "Abstract 2770", "DOI": "10.1182/blood-2008-03-147181", "volume": "112", "author": "P Richardson", "year": "2008", "unstructured": "Richardson P, Hofmeister CC, Zimmerman TM, Chanan-Khan AA, Spear MA, Palladino MA et al. Phase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myeloma. Blood 2008; 112: Abstract 2770.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR162", "doi-asserted-by": "publisher", "first-page": "2283", "DOI": "10.1016/S0960-894X(99)00376-5", "volume": "9", "author": "N Sin", "year": "1999", "unstructured": "Sin N, Kim KB, Elofsson M, Meng L, Auth H, Kwok BH et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999; 9: 2283\u20132288.", "journal-title": "Bioorg Med Chem Lett"}, {"key": "BFleu2009173_CR163", "doi-asserted-by": "publisher", "first-page": "Abstract 2657", "DOI": "10.1182/blood-2008-03-144634", "volume": "112", "author": "S Arastu-Kapur", "year": "2008", "unstructured": "Arastu-Kapur S, Shenk K, Parlati F, Bennett MK . Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib. Blood 2008; 112: Abstract 2657.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR164", "first-page": "Abstract 411", "volume": "110", "author": "M Alsina", "year": "2007", "unstructured": "Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A . Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood 2007; 110: Abstract 411.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR165", "first-page": "Abstract", "volume": "110", "author": "RZ Orlowski", "year": "2007", "unstructured": "Orlowski RZ, Stewart K, Vallone M, Molineaux C, Kunkel L, Gericitano J et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results. Blood 2007; 110: Abstract 409.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR166", "first-page": "Abstract 864", "volume": "112", "author": "S Jagannath", "year": "2008", "unstructured": "Jagannath S, Vij R, Stewart AK, Somlo G, Jakubowiak A, Reiman T et al. Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM). Blood 2008; 112: Abstract 864.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR167", "first-page": "Abstract 865", "volume": "112", "author": "R Vij", "year": "2008", "unstructured": "Vij R, Wang M, Orlowski R, Stewart AK, Jagannath S, Kukreti V et al. Initial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM). Blood 2008; 112: Abstract 865.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR168", "doi-asserted-by": "publisher", "first-page": "2516", "DOI": "10.1182/blood-2007-10-116129", "volume": "111", "author": "SK Kumar", "year": "2008", "unstructured": "Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR169", "doi-asserted-by": "publisher", "first-page": "1152", "DOI": "10.1038/leu.2008.402", "volume": "23", "author": "E Kastritis", "year": "2009", "unstructured": "Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152\u20131157.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR170", "first-page": "Abstract 650", "volume": "112", "author": "JF San Miguel", "year": "2008", "unstructured": "San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff MH et al. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan\u2013prednisone versus melphalan\u2013prednisone in newly diagnosed multiple myeloma. Blood 2008; 112: Abstract 650.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR171", "first-page": "Abstract 2781", "volume": "112", "author": "DD Siegel", "year": "2008", "unstructured": "Siegel DD, Sezer O, San Miguel JF, Mateos M-V, Prosser I, Cavo M et al. A phase IB, multicenter, open-label, dose-escalation study of oral panobinostat (LBH589) and i.v. bortezomib in patients with relapsed multiple myeloma. Blood 2008; 112: Abstract 2781.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR172", "doi-asserted-by": "publisher", "first-page": "2133", "DOI": "10.1056/NEJMoa070596", "volume": "357", "author": "DM Weber", "year": "2007", "unstructured": "Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133\u20132142.", "journal-title": "N Engl J Med"}, {"key": "BFleu2009173_CR173", "doi-asserted-by": "publisher", "first-page": "2123", "DOI": "10.1056/NEJMoa070594", "volume": "357", "author": "M Dimopoulos", "year": "2007", "unstructured": "Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123\u20132132.", "journal-title": "N Engl J Med"}, {"key": "BFleu2009173_CR174", "doi-asserted-by": "publisher", "first-page": "1343", "DOI": "10.1038/leu.2008.123", "volume": "22", "author": "MA Dimopoulos", "year": "2008", "unstructured": "Dimopoulos MA, Kastritis E, Rajkumar SV . Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008; 22: 1343\u20131353.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR175", "doi-asserted-by": "publisher", "first-page": "4445", "DOI": "10.1182/blood-2008-02-141614", "volume": "112", "author": "M Wang", "year": "2008", "unstructured": "Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008; 112: 4445\u20134451.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR176", "doi-asserted-by": "publisher", "first-page": "2765", "DOI": "10.1182/blood-2007-07-100651", "volume": "111", "author": "R Piva", "year": "2008", "unstructured": "Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008; 111: 2765\u20132775.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR177", "doi-asserted-by": "publisher", "first-page": "1068", "DOI": "10.1021/jm7010589", "volume": "51", "author": "BD Dorsey", "year": "2008", "unstructured": "Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008; 51: 1068\u20131072.", "journal-title": "J Med Chem"}, {"key": "BFleu2009173_CR178", "doi-asserted-by": "publisher", "first-page": "3028", "DOI": "10.1021/jm801329v", "volume": "52", "author": "HJ Zhou", "year": "2009", "unstructured": "Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009; 52: 3028\u20133038.", "journal-title": "J Med Chem"}, {"key": "BFleu2009173_CR179", "doi-asserted-by": "publisher", "first-page": "4667", "DOI": "10.1182/blood-2008-07-171637", "volume": "113", "author": "DJ Kuhn", "year": "2009", "unstructured": "Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ . Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and non-specific proteasome inhibitors. Blood 2009; 113: 4667\u20134676.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR180", "doi-asserted-by": "publisher", "first-page": "231", "DOI": "10.1038/onc.2008.385", "volume": "28", "author": "K Noborio-Hatano", "year": "2009", "unstructured": "Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 2009; 28: 231\u2013242.", "journal-title": "Oncogene"}, {"key": "BFleu2009173_CR181", "doi-asserted-by": "publisher", "first-page": "6282", "DOI": "10.1158/0008-5472.CAN-05-0676", "volume": "65", "author": "JZ Qin", "year": "2005", "unstructured": "Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005; 65: 6282\u20136293.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR182", "doi-asserted-by": "publisher", "first-page": "1189", "DOI": "10.1038/sj.onc.1210744", "volume": "27", "author": "DA Fennell", "year": "2008", "unstructured": "Fennell DA, Chacko A, Mutti L . BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008; 27: 1189\u20131197.", "journal-title": "Oncogene"}, {"key": "BFleu2009173_CR183", "doi-asserted-by": "publisher", "first-page": "5418", "DOI": "10.1158/0008-5472.CAN-06-4322", "volume": "67", "author": "P Gomez-Bougie", "year": "2007", "unstructured": "Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, Trichet V, Robillard N, Philippe M et al. Noxa upregulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418\u20135424.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR184", "doi-asserted-by": "publisher", "first-page": "3828", "DOI": "10.1158/0008-5472.CAN-04-3684", "volume": "65", "author": "TH Landowski", "year": "2005", "unstructured": "Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT . Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65: 3828\u20133836.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR185", "doi-asserted-by": "publisher", "first-page": "7500", "DOI": "10.1158/0008-5472.CAN-04-0124", "volume": "64", "author": "K Podar", "year": "2004", "unstructured": "Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500\u20137506.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR186", "doi-asserted-by": "publisher", "first-page": "3131", "DOI": "10.1182/blood-2007-11-120576", "volume": "111", "author": "DH Shin", "year": "2008", "unstructured": "Shin DH, Chun YS, Lee DS, Huang LE, Park JW . Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008; 111: 3131\u20133136.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR187", "doi-asserted-by": "publisher", "first-page": "1309", "DOI": "10.1182/blood-2007-03-078535", "volume": "111", "author": "J Shi", "year": "2008", "unstructured": "Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE et al. Bortezomib downregulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008; 111: 1309\u20131317.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR188", "doi-asserted-by": "publisher", "first-page": "4839", "DOI": "10.1182/blood-2006-10-054221", "volume": "109", "author": "R Spisek", "year": "2007", "unstructured": "Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV . Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109: 4839\u20134845.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR189", "first-page": "1104", "volume": "87", "author": "D Chauhan", "year": "1996", "unstructured": "Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 1996; 87: 1104\u20131112.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR190", "doi-asserted-by": "publisher", "first-page": "8386", "DOI": "10.1038/sj.onc.1207170", "volume": "22", "author": "T Hideshima", "year": "2003", "unstructured": "Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003; 22: 8386\u20138393.", "journal-title": "Oncogene"}, {"key": "BFleu2009173_CR191", "doi-asserted-by": "publisher", "first-page": "721", "DOI": "10.1038/sj.onc.1210679", "volume": "27", "author": "K Podar", "year": "2008", "unstructured": "Podar K, Gouill SL, Zhang J, Opferman JT, Zorn E, Tai YT et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene 2008; 27: 721\u2013731.", "journal-title": "Oncogene"}, {"key": "BFleu2009173_CR192", "first-page": "1136", "volume": "9", "author": "MH Ma", "year": "2003", "unstructured": "Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136\u20131144.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR193", "doi-asserted-by": "publisher", "first-page": "1530", "DOI": "10.1182/blood-2002-08-2543", "volume": "101", "author": "T Hideshima", "year": "2003", "unstructured": "Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530\u20131534.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR194", "doi-asserted-by": "publisher", "first-page": "4907", "DOI": "10.1182/blood-2005-08-3531", "volume": "107", "author": "EA Obeng", "year": "2006", "unstructured": "Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH . Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907\u20134916.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR195", "doi-asserted-by": "publisher", "first-page": "974", "DOI": "10.1080/10428190902895780", "volume": "50", "author": "H Dong", "year": "2009", "unstructured": "Dong H, Chen L, Chen X, Gu H, Gao G, Gao Y et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma 2009; 50: 974\u2013984.", "journal-title": "Leuk Lymphoma"}, {"key": "BFleu2009173_CR196", "doi-asserted-by": "publisher", "first-page": "184", "DOI": "10.1158/0008-5472.CAN-05-1195", "volume": "66", "author": "AM Roccaro", "year": "2006", "unstructured": "Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66: 184\u2013191.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR197", "first-page": "841", "volume": "1", "author": "YH Ling", "year": "2002", "unstructured": "Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, Adams J et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2\u2013M phase arrest and apoptosis. Mol Cancer Ther 2002; 1: 841\u2013849.", "journal-title": "Mol Cancer Ther"}, {"key": "BFleu2009173_CR198", "doi-asserted-by": "publisher", "first-page": "14671", "DOI": "10.1074/jbc.273.24.14671", "volume": "273", "author": "TW Loo", "year": "1998", "unstructured": "Loo TW, Clarke DM . Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions. J Biol Chem 1998; 273: 14671\u201314674.", "journal-title": "J Biol Chem"}, {"key": "BFleu2009173_CR199", "doi-asserted-by": "publisher", "first-page": "1724", "DOI": "10.1096/fasebj.13.13.1724", "volume": "13", "author": "TW Loo", "year": "1999", "unstructured": "Loo TW, Clarke DM . The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy. FASEB J 1999; 13: 1724\u20131732.", "journal-title": "FASEB J"}, {"issue": "3A", "key": "BFleu2009173_CR200", "first-page": "1869", "volume": "26", "author": "N Takigawa", "year": "2006", "unstructured": "Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM et al. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms. Anticancer Res 2006; 26 (3A): 1869\u20131876.", "journal-title": "Anticancer Res"}, {"key": "BFleu2009173_CR201", "doi-asserted-by": "publisher", "first-page": "8746", "DOI": "10.1158/0008-5472.CAN-04-2894", "volume": "64", "author": "L Catley", "year": "2004", "unstructured": "Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K et al. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas upregulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res 2004; 64: 8746\u20138753.", "journal-title": "Cancer Res"}, {"key": "BFleu2009173_CR202", "doi-asserted-by": "publisher", "first-page": "883", "DOI": "10.1016/j.bcp.2007.10.026", "volume": "75", "author": "LM Congdon", "year": "2008", "unstructured": "Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH . Proteasomal inhibition stabilizes topoisomerase II alpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochem Pharmacol 2008; 75: 883\u2013890.", "journal-title": "Biochem Pharmacol"}, {"key": "BFleu2009173_CR203", "doi-asserted-by": "publisher", "first-page": "937", "DOI": "10.1200/JCO.2005.03.2383", "volume": "24", "author": "JR Berenson", "year": "2006", "unstructured": "Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937\u2013944.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR204", "doi-asserted-by": "publisher", "first-page": "623", "DOI": "10.1007/s00277-008-0501-0", "volume": "87", "author": "JR Berenson", "year": "2008", "unstructured": "Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP et al. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Ann Hematol 2008; 87: 623\u2013631.", "journal-title": "Ann Hematol"}, {"key": "BFleu2009173_CR205", "doi-asserted-by": "publisher", "first-page": "1069", "DOI": "10.1158/1078-0432.CCR-08-1261", "volume": "15", "author": "JR Berenson", "year": "2009", "unstructured": "Berenson JR, Yellin O, Patel R, Duvivier H, Nassir Y, Mapes R et al. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2009; 15: 1069\u20131075.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR206", "first-page": "Abstract 867", "volume": "112", "author": "J-F Rossi", "year": "2008", "unstructured": "Rossi J-F, Manges RF, Sutherland HJ, Jagannath S, Voorhees P, Sonneveld P et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood 2008; 112: Abstract 867.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR207", "doi-asserted-by": "publisher", "first-page": "171", "DOI": "10.1080/10428190500272721", "volume": "47", "author": "S Ciolli", "year": "2006", "unstructured": "Ciolli S, Leoni F, Gigli F, Rigacci L, Bosi A . Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 2006; 47: 171\u2013173.", "journal-title": "Leuk Lymphoma"}, {"key": "BFleu2009173_CR208", "doi-asserted-by": "publisher", "first-page": "1419", "DOI": "10.1038/leu.2008.99", "volume": "22", "author": "M Pineda-Roman", "year": "2008", "unstructured": "Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A et al. VTD combination therapy with bortezomib\u2013thalidomide\u2013dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22: 1419\u20131427.", "journal-title": "Leukemia"}, {"key": "BFleu2009173_CR209", "doi-asserted-by": "publisher", "first-page": "1762", "DOI": "10.1158/1078-0432.CCR-06-1812", "volume": "13", "author": "JR Berenson", "year": "2007", "unstructured": "Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS . A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007; 13: 1762\u20131768.", "journal-title": "Clin Cancer Res"}, {"key": "BFleu2009173_CR210", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1111/j.1365-2141.2007.06656.x", "volume": "138", "author": "M Kropff", "year": "2007", "unstructured": "Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007; 138: 330\u2013337.", "journal-title": "Br J Haematol"}, {"key": "BFleu2009173_CR211", "doi-asserted-by": "publisher", "first-page": "1160", "DOI": "10.1093/annonc/mdn018", "volume": "19", "author": "A Palumbo", "year": "2008", "unstructured": "Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008; 19: 1160\u20131165.", "journal-title": "Ann Oncol"}, {"key": "BFleu2009173_CR212", "first-page": "2767", "volume": "109", "author": "A Palumbo", "year": "2007", "unstructured": "Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007; 109: 2767\u20132772.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR213", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.3816/CLM.2006.n.028", "volume": "6", "author": "A Palumbo", "year": "2006", "unstructured": "Palumbo A, Avonto I, Bruno B, Falcone A, Scalzulli PR, Ambrosini MT et al. Intermediate-dose melphalan (100\u2009mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. Clin Lymphoma Myeloma 2006; 6: 475\u2013477.", "journal-title": "Clin Lymphoma Myeloma"}, {"key": "BFleu2009173_CR214", "first-page": "Abstract 94", "volume": "112", "author": "W Bensinger", "year": "2008", "unstructured": "Bensinger W, Jagannath S, Vescio R, Camacho ES, Wolf JL, Irwin DH et al. A phase II study of bortezomib (Velcade\u00ae), cyclophosphamide (Cytoxan\u00ae), thalidomide (Thalomid\u00ae) and dexamethasone as first-line therapy for multiple myeloma. Blood 2008; 112: Abstract 94.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR215", "doi-asserted-by": "publisher", "first-page": "Abstract 93", "DOI": "10.1182/blood-2008-07-167767", "volume": "112", "author": "S Kumar", "year": "2008", "unstructured": "Kumar S, Flinn IW, Noga SJ, Hari P, Rifkin RM, Callander NS et al. Safety and efficacy of novel combination therapy with bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in newly diagnosed multiple myeloma: initial results from the phase I/II multi-center EVOLUTION study. Blood 2008; 112: Abstract 93.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR216", "doi-asserted-by": "publisher", "first-page": "4452", "DOI": "10.1200/JCO.2007.12.3323", "volume": "25", "author": "L Rosinol", "year": "2007", "unstructured": "Rosinol L, Oriol A, Mateos MV, Sureda A, Garcia-Sanchez P, Gutierrez N et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452\u20134458.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR217", "first-page": "Abstract 653", "volume": "112", "author": "P Sonneveld", "year": "2008", "unstructured": "Sonneveld P, van der Holt B, Schmidt-Wolf IGH, Bertsch U, el Jarari L, Salwender H-J et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple pyeloma (MM). Blood 2008; 112: Abstract 653.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR218", "doi-asserted-by": "publisher", "first-page": "Abstract 654", "DOI": "10.1182/blood-2008-02-141598", "volume": "112", "author": "L Rosinol", "year": "2008", "unstructured": "Rosinol L, Cibeira MT, Martinez J, Mateos MV, Terol MJ, de la Rubia J et al. Thalidomide/dexamethasone (TD) vs bortezomib(Velcade\u00ae)/thalidomide/dexamethasone (VTD) vs VBMCP/VBAD/Velcade\u00ae as induction regimens prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): first results of a prospective phase III PETHEMA/Gem trial. Blood 2008; 112: Abstract 654.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR219", "doi-asserted-by": "publisher", "first-page": "433", "DOI": "10.1111/j.1600-0609.2009.01244.x", "volume": "82", "author": "JR Berenson", "year": "2009", "unstructured": "Berenson JR, Yellin O, Woytowitz D, Flam MS, Cartmell A, Patel R et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol 2009; 82: 433\u2013439.", "journal-title": "Eur J Haematol"}, {"key": "BFleu2009173_CR220", "first-page": "Abstract 4819", "volume": "110", "author": "AG Bilalis", "year": "2007", "unstructured": "Bilalis AG, Papadimitriou K, Pouli A, Papanastasiou K, Tsakanikas S, Stefanitsi P et al. Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Blood 2007; 110: Abstract 4819.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR221", "first-page": "Abstract 5088", "volume": "108", "author": "MT Petrucci", "year": "2006", "unstructured": "Petrucci MT, Gallucci C, Federico V, Del Bianco P, Foa R . Velcade as retreatment of multiple myeloma patients previously responsive to Velcade. Blood 2006; 108: Abstract 5088.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR222", "first-page": "Abstract 17539", "volume": "24", "author": "M Druck", "year": "2006", "unstructured": "Druck M, Walters IB, Carloss H, Sood R, Leblanc AL, Noga SJ . A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib. J Clin Oncol 2006; 24: Abstract 17539.", "journal-title": "J Clin Oncol"}, {"key": "BFleu2009173_CR223", "first-page": "Abstract 2775", "volume": "112", "author": "I Hrusovsky", "year": "2008", "unstructured": "Hrusovsky I, Emmerich B, von Rohr A, Engelhardt M, Voegeli J, Taverna C et al. Bortezomib retreatment in relapsed multiple myeloma (MM): results from a binational, multicenter retrospective survey. Blood 2008; 112: Abstract 2775.", "journal-title": "Blood"}, {"key": "BFleu2009173_CR224", "first-page": "Abstract 3690", "volume": "112", "author": "MT Petrucci", "year": "2008", "unstructured": "Petrucci MT, Blau IW, Corradini P, Dimopoulos MA, Drach J, Giraldo P et al. Efficacy and safety of re-treatment with bortezomib (Velcade\u00a9) in patients with multiple myeloma: results from a prospective international phase II trial. Blood 2008; 112: Abstract 3690.", "journal-title": "Blood"}], "container-title": ["Leukemia"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/leu2009173.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu2009173", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/leu2009173.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 15]], "date-time": "2019-05-15T05:26:09Z", "timestamp": 1557897969000}, "score": 20.36168, "issued": {"date-parts": [[2009, 9, 10]]}, "references-count": 224, "journal-issue": {"published-print": {"date-parts": [[2009, 11]]}, "issue": "11"}, "alternative-id": ["BFleu2009173"], "URL": "http://dx.doi.org/10.1038/leu.2009.173", "relation": {"cites": []}, "ISSN": ["0887-6924", "1476-5551"], "issn-type": [{"value": "0887-6924", "type": "print"}, {"value": "1476-5551", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T11:37:49Z", "timestamp": 1575459469851}, "reference-count": 107, "publisher": "Informa UK Limited", "issue": "6", "funder": [{"DOI": "10.13039/100005189", "name": "Leukemia and Lymphoma Society", "doi-asserted-by": "publisher", "award": ["SCOR-12206-17"]}, {"DOI": "10.13039/100000054", "name": "National Cancer Institute", "doi-asserted-by": "publisher", "award": ["CA032102", "CA184464", "CA142509", "CA194264"]}], "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["Expert Opinion on Drug Metabolism & Toxicology"], "published-print": {"date-parts": [[2019, 6, 3]]}, "DOI": "10.1080/17425255.2019.1621839", "type": "journal-article", "created": {"date-parts": [[2019, 5, 20]], "date-time": "2019-05-20T07:29:01Z", "timestamp": 1558337341000}, "page": "459-473", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma"], "prefix": "10.1080", "volume": "15", "author": [{"given": "Muhamed", "family": "Baljevic", "sequence": "first", "affiliation": [{"name": "Division of Hematology and Oncology, The University of Nebraska Medical Center, Omaha, NE, USA"}, {"name": "Fred &amp; Pamela Buffett Cancer Center, Omaha, NE, USA"}]}, {"given": "Robert Z.", "family": "Orlowski", "sequence": "additional", "affiliation": [{"name": "Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}, {"name": "Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}]}], "member": "301", "published-online": {"date-parts": [[2019, 5, 31]]}, "reference": [{"issue": "4", "key": "CIT0001", "first-page": "399", "volume": "86", "author": "Palumbo A", "year": "2001", "journal-title": "Haematologica"}, {"key": "CIT0002", "DOI": "10.1200/JOP.18.00111", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1200/JCO.2002.01.133", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1056/NEJMoa030288", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1517/17425255.2013.817556", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1080/17425255.2018.1417388", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1111/j.1365-2141.2004.05188.x", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1056/NEJMoa0801479", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.3324/haematol.13285", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1182/blood-2012-05-425934", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1056/NEJMoa1714678", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1056/NEJMoa1606038", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1016/S1470-2045(14)70440-1", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1053/j.seminhematol.2012.04.006", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1126/science.7732382", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1002/anie.201509092", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1016/j.chembiol.2018.11.007", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1038/nrd1959", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1371/journal.pone.0053263", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1038/nrclinonc.2016.206", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "CIT0024", "first-page": "2615", "volume": "59", "author": "Adams J", "year": "1999", "journal-title": "Cancer Res"}, {"key": "CIT0025", "DOI": "10.1158/1078-0432.CCR-10-1950", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1016/S0960-894X(98)00029-8", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1158/1078-0432.CCR-03-0781", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1200/JCO.2004.02.106", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1002/cncr.23606", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1182/blood-2010-07-294983", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1016/S1470-2045(11)70081-X", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1007/s00280-010-1283-3", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1007/s40262-012-0010-0", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1124/dmd.104.002956", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1124/dmd.105.005710", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1021/tx050313d", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1007/s00280-011-1637-5", "doi-asserted-by": "publisher"}, {"key": "CIT0038", "DOI": "10.1158/1078-0432.CCR-11-2873", "doi-asserted-by": "publisher"}, {"issue": "8", "key": "CIT0039", "first-page": "2505", "volume": "8", "author": "Aghajanian C", "year": "2002", "journal-title": "Clin Cancer Res"}, {"key": "CIT0040", "DOI": "10.1056/NEJMoa043445", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.1182/blood-2006-08-036947", "doi-asserted-by": "publisher"}, {"key": "CIT0042", "DOI": "10.1016/S0140-6736(16)31594-X", "doi-asserted-by": "publisher"}, {"key": "CIT0043", "DOI": "10.1200/JCO.2009.26.0638", "doi-asserted-by": "publisher"}, {"key": "CIT0044", "DOI": "10.1016/S0140-6736(10)61424-9", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1200/JCO.2011.39.6820", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.18632/oncotarget.18722", "doi-asserted-by": "publisher"}, {"key": "CIT0047", "DOI": "10.1016/S0960-894X(99)00376-5", "doi-asserted-by": "publisher"}, {"key": "CIT0048", "DOI": "10.1182/blood-2007-01-065888", "doi-asserted-by": "publisher"}, {"key": "CIT0049", "DOI": "10.7164/antibiotics.45.1746", "doi-asserted-by": "publisher"}, {"key": "CIT0050", "DOI": "10.1124/dmd.111.039164", "doi-asserted-by": "publisher"}, {"key": "CIT0051", "DOI": "10.1182/blood-2012-10-459883", "doi-asserted-by": "publisher"}, {"key": "CIT0052", "DOI": "10.1158/1078-0432.CCR-09-0822", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "DOI": "10.1124/dmd.112.047662", "doi-asserted-by": "publisher"}, {"key": "CIT0054", "DOI": "10.1038/leu.2013.29", "doi-asserted-by": "publisher"}, {"key": "CIT0055", "DOI": "10.1177/1078155212470388", "doi-asserted-by": "publisher"}, {"key": "CIT0056", "DOI": "10.1038/leu.2017.212", "doi-asserted-by": "publisher"}, {"key": "CIT0057", "DOI": "10.1002/ajh.23387", "doi-asserted-by": "publisher"}, {"key": "CIT0058", "DOI": "10.1158/1078-0432.CCR-11-3007", "doi-asserted-by": "publisher"}, {"key": "CIT0059", "DOI": "10.1158/1078-0432.CCR-12-3352", "doi-asserted-by": "publisher"}, {"key": "CIT0060", "DOI": "10.1182/blood-2015-05-643320", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.1182/blood-2012-04-422683", "doi-asserted-by": "publisher"}, {"key": "CIT0062", "DOI": "10.1111/bjh.13296", "doi-asserted-by": "publisher"}, {"key": "CIT0063", "DOI": "10.1182/blood-2012-03-414359", "doi-asserted-by": "publisher"}, {"key": "CIT0064", "DOI": "10.1111/j.1365-2141.2012.09232.x", "doi-asserted-by": "publisher"}, {"key": "CIT0065", "DOI": "10.1056/NEJMoa1411321", "doi-asserted-by": "publisher"}, {"key": "CIT0066", "DOI": "10.1200/JCO.2017.76.5032", "doi-asserted-by": "publisher"}, {"key": "CIT0067", "DOI": "10.1182/blood-2015-11-683854", "doi-asserted-by": "publisher"}, {"key": "CIT0068", "DOI": "10.1016/S1470-2045(18)30354-1", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "DOI": "10.3324/haematol.2018.208272", "doi-asserted-by": "publisher"}, {"key": "CIT0070", "DOI": "10.1001/jamaoncol.2017.4519", "doi-asserted-by": "publisher"}, {"key": "CIT0071", "author": "Muz B", "volume": "10", "first-page": "217", "year": "2016", "journal-title": "Drug Des Devel Ther"}, {"key": "CIT0072", "DOI": "10.1158/0008-5472.CAN-09-2766", "doi-asserted-by": "publisher"}, {"key": "CIT0075", "DOI": "10.1002/jcph.719", "doi-asserted-by": "publisher"}, {"key": "CIT0076", "DOI": "10.1056/NEJMoa1516282", "doi-asserted-by": "publisher"}, {"key": "CIT0077", "DOI": "10.1007/s40262-017-0526-4", "doi-asserted-by": "publisher"}, {"key": "CIT0078", "author": "Gupta N", "journal-title": "Clin Pharmacokinet"}, {"key": "CIT0079", "DOI": "10.1111/bcp.12542", "doi-asserted-by": "publisher"}, {"key": "CIT0080", "DOI": "10.1111/bcp.12991", "doi-asserted-by": "publisher"}, {"key": "CIT0081", "DOI": "10.1007/s10637-017-0509-1", "doi-asserted-by": "publisher"}, {"key": "CIT0082", "DOI": "10.1111/bjh.14125", "doi-asserted-by": "publisher"}, {"key": "CIT0083", "DOI": "10.1182/blood-2014-01-548826", "doi-asserted-by": "publisher"}, {"key": "CIT0084", "DOI": "10.1182/blood-2014-01-548941", "doi-asserted-by": "publisher"}, {"key": "CIT0085", "DOI": "10.1182/blood-2016-05-717769", "doi-asserted-by": "publisher"}, {"key": "CIT0086", "DOI": "10.1016/S1470-2045(14)71125-8", "doi-asserted-by": "publisher"}, {"issue": "22", "key": "CIT0087", "doi-asserted-by": "crossref", "first-page": "abstract 674", "DOI": "10.1182/blood.V128.22.674.674", "volume": "128", "author": "Moreau P, Hulin C", "year": "2016", "journal-title": "Blood"}, {"key": "CIT0088", "DOI": "10.1111/bjh.15394", "doi-asserted-by": "publisher"}, {"issue": "23", "key": "CIT0089", "doi-asserted-by": "crossref", "first-page": "abstract 3155", "DOI": "10.1182/blood.V126.23.3155.3155", "volume": "126", "author": "Shah JJ, Feng L", "year": "2015", "journal-title": "Blood"}, {"key": "CIT0090", "DOI": "10.1016/S0140-6736(18)33003-4", "doi-asserted-by": "publisher"}, {"key": "CIT0091", "DOI": "10.1200/JCO.2016.34.15_suppl.TPS8068", "doi-asserted-by": "publisher"}, {"key": "CIT0092", "DOI": "10.1016/j.ccr.2005.10.013", "doi-asserted-by": "publisher"}, {"key": "CIT0093", "DOI": "10.1016/j.bmc.2008.10.075", "doi-asserted-by": "publisher"}, {"key": "CIT0094", "DOI": "10.1021/ja058320b", "doi-asserted-by": "publisher"}, {"key": "CIT0095", "DOI": "10.1182/blood-2009-03-213009", "doi-asserted-by": "publisher"}, {"key": "CIT0096", "DOI": "10.1158/1078-0432.CCR-15-2616", "doi-asserted-by": "publisher"}, {"key": "CIT0097", "DOI": "10.1182/blood-2015-12-686378", "doi-asserted-by": "publisher"}, {"key": "CIT0098", "DOI": "10.1111/bjh.14113", "doi-asserted-by": "publisher"}, {"key": "CIT0099", "DOI": "10.1111/bjh.14987", "doi-asserted-by": "publisher"}, {"key": "CIT0100", "DOI": "10.1111/bjh.14498", "doi-asserted-by": "publisher"}, {"key": "CIT0101", "DOI": "10.1021/jm801329v", "doi-asserted-by": "publisher"}, {"key": "CIT0102", "DOI": "10.1182/blood-2009-09-243402", "doi-asserted-by": "publisher"}, {"key": "CIT0103", "DOI": "10.1124/dmd.117.075226", "doi-asserted-by": "publisher"}, {"key": "CIT0104", "DOI": "10.1007/s10637-016-0327-x", "doi-asserted-by": "publisher"}, {"key": "CIT0105", "author": "R SM V", "volume": "124", "first-page": "34", "year": "2014", "journal-title": "Blood", "DOI": "10.1182/blood.V124.21.34.34", "doi-asserted-by": "crossref"}, {"key": "CIT0106", "DOI": "10.1182/blood-2015-05-643320", "doi-asserted-by": "publisher"}, {"key": "CIT0107", "DOI": "10.1016/S1470-2045(15)00464-7", "doi-asserted-by": "publisher"}, {"key": "CIT0108", "DOI": "10.1038/leu.2013.115", "doi-asserted-by": "publisher"}, {"key": "CIT0109", "DOI": "10.1158/0008-5472.CAN-13-2397", "doi-asserted-by": "publisher"}, {"key": "CIT0110", "DOI": "10.1038/bcj.2017.56", "doi-asserted-by": "publisher"}, {"key": "CIT0111", "DOI": "10.1182/blood-2018-05-849893", "doi-asserted-by": "publisher"}, {"key": "CIT0112", "DOI": "10.1016/j.ccell.2016.03.026", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Drug Metabolism & Toxicology"], "language": "en", "link": [{"URL": "https://www.tandfonline.com/doi/pdf/10.1080/17425255.2019.1621839", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T21:00:58Z", "timestamp": 1574715658000}, "score": 20.22953, "issued": {"date-parts": [[2019, 5, 31]]}, "references-count": 107, "journal-issue": {"published-online": {"date-parts": [[2019, 5, 29]]}, "published-print": {"date-parts": [[2019, 6, 3]]}, "issue": "6"}, "alternative-id": ["10.1080/17425255.2019.1621839"], "URL": "http://dx.doi.org/10.1080/17425255.2019.1621839", "relation": {"cites": []}, "ISSN": ["1742-5255", "1744-7607"], "issn-type": [{"value": "1742-5255", "type": "print"}, {"value": "1744-7607", "type": "electronic"}], "subject": ["Toxicology", "Pharmacology", "General Medicine"], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iemt20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iemt20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}, {"value": "2019-04-04", "order": 0, "name": "received", "label": "Received", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-05-17", "order": 2, "name": "accepted", "label": "Accepted", "group": {"name": "publication_history", "label": "Publication History"}}, {"value": "2019-05-31", "order": 3, "name": "published", "label": "Published", "group": {"name": "publication_history", "label": "Publication History"}}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T17:01:14Z", "timestamp": 1574787674053}, "reference-count": 37, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 8, 1]], "date-time": "2017-08-01T00:00:00Z", "timestamp": 1501545600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["Microbial Pathogenesis"], "published-print": {"date-parts": [[2017, 8]]}, "DOI": "10.1016/j.micpath.2017.05.037", "type": "journal-article", "created": {"date-parts": [[2017, 5, 29]], "date-time": "2017-05-29T16:31:33Z", "timestamp": 1496075493000}, "page": "99-109", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Dendritic cells during mousepox: The role of delayed apoptosis in the pathogenesis of infection"], "prefix": "10.1016", "volume": "109", "author": [{"given": "Piotr", "family": "Orlowski", "sequence": "first", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0001-6937-1078", "authenticated-orcid": false, "given": "Maja", "family": "Pardecka", "sequence": "additional", "affiliation": []}, {"given": "Joanna", "family": "Cymerys", "sequence": "additional", "affiliation": []}, {"given": "Malgorzata", "family": "Krzyzowska", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Microbial Pathogenesis"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0882401016305848?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0882401016305848?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 7]], "date-time": "2019-03-07T15:37:00Z", "timestamp": 1551973020000}, "score": 19.632473, "issued": {"date-parts": [[2017, 8]]}, "references-count": 37, "alternative-id": ["S0882401016305848"], "URL": "http://dx.doi.org/10.1016/j.micpath.2017.05.037", "ISSN": ["0882-4010"], "issn-type": [{"value": "0882-4010", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Dendritic cells during mousepox: The role of delayed apoptosis in the pathogenesis of infection", "name": "articletitle", "label": "Article Title"}, {"value": "Microbial Pathogenesis", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.micpath.2017.05.037", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2017 Elsevier Ltd. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T21:04:34Z", "timestamp": 1574111074974}, "reference-count": 0, "publisher": "American Chemical Society (ACS)", "issue": "30", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Biochemistry"], "published-print": {"date-parts": [[1999, 7]]}, "DOI": "10.1021/bi990735k", "type": "journal-article", "created": {"date-parts": [[2002, 7, 26]], "date-time": "2002-07-26T05:32:25Z", "timestamp": 1027661545000}, "page": "9768-9777", "source": "Crossref", "is-referenced-by-count": 25, "title": ["Components of the Bovine Pituitary Multicatalytic Proteinase Complex (Proteasome) Cleaving Bonds after Hydrophobic Residues\u2020"], "prefix": "10.1021", "volume": "38", "author": [{"given": "Christopher", "family": "Cardozo", "sequence": "first", "affiliation": []}, {"given": "Charlene", "family": "Michaud", "sequence": "additional", "affiliation": []}, {"given": "Marian", "family": "Orlowski", "sequence": "additional", "affiliation": []}], "member": "316", "container-title": ["Biochemistry"], "language": "en", "link": [{"URL": "https://pubs.acs.org/doi/pdf/10.1021/bi990735k", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 30]], "date-time": "2019-09-30T03:04:36Z", "timestamp": 1569812676000}, "score": 18.997328, "issued": {"date-parts": [[1999, 7]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1999, 7]]}, "issue": "30"}, "alternative-id": ["10.1021/bi990735k"], "URL": "http://dx.doi.org/10.1021/bi990735k", "ISSN": ["0006-2960", "1520-4995"], "issn-type": [{"value": "0006-2960", "type": "print"}, {"value": "1520-4995", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}